<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152162</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0006-3002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta</Title>
                <ISOAbbreviation>Biochim. Biophys. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dephosphorylation of CCAAT/enhancer-binding protein ?? by protein phosphatase 2A containing B56?? is required at the early time of adipogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1388-1981(14)00163-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbalip.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">It is known that protein phosphatase 2A (PP2A) expression is increased in high-fat diet (HFD)-induced obese mice, but role of PP2A in adipogenesis as well as obesity remains to be addressed. In this study, the role of PP2A in adipogenesis was explored. Preadipocytes were treated with okadaic acid (OA) during adipogenesis and the degree of adipogenesis was determined. The OA treatment blocked adipogenesis at the early time of adipogenesis, but not at the late time. In the early time of adipogenesis, CCAAT/enhancer-binding protein ?? (C/EBP??) activation is preceded by the expression of key adipogenic transcription factors including PPAR?? and C/EBP??, which function at the late time of adipogenesis, and then C/EBP?? is degraded. However, the inhibition of PP2A by OA treatment sustained phosphorylation of C/EBP?? and delayed its degradation. In turn, PPAR?? and C/EBP?? activation were altered. Among the various regulatory B56 subunits consisting of PP2A holoenzyme, B56?? was directly bound to C/EBP?? and was responsible for the dephosphorylation of C/EBP?? by PP2A. Taken together, these findings suggest that the phosphorylation of C/EBP?? after hormonal induction has to be inactivated by PP2A containing B56?? at the early time of adipogenesis to allow the completion of adipogenesis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Miyoung</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Yeon A</ForeName>
                    <Initials>YA</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Hee Gu</ForeName>
                    <Initials>HG</Initials>
                    <Affiliation>Korea Research Institute of Bioscience and Biotechnology, Daejon 305-333, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Keun Il</ForeName>
                    <Initials>KI</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lim</LastName>
                    <ForeName>Jong-Seok</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Myeong-Sok</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oh</LastName>
                    <ForeName>Ki-Sook</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Young</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Life Science, Sookmyung Women's University, Seoul 140-742, Korea. Electronic address: yyang@sookmyung.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochim Biophys Acta</MedlineTA>
            <NlmUniqueID>0217513</NlmUniqueID>
            <ISSNLinking>0006-3002</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipogenesis</Keyword>
            <Keyword MajorTopicYN="N">B56??</Keyword>
            <Keyword MajorTopicYN="N">C/EBP??</Keyword>
            <Keyword MajorTopicYN="N">Extracellular signal regulated kinase (ERK)</Keyword>
            <Keyword MajorTopicYN="N">Protein phosphatase 2A (PP2A)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1388-1981(14)00163-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbalip.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25152162</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152124</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0253-2727</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>35</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi</Title>
                <ISOAbbreviation>Zhonghua Xue Ye Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[RNAi-mediated silencing of CD147 inhibits the proliferation and infiltrations of leukemic cells SHI-1].</ArticleTitle>
            <Pagination>
                <MedlinePgn>737-42</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-2727.2014.08.015</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the role of CD147 gene on the proliferation and infiltration of a human monocytic leukemic cell line SHI-1.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The expression of CD147 in SHI-1 cells was knockdowned by the lentiviral vector. The expressions of CD147, MMP-2 and MMP-9 were detected by semiquantitative RT-PCR. The protein of CD147 was detected by Western blotting. The capabilities of proliferation and infiltration of SHI-1 cell were examined by MTT and trans- matrigel invasion assay co-cultured with leukemia BMSC in vitro. SHI-1 cells were inoculated subcutaneously or via tail vein into nude mice to investigate its growth and infiltrative ability in vivo.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mRNA and protein of CD147 in SHI-1/CD147i cells decreased by 85% and 91%, respectively after the SHI-1 cells were infected by the lentivirus containing the CD147 siRNA. The proliferation capability of SHI-1/CD147i cells significantly decreased than those of SHI-1 and SHI-1/NC cells. The mRNA expressions of MMP-2, MMP-9 in SHI-1/CD147i cells were significantly lower than those in SHI-1/NC and SHI-1 cells. The SHI-1/CD147i cells showed significantly lower invasion rate than SHI-1 cells and SHI-1/NC cells when co-cultured with BMSCs. The neoplasms formed by SHI-1/CD147i cells in the subcutaneous of mice were significantly smaller than of the neoplasms formed by SHI-1 and SHI-1/NC cells. In nude mice inoculated via caudal vein with SHI/CD147i cells, mice demonstrated longer survival and moderate infiltration characteristic than those inoculated with SHI and SHI-1/NC cells.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CD147 might play important roles in the proliferation and infiltration of leukemia cells. CD147 should be a potential target for the treatment of acute leukemia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tu</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhenjiang</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Aiping</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fei</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Huihui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Qiong</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Wenfeng</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Hematology, the Second Hospital Affiliated to Nanchang University, Nanchang 330006, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Xue Ye Xue Za Zhi</MedlineTA>
            <NlmUniqueID>8212398</NlmUniqueID>
            <ISSNLinking>0253-2727</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.0253-2727.2014.08.015</ArticleId>
            <ArticleId IdType="pubmed">25152124</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152112</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0253-2727</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>35</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi</Title>
                <ISOAbbreviation>Zhonghua Xue Ye Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[The relationship between NLRP3 inflammsomes expression and liver damage after allogeneic hematopoietic stem cell transplantation in mice model].</ArticleTitle>
            <Pagination>
                <MedlinePgn>684-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-2727.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the function of nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammsomes in liver damage after allogeneic hematopoietic stem cell transplantation (allo-HSCT).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The study presented a murine (BALB/c-based) model of allo-HSCT. Chimera rate was measured by flow cytometry. The hematoxylin-eosin, Masson's trichrome, immunohistochemistry staining were used to observe the pathology changes in liver, then measured the degree of liver damage. Inflammation cells and NLRP3 were measured by Western blot, cytokines IL-1??, IL-18 and NLRP3 related genes were tested with real-time quantitative polymerase chain reaction (q-PCR).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Hematopoietic stem cells had been successfully transplanted, the chimera rate was geater than 97% on the 10th day. Liver damage occurred after allo-HSCT and suffered infiltration of inflammation cells, which reached the peak on day 15, then moved to moderate; the cytokines IL-1??, IL-18 had the similar trend with liver injury, and reached the highest level on day 15, their mRNA expressions increased by (1.19??0.40) fold and (1.64??0.76) fold, respectively; Meanwhile, caspase-1 had the similar trend, its mRNA expression increased by (3.51??0.46) fold on day 15; the inflammasomes NLRP1, NLRP3, NLRC4 and NLRP5 expressed in liver on day 15 of post-allo-HSCT, and NLRP3 inflammasome expressed highest among them. The mRNA and protein level of NLRP3 inflammasomes were kept with the serious degree of the liver damage, its mRNA expression increased by (2.91??0.41) fold on day 15.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NLRP3 inflammsome expressed in liver injury during allo-HSCT in mice, and may be one of the important factors contributed to liver injury.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Yujin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Jinyu</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jinyan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Ting</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hua</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Mimi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Na</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Kailin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Lingyu</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Hepatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Xue Ye Xue Za Zhi</MedlineTA>
            <NlmUniqueID>8212398</NlmUniqueID>
            <ISSNLinking>0253-2727</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.0253-2727.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25152112</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152078</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2042-0226</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular &amp; molecular immunology</Title>
                <ISOAbbreviation>Cell. Mol. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/cmi.2014.60</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The pro-inflammation factor high-mobility group box protein 1 (HMGB1) has been implicated in the pathogenesis of asthma. In this study, we used a murine model of chronic asthma to evaluate the effects of HMGB1 on airway remodeling. Female BALB/c mice were randomly divided into four groups: control, ovalbumin (OVA) asthmatic, OVA+isotype antibody and OVA+anti-HMGB1 antibody. Anti-HMGB1 antibody therapy was started on day 21 and was administered three times per week for 6 weeks before intranasal challenge with OVA. In this mouse model, HMGB1 expression is significantly elevated. The anti-HMGB1 antibody group exhibited decreased levels of immunoglobulin E (IgE) and inflammatory mediators and reduced inflammatory cell accumulation, airway hyperresponsiveness (AHR), mucus synthesis, smooth muscle thickness and lung collagen content compared with the OVA groups. Treatment with HMGB1 increased proliferation, migration, collagen secretion and ??-smooth muscle actin (SMA) expression in MRC-5 cells. Treatment with the HMGB1/IL-1?? complex significantly increased the expression and secretion of transforming growth factor (TGF-??1), matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF). Altogether, these results suggest that blocking HMGB1 activity may reverse airway remodeling by suppressing airway inflammation and modulating lung fibroblast phenotype and activation.Cellular &amp; Molecular Immunology advance online publication, 25 August 2014; doi:10.1038/cmi.2014.60.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hou</LastName>
                    <ForeName>Changchun</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Kong</LastName>
                    <ForeName>Jinliang</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Liang</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Wen</LastName>
                    <ForeName>Hanchun</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zheng</LastName>
                    <ForeName>Xiaowen</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Lihong</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yiqiang</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Mol Immunol</MedlineTA>
            <NlmUniqueID>101242872</NlmUniqueID>
            <ISSNLinking>1672-7681</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cmi201460</ArticleId>
            <ArticleId IdType="doi">10.1038/cmi.2014.60</ArticleId>
            <ArticleId IdType="pubmed">25152078</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152064</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-1166</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of molecular neuroscience : MN</Title>
                <ISOAbbreviation>J. Mol. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sleep Fragmentation Has Differential Effects on Obese and Lean Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Chronic sleep fragmentation (SF), common in patients with sleep apnea, correlates with the development of obesity. We hypothesized that SF differentially affects neurobehavior in lean wild-type (WT) and obese pan-leptin receptor knockout (POKO) mice fed the same normal diet. First, we established an SF paradigm by interrupting sleep every 2??min during the inactive light span. The maneuver was effective in decreasing sleep duration and bout length, and in increasing sleep state transition and waking, without significant rebound sleep in the dark span. Changes of sleep architecture were evident in the light span and consistent across days 1-10 of SF. There was reduced NREM, shortened sleep latency, and increased state transitions. During the light span of the first day of SF, there also was reduction of REM and increased delta power of slow-wave sleep. Potential effects of SF on thermal pain threshold, locomotor activity, and anxiety were then tested. POKO mice had a lower circadian amplitude of pain latency than WT mice in the hot plate test, and both groups had lowest tolerance at 4??pm (zeitgeber time (ZT) 10) and longest latency at 4??am (ZT 22). SF increased the pain threshold in WT but not in POKO mice when tested at 8??a.m. (ZT 2). Both the POKO mutation and SF resulted in reduced physical activity and increased anxiety, but there was no additive effect of these two factors. Overall, SF and the POKO mutation differentially regulate mouse behavior. The results suggest that obesity can blunt neurobehavioral responses to SF.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Junyun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Blood Brain Barrier Group, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kastin</LastName>
                    <ForeName>Abba J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yuping</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Pan</LastName>
                    <ForeName>Weihong</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Mol Neurosci</MedlineTA>
            <NlmUniqueID>9002991</NlmUniqueID>
            <ISSNLinking>0895-8696</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-014-0403-7</ArticleId>
            <ArticleId IdType="pubmed">25152064</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152050</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0015-5500</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>60</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Folia biologica</Title>
                <ISOAbbreviation>Folia Biol. (Praha)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adipose Cells Induce Phospho-Thr-172 AMPK Production by Epinephrine or CL316243 in Mouse 3T3-L1 Adipocytes or MAPK Activation and G Protein-Associated PI3K Responses Induced by CL316243 or Aluminum Fluoride in Rat White Adipocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>168-79</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Responses of adipose cells to adrenoceptor regulation, including that of ??-adrenoceptor (AR), and the signalling machinery involved in these responses are not sufficiently understood; information that is helpful for elucidating the adrenoceptor (adrenergic and ??-AR)-responsive machinery is insufficient. We examined phospho-Thr-172 AMPK production in mouse-derived 3T3-L1 adipocytes treated with epinephrine or CL316243 (a ??3-AR agonist) for 15 min. We also examined MAPK activation or G protein-associated PI3K activation or -associated PI3K p85 complex formation in rat epididymal (white) adipocytes treated with CL316243 for 15 min or aluminum fluoride (a G-protein signalling activator) for 20 min. Furthermore, we examined the effect of PTX (a trimeric G-protein inactivator) on p85 complex formation induced by aluminum fluoride treatment. Western blot analysis revealed that epinephrine or CL316243 treatment increased the phospho- Thr-172 AMPK (an active form of AMPK) level in 3T3-L1 adipocytes. Activated kinase analysis with a specific substrate showed that CL316243 or aluminum fluoride treatment activated MAPK in rat adipocytes. Immunoprecipitation experiments with a G-protein ?? subunit (G??) antibody showed that treatment of rat adipocytes with CL316243 activated PI3K and increased the PI3K p85 level in the G?? antibody immunoprecipitates. Such an increase in the p85 level was similarly elicited by aluminum fluoride treatment in a PTX-sensitive manner. Our results provide possible clues for clarifying the signalling machinery involved in adrenoceptor responses, including those of ??3-AR, in mouse-derived adipocytes and rat white adipocytes. Our findings advance the understanding of responses to adrenoceptor regulation in adipose cells and of the cellular signalling machinery present in the cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ohsaka</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pharmacology, Faculty of Pharmaceutical Sciences, Chiba Institute of Science, Choshi, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishino</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Ritsumeikan Global Innovation Research Organization, Ritsumeikan University, Kusatsu, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Yokohama College of Pharmacy, Yokohama, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Czech Republic</Country>
            <MedlineTA>Folia Biol (Praha)</MedlineTA>
            <NlmUniqueID>0234640</NlmUniqueID>
            <ISSNLinking>0015-5500</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">FB2014A0020</ArticleId>
            <ArticleId IdType="pubmed">25152050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152047</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2091</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC biochemistry</Title>
                <ISOAbbreviation>BMC Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chemical-genetic induction of Malonyl-CoA decarboxylase in skeletal muscle.</ArticleTitle>
            <Pagination>
                <MedlinePgn>20</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Defects in skeletal muscle fatty acid oxidation have been implicated in the etiology of insulin resistance. Malonyl-CoA decarboxylase (MCD) has been a target of investigation because it reduces the concentration of malonyl-CoA, a metabolite that inhibits fatty acid oxidation. The in vivo role of muscle MCD expression in the development of insulin resistance remains unclear.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">To determine the role of MCD in skeletal muscle of diet induced obese and insulin resistant mouse models we generated mice expressing a muscle specific transgene for MCD (Tg-fMCDSkel) stabilized posttranslationally by the small molecule, Shield-1. Tg-fMCDSkel and control mice were placed on either a high fat or low fat diet for 3.5 months. Obese and glucose intolerant as well as lean control Tg-fMCDSkel and nontransgenic control mice were treated with Shield-1 and changes in their body weight and insulin sensitivity were determined upon induction of MCD. Inducing MCD activity &gt;5-fold in skeletal muscle over two weeks did not alter body weight or glucose intolerance of obese mice. MCD induction further potentiated the defects in insulin signaling of obese mice. In addition, key enzymes in fatty acid oxidation were suppressed following MCD induction.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Acute induction of MCD in the skeletal muscle of obese and glucose intolerant mice did not improve body weight and decreased insulin sensitivity compared to obese nontransgenic controls. Induction of MCD in skeletal muscle resulted in a suppression of mitochondrial oxidative genes suggesting a redundant and metabolite driven regulation of gene expression.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rodriguez</LastName>
                    <ForeName>Susana</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Ellis</LastName>
                    <ForeName>Jessica M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Wolfgang</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Biochem</MedlineTA>
            <NlmUniqueID>101084098</NlmUniqueID>
            <ISSNLinking>1471-2091</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2091-15-20</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2091-15-20</ArticleId>
            <ArticleId IdType="pubmed">25152047</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152037</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1880-313X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical research (Tokyo, Japan)</Title>
                <ISOAbbreviation>Biomed. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CGRP, a neurotransmitter of enteric sensory neurons, contributes to the development of food allergy due to the augmentation of microtubule reorganization in mucosal mast cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>285-93</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Neuro-immune interaction in the gut is substantially involved in the maintenance of intestinal immune homeostasis and the pathology of intestinal immune diseases. We have previously demonstrated that mucosal mast cells and nerve fibers containing CGRP, a neurotransmitter of intrinsic enteric sensory neurons, are markedly increased and exist in close proximity to each other in the colon of food allergy (FA) mice. In the present study, a CGRP-receptor antagonist BIBN4096BS significantly alleviated allergic symptoms in the murine FA model. In addition, the elevated numbers of mucosal mast cells in the proximal colon of FA mice were significantly decreased in that of BIBN4096BS-treated FA mice. Thus, we investigated the effects of CGRP on calcium-independent process in degranulation of mucosal mast cells since CGRP increases intracellular cAMP levels, but not Ca(2+) concentration. CGRP did not alter a calcium ionophore A23187-increased cytosolic Ca(2+) concentration in mucosal-type bone marrow-derived mast cells (mBMMCs), but did augment microtubule reorganization in resting and A23187-activated mBMMCs. Furthermore, CGRP alone failed to cause the degranulation of mBMMCs, but CGRP significantly enhanced the degranulation of mBMMCs induced by A23187. Together, these data indicate that CGRP- enhanced microtubule reorganization augments IgE-independent/non-antigenic stimuli-induced mucosal mast cell degranulation, thereby contributing to the development of FA.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ji-Hyun</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, University of Toyama.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jaemin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yashiro</LastName>
                    <ForeName>Tomoe</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamada</LastName>
                    <ForeName>Takayuki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayashi</LastName>
                    <ForeName>Shusaku</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kadowaki</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biomed Res</MedlineTA>
            <NlmUniqueID>8100317</NlmUniqueID>
            <ISSNLinking>0388-6107</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">DN/JST.JSTAGE/biomedres/35.285</ArticleId>
            <ArticleId IdType="pubmed">25152037</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152036</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1880-313X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical research (Tokyo, Japan)</Title>
                <ISOAbbreviation>Biomed. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunomagnetic exclusion of PECAM-1-positive endothelial cells in fetal mouse liver cell cultures causes impaired growth and gene expression of hepatoblasts and stellate cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>271-83</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Previous studies using mice having defective VEGF signaling have demonstrated that vascular development is indispensable for early hepatic organogenesis. However, not only whether its action lasts during later hepatic development, but also what molecules are involved in that action remains to be determined. The present study was undertaken to examine the effects of primitive sinusoidal endothelial cells on hepatic growth and maturation in primary culture of fetal mouse liver cells, and to determine their molecular mechanisms. When endothelial cells were excluded from E12.5 liver cell cultures by using PECAM-1-antibody-coated magnetic beads, the growth of hepatoblasts and stellate cells was conspicuously reduced and hepatic maturation was also suppressed. Conditioned medium prepared from fetal liver cell cultures containing almost all hepatic cell types stimulated the growth and gene expression of hepatoblasts and stellate cells similarly to the cultures in the presence of endothelial cells. HGF mRNA expression was downregulated in endothelial cellfree cultures of fetal liver cells, and the addition of HGF to the culture medium rescued the cells from the effects of endothelial cell depletion. These data suggest that humoral factors, including HGF, which are produced by endothelial cells or stellate cells, are involved in fetal hepatocyte growth and maturation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sugiyama</LastName>
                    <ForeName>Yoshinori</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takabe</LastName>
                    <ForeName>Yurie</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yagi</LastName>
                    <ForeName>Shinomi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiojiri</LastName>
                    <ForeName>Nobuyoshi</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biomed Res</MedlineTA>
            <NlmUniqueID>8100317</NlmUniqueID>
            <ISSNLinking>0388-6107</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">DN/JST.JSTAGE/biomedres/35.271</ArticleId>
            <ArticleId IdType="pubmed">25152036</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152034</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1880-313X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical research (Tokyo, Japan)</Title>
                <ISOAbbreviation>Biomed. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nitric oxide-mediated injury of interstitial cells of Cajal and intestinal dysmotility under endotoxemia of mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>251-62</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Gastrointestinal dysmotility is frequently observed under septic conditions, yet its precise mechanisms remain to be elucidated. In this study, we have investigated the mechanisms of intestinal dysmotility by lipopolysaccharides (LPS) and the role of the interstitial cells of Cajal (ICCs) in motility disorders using a mouse endotoxin model. The injection of LPS caused time- and dose-dependent decreases in the intestinal contractility, which was associated with similar time- and dose-dependent decreases in the number of KIT-positive fibroblast-like cells located in the intermuscular layer. iNOS inhibitors, L-NAME and aminoguanidine (AG), but not 7-nitroindazole (7NI), a specific nNOS inhibitor, inhibited the LPS-induced decreases in both the contractility and the number of KIT-positive cells. A spontaneous NO releaser, FK409, not only diminished spontaneous electrical potential and phasic contractions, but also decreased the number of KIT-positive cells. Pretreatment with gadolinium inhibited the activation of macrophages and the induction of iNOS in intestinal resident macrophages, and restored the number of KIT-positive cells and intestinal contractions. These results suggested that NO produced from intestinal macrophages via iNOS induced by LPS, may be involved in the ICCs injury and intestinal dysmotility under septic conditions.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ueshima</LastName>
                    <ForeName>Shigeyuki</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Surgery, Osaka University Graduate School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishida</LastName>
                    <ForeName>Toshirou</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Masato</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuda</LastName>
                    <ForeName>Hikaru</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawa</LastName>
                    <ForeName>Yoshiki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uchiyama</LastName>
                    <ForeName>Yasuo</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biomed Res</MedlineTA>
            <NlmUniqueID>8100317</NlmUniqueID>
            <ISSNLinking>0388-6107</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">DN/JST.JSTAGE/biomedres/35.251</ArticleId>
            <ArticleId IdType="pubmed">25152034</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25152033</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1880-313X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical research (Tokyo, Japan)</Title>
                <ISOAbbreviation>Biomed. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>S100A1 and S100B are dispensable for endochondral ossification during skeletal development.</ArticleTitle>
            <Pagination>
                <MedlinePgn>243-50</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>S100A1 and S100B are induced by the SOX trio transcription factors (SOX9, SOX5, and SOX6) in chondrocytes, and inhibit their hypertrophic differentiation in culture. However, functional roles of S100A1 and S100B during in vivo skeletal development are yet to be determined. Here we show that mice deficient of both the S100a1 and S100b genes displayed normal skeletal growth from embryonic stage to adulthood. Although no compensatory upregulation of other S100 family members was observed in S100a1/S100b double mutants, the related S100a2, S100a4, S100a10, and S100a11 were expressed at similarly high levels to S100a1 and S100b in mouse primary chondrocytes. Furthermore, overexpression of these other S100 members suppressed the hypertrophic differentiation of chondrocytes in vitro as efficiently as S100A1 and S100B. Taken together, the present study demonstrates that S100A1 and S100B are dispensable for endochondral ossification during skeletal development, most likely because their deficiency may be masked by other S100 proteins which have similar functions to those of S100A1 and S100B.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Yoshifumi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Sensory &amp; Motor System Medicine, Faculty of Medicine, University of Tokyo.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chung</LastName>
                    <ForeName>Ung-Il</ForeName>
                    <Initials>UI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Sakae</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heierhorst</LastName>
                    <ForeName>J??rg</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buchou</LastName>
                    <ForeName>Thierry</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baudier</LastName>
                    <ForeName>Jacques</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawaguchi</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>Taku</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biomed Res</MedlineTA>
            <NlmUniqueID>8100317</NlmUniqueID>
            <ISSNLinking>0388-6107</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">DN/JST.JSTAGE/biomedres/35.243</ArticleId>
            <ArticleId IdType="pubmed">25152033</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25152027</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1745-7254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Acta pharmacologica Sinica</Title>
                <ISOAbbreviation>Acta Pharmacol. Sin.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Alpha-lipoic acid attenuates insulin resistance and improves glucose metabolism in high fat diet-fed mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/aps.2014.64</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Aim:To investigate whether alpha-lipoic acid (ALA) could attenuate the insulin resistance and metabolic disorders in high fat diet-fed mice.Methods:Male mice were fed a high fat diet (HFD) plus ALA (100 and 200 mg??kg(-1)??d(-1)) or HFD plus a positive control drug metformin (300 mg??kg(-1)??d(-1)) for 24 weeks. During the treatments, the relevant physiological and metabolic parameters of the mice were measured. After the mice were euthanized, blood samples and livers were collected. The expression of proteins and genes related to glucose metabolism in livers were analyzed by immunoblotting and real time-PCR.Results:HFD induced non-alcoholic fatty liver disease (NAFLD) and abnormal physiological and metabolic parameters in the mice, which were dose-dependently attenuated by ALA. ALA also significantly reduced HFD-induced hyperglycemia and insulin resistance in HFD-fed mice. Furthermore, ALA significantly upregulated the glycolytic enzymes GCK, HK-1 and PK, and the glycogen synthesis enzyme GS, and downregulated the gluconeogenic enzymes PEPCK and G6Pase, thus decreased glucose production, and promoted glycogen synthesis and glucose utilization in livers. Moreover, ALA markedly increased PKB/Akt and GSK3?? phosphorylation, and nuclear carbohydrate response element binding protein (ChREBP) expression in livers. Metformin produced similar effects as ALA in HFD-fed mice.Conclusion:ALA is able to sustain glucose homeostasis and prevent the development of NAFLD in HFD-fed mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>1] Department of Endocrinology, Provincial Hospital Affiliated to Shandong University, Ji-nan 250021, China [2] Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan 750004, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Wang</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Biochemistry and Molecular Biology, Ningxia Medical University, Yinchuan 750004, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Biochemistry and Molecular Biology, Ningxia Medical University, Yinchuan 750004, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Biochemistry and Molecular Biology, Ningxia Medical University, Yinchuan 750004, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gao</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Central Lab Provincial Hospital Affiliated to Shandong University, Ji-nan 250021, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Jia-Jun</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>1] Department of Endocrinology, Provincial Hospital Affiliated to Shandong University, Ji-nan 250021, China [2] Institute of Endocrinology, Shandong Academy of Clinical Medicine, Ji-nan 250021, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Acta Pharmacol Sin</MedlineTA>
            <NlmUniqueID>100956087</NlmUniqueID>
            <ISSNLinking>1671-4083</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">aps201464</ArticleId>
            <ArticleId IdType="doi">10.1038/aps.2014.64</ArticleId>
            <ArticleId IdType="pubmed">25152027</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151997</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-2513</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Immunopharmacology and immunotoxicology</Title>
                <ISOAbbreviation>Immunopharmacol Immunotoxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunomodulatory effects of EGCG fraction of green tea extract in innate and adaptive immunity via T regulatory cells in murine model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Green tea is a widely consumed beverage known for its beneficial anti-inflammatory, anti-oxidative, anti-mutagenic, anti-carcinogenic, and cardioprotective properties. Here, we administered epigallocatechin gallate fraction of green tea extract (EGTE) to mice for 6 weeks and examined the effects on the innate and adaptive immune responses by measuring phagocytic and natural killer (NK) cell activity, as well as antigen-specific proliferation, cytolysis, cytokine secretion, and antibody production. Our data show that EGTE administration increased NK cell cytolysis and peritoneal cell phagocytosis, as well as splenocyte proliferation and secretion of IL-2 and IFN-??. Of note, EGTE treatment decreased the production antigen-specific IgE via increased the proportion of CD4(+) CD25(+) regulatory T lymphocytes in the spleen, suggesting that EGTE may play a role in regulating the allergic response.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kuo</LastName>
                    <ForeName>Chao-Lin</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University , Taichung, Taiwan , ROC .</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Tung-Sheng</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author>
                    <LastName>Liou</LastName>
                    <ForeName>Shaw-Yih</ForeName>
                    <Initials>SY</Initials>
                </Author>
                <Author>
                    <LastName>Hsieh</LastName>
                    <ForeName>Chang-Chi</ForeName>
                    <Initials>CC</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Immunopharmacol Immunotoxicol</MedlineTA>
            <NlmUniqueID>8800150</NlmUniqueID>
            <ISSNLinking>0892-3973</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EGCG fraction of green tea</Keyword>
            <Keyword MajorTopicYN="N">IgE</Keyword>
            <Keyword MajorTopicYN="N">NK cytolysis</Keyword>
            <Keyword MajorTopicYN="N">Treg</Keyword>
            <Keyword MajorTopicYN="N">phagocytosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08923973.2014.953637</ArticleId>
            <ArticleId IdType="pubmed">25151997</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151985</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0392-856X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental rheumatology</Title>
                <ISOAbbreviation>Clin. Exp. Rheumatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Blockade of macrophage autophagy ameliorates activated lymphocytes-derived DNA induced murine lupus possibly via inhibition of proinflammatory cytokines production.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is a typical inflammatory autoimmune disease for its unknown pathogenesis and potential fatality. It has been reported that autophagy has a crosstalk with autoimmunity, but its impact on the pathogenesis of SLE remains unclear. Here, we investigated the role of autophagy in inflammatory response of macrophages under SLE conditions.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">First, we detected the expression of autophagy-related genes (Atg5, Atg12 and Beclin 1) in the macrophages derived from activated lymphocytes-derived DNA (ALD-DNA) induced murine lupus as well as in the PBMC from SLE patients. And then through adoptive transfer of Beclin 1 knockdown macrophages, we further investigated the potential effect of macrophage autophagy on the SLE-associated inflammatory response and disease severity by evaluating serum anti-dsDNA antibodies and proteinuria levels, immune complex deposition as well as renal pathological changes.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that autophagy related genes were significantly upregulated in the splenic and renal macrophages of lupus mice and in the PBMC of SLE patients. Adoptive transfer of Beclin 1 knockdown macrophages could significantly decrease the anti-dsDNA antibodies and proteinuria levels, robustly reduce renal immune complex deposition and remit glomerulonephritis, indicating the amelioration of murine lupus. This protective effect was associated with the obviously decreased production of proinflammatory cytokines IL-6 and TNF-??.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggested that aberrant activated autophagy in macrophages contributed to the pathogenesis of murine lupus possibly via promoting the production of proinflammatory cytokines TNF-?? and IL-6, and inhibition of autophagy might represent a novel regulation strategy for excessive activation of proinflammatory macrophages and a new therapeutic regime for SLE.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Baihui</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Science, Soochow University, Suzhou, China. rainpeerless@126.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yue</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Dong</LastName>
                    <ForeName>Chunsheng</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Yongbing</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Xiong</LastName>
                    <ForeName>Sidong</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Rheumatol</MedlineTA>
            <NlmUniqueID>8308521</NlmUniqueID>
            <ISSNLinking>0392-856X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">7953</ArticleId>
            <ArticleId IdType="pubmed">25151985</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151980</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of controlled release : official journal of the Controlled Release Society</Title>
                <ISOAbbreviation>J Control Release</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pollen grains for oral vaccination.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0168-3659(14)00592-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jconrel.2014.08.010</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Oral vaccination can offer a painless and convenient method of vaccination. Furthermore, in addition to systemic immunity it has potential to stimulate mucosal immunity through antigen-processing by the gut-associated lymphoid tissues. In this study we propose the concept that pollen grains can be engineered for use as a simple modular system for oral vaccination. We demonstrate feasibility of this concept by using spores of Lycopodium clavatum (clubmoss) (LSs). We show that LSs can be chemically cleaned to remove native proteins to create intact clean hollow LS shells. Empty pollen shells were successfully filled with molecules of different sizes demonstrating their potential to be broadly applicable as a vaccination system. Using ovalbumin (OVA) as a model antigen, LSs formulated with OVA were orally fed to mice. LSs stimulated significantly higher anti-OVA serum IgG and fecal IgA antibodies compared to those induced by use of cholera toxin as a positive-control adjuvant. The antibody response was not affected by pre-neutralization of the stomach acid, and persisted for up to seven months. Confocal microscopy revealed that LSs can translocate in to mouse intestinal wall. Overall, this study lays the foundation of using LSs as a novel approach for oral vaccination.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Atwe</LastName>
                    <ForeName>Shashwati U</ForeName>
                    <Initials>SU</Initials>
                    <Affiliation>Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Yunzhe</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gill</LastName>
                    <ForeName>Harvinder Singh</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA. Electronic address: harvinder.gill@ttu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Control Release</MedlineTA>
            <NlmUniqueID>8607908</NlmUniqueID>
            <ISSNLinking>0168-3659</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">lycopodium spores</Keyword>
            <Keyword MajorTopicYN="N">mucosal vaccination</Keyword>
            <Keyword MajorTopicYN="N">oral vaccination</Keyword>
            <Keyword MajorTopicYN="N">pollen shells</Keyword>
            <Keyword MajorTopicYN="N">sporopollenin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0168-3659(14)00592-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jconrel.2014.08.010</ArticleId>
            <ArticleId IdType="pubmed">25151980</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151978</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of controlled release : official journal of the Controlled Release Society</Title>
                <ISOAbbreviation>J Control Release</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0168-3659(14)00594-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jconrel.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Phenylketonuria (PKU) is an autosomal recessive genetic disease caused by defects in the phenylalanine hydroxylase gene. Preclinical and clinical investigations suggest that phenylalanine ammonia lyase (PAL) could be an effective alternative for the treatment of PKU. The aim of this study is to investigate if erythrocytes loaded with PAL may act as a safe delivery system able to overcome bioavailability issues and to provide, in vivo, a therapeutically relevant concentration of enzyme. Murine erythrocytes were loaded with recombinant PAL from Anabaena variabilis (rAvPAL) and their ability to perform as bioreactors was assessed in vivo in adult BTBR-Pah(enu2) mice, the genetic murine model of PKU. Three groups of mice were treated with a single i.v. injection of rAvPAL-RBCs at three different doses to select the most appropriate one for assessment of efficacy. Repeated administrations at 9-10 day-intervals of the selected dose for 10weeks showed that the therapeutic effect was persistent and not affected by the generation of antibodies induced by the recombinant enzyme. This therapeutic approach deserves further in vivo evaluation either as a potential option for the treatment of PKU patients or as a possible model for the substitutive enzymatic treatment of other inherited metabolic disorders.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rossi</LastName>
                    <ForeName>Luigia</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Biomolecular Sciences, University of Urbino &quot;Carlo Bo&quot;, via Saffi 2, 61029 Urbino (PU), Italy; EryDel SpA, via Sasso 36, 61029 Urbino (PU), Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pierig??</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Biomolecular Sciences, University of Urbino &quot;Carlo Bo&quot;, via Saffi 2, 61029 Urbino (PU), Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carducci</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Experimental Medicine, Sapienza University, viale del Policlinico 155, 00161 Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gabucci</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Biomolecular Sciences, University of Urbino &quot;Carlo Bo&quot;, via Saffi 2, 61029 Urbino (PU), Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pascucci</LastName>
                    <ForeName>Tiziana</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Psychology and Centro &quot;Daniel Bovet&quot;, Sapienza University, via dei Marsi 78, 00185 Rome, Italy; Fondazione Santa Lucia, IRCCS, via Ardeatina 306, 00142 Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Canonico</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Earth, Life and Environmental Sciences, University of Urbino &quot;Carlo Bo&quot;, Campus Scientifico Enrico Mattei - via C?? Le Suore 2/4, 61029 Urbino (PU), Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bell</LastName>
                    <ForeName>Sean M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>BioMarin Pharmaceutical, Inc., 105 Digital Drive, Novato, CA 94949.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fitzpatrick</LastName>
                    <ForeName>Paul A</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>BioMarin Pharmaceutical, Inc., 105 Digital Drive, Novato, CA 94949.</Affiliation>
                </Author>
                <Author>
                    <LastName>Leuzzi</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Pediatrics and Child Neurology and Psychiatry, Sapienza University, via dei Sabelli 108, 00185 Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Magnani</LastName>
                    <ForeName>Mauro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biomolecular Sciences, University of Urbino &quot;Carlo Bo&quot;, via Saffi 2, 61029 Urbino (PU), Italy; EryDel SpA, via Sasso 36, 61029 Urbino (PU), Italy. Electronic address: mauro.magnani@uniurb.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Control Release</MedlineTA>
            <NlmUniqueID>8607908</NlmUniqueID>
            <ISSNLinking>0168-3659</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PKU mouse model</Keyword>
            <Keyword MajorTopicYN="N">carrier erythrocytes</Keyword>
            <Keyword MajorTopicYN="N">drug delivery</Keyword>
            <Keyword MajorTopicYN="N">enzyme replacement therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0168-3659(14)00594-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jconrel.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25151978</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151962</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5594</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncogene</Title>
                <ISOAbbreviation>Oncogene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Homeodomain-interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1??</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/onc.2014.278</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Homeodomain-interacting protein kinase 2 (HIPK2) is a potential tumor suppressor that has a crucial role in the DNA damage response (DDR) by regulating cell-cycle checkpoint activation and apoptosis. However, it is unclear whether HIPK2 exerts distinct roles in DNA damage repair. The aim of this study was to identify novel target molecule(s) of HIPK2, which mediates HIPK2-dependent DNA damage repair. HIPK2-knockdown human colon cancer cells (HCT116) or hipk1/hipk2 double-deficient mouse embryonic fibroblasts could not remove histone H2A.X phosphorylated at Ser139 (??H2A.X) after irradiation with a sublethal dose (10???J/m(2)) of ultraviolet (UV)-C, resulting in apoptosis. Knockdown of HIPK2 in p53-null HCT116 cells similarly promoted the UV-C-induced ??H2A.X accumulation and apoptosis. Proteomic analysis of HIPK2-associated proteins using liquid chromatography-tandem mass spectrometry identified heterochromatin protein 1?? (HP1??) as a novel target for HIPK2. Immunoprecipitation experiments with HCT116 cells expressing FLAG-tagged HIPK2 and one of the HA-tagged HP1 family members demonstrated that HIPK2 specifically associated with HP1??, but not with HP1?? or HP1??, through its chromo-shadow domain. Mutation of the HP1box motif (883-PTVSV-887) within HIPK2 abolished the association. HP1?? knockdown also enhanced accumulation of ??H2A.X and apoptosis after sublethal UV-C irradiation. In vitro kinase assay demonstrated an HP1??-phosphorylating activity of HIPK2. Sublethal UV-C irradiation phosphorylated HP1??. This phosphorylation was absent in endogenous HIPK2-silenced cells with HIPK2 3'UTR siRNA. Overexpression of FLAG-HIPK2, but not the HP1box-mutated or kinase-dead HIPK2 mutant, in the HIPK2-silenced cells increased HP1?? binding to trimethylated (Lys9) histone H3 (H3K9me3), rescued the UV-C-induced phosphorylation of HP1??, triggered release of HP1?? from histone H3K9me3 and suppressed ??H2A.X accumulation. Our results suggest that HIPK2-dependent phosphorylation of HP1?? may participate in the regulation of dynamic interaction between HP1?? and histone H3K9me3 to promote DNA damage repair. This HIPK2/HP1?? pathway may uncover a new functional aspect of HIPK2 as a tumor suppressor.Oncogene advance online publication, 25 August 2014; doi:10.1038/onc.2014.278.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Akaike</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kuwano</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishida</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kurokawa</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kajita</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kano</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Masuda</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rokutan</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Stress Science, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncogene</MedlineTA>
            <NlmUniqueID>8711562</NlmUniqueID>
            <ISSNLinking>0950-9232</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">onc2014278</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2014.278</ArticleId>
            <ArticleId IdType="pubmed">25151962</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151961</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5594</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncogene</Title>
                <ISOAbbreviation>Oncogene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/onc.2014.261</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrP(C)) triggers a large number of trophic effects in the nervous system. We found that both PrP(C) and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrP(C) and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrP(C) binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrP(C) binding site (HOP230-245) abrogates this effect. PrP(C) knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrP(C)-HOP engagement is a promising approach for GBM therapy.Oncogene advance online publication, 25 August 2014; doi:10.1038/onc.2014.261.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lopes</LastName>
                    <ForeName>M H</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of S??o Paulo, S??o Paulo, Brazil [3] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Santos</LastName>
                    <ForeName>T G</ForeName>
                    <Initials>TG</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rodrigues</LastName>
                    <ForeName>B R</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Queiroz-Hazarbassanov</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cunha</LastName>
                    <ForeName>I W</ForeName>
                    <Initials>IW</Initials>
                    <Affiliation>Department of Pathology, AC Camargo Cancer Center, S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wasilewska-Sampaio</LastName>
                    <ForeName>A P</ForeName>
                    <Initials>AP</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Costa-Silva</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Marchi</LastName>
                    <ForeName>F A</ForeName>
                    <Initials>FA</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil [3] Inter-institutional Grad Program on Bioinformatics, Institute of Mathematics and Statistics, USP-S??o Paulo University, S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bleggi-Torres</LastName>
                    <ForeName>L F</ForeName>
                    <Initials>LF</Initials>
                    <Affiliation>1] Department of Pathology, Federal University of Paran??, Curitiba, Brazil [2] Pel?? Pequeno Pr??ncipe Research Institute, Curitiba, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sanematsu</LastName>
                    <ForeName>P I</ForeName>
                    <Initials>PI</Initials>
                    <Affiliation>Department of Neurosurgery, AC Camargo Cancer Center, S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Suzuki</LastName>
                    <ForeName>S H</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Department of Neurosurgery, AC Camargo Cancer Center, S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oba-Shinjo</LastName>
                    <ForeName>S M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Neurology, School of Medicine, University of S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Marie</LastName>
                    <ForeName>S K N</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Department of Neurology, School of Medicine, University of S??o Paulo, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Toulmin</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hill</LastName>
                    <ForeName>A F</ForeName>
                    <Initials>AF</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martins</LastName>
                    <ForeName>V R</ForeName>
                    <Initials>VR</Initials>
                    <Affiliation>1] International Research Center, AC Camargo Cancer Center, S??o Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), S??o Paulo, Brazil [3] Ludwig Institute for Cancer Research, S??o Paulo, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncogene</MedlineTA>
            <NlmUniqueID>8711562</NlmUniqueID>
            <ISSNLinking>0950-9232</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">onc2014261</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2014.261</ArticleId>
            <ArticleId IdType="pubmed">25151961</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151953</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-8584</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of molecular and cellular cardiology</Title>
                <ISOAbbreviation>J. Mol. Cell. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0022-2828(14)00258-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yjmcc.2014.08.011</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Ischemic preconditioning (PC) is an adaptive response to transient myocardial ischemia that protects the heart from subsequent ischemia/reperfusion (I/R) injury. However, the mechanisms underlying its cardioprotective effects remain unclear.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Myocardium of adult male C57/BL6 mice, preconditioned by 6cycles of 4minutes coronary occlusion and reperfusion, showed nuclear translocation of ATF3, and ATF6 and PERK phosphorylation 30min after PC. The abundance of ER proteins, ATF3 and ATF4 was increased 24h after PC; however, there was no evidence of IRE-1 activation in WT or ER-stress activated indicator (ERAI) mice expressing XBP-1-Venus fusion protein. PC-induced nuclear translocation of ATF3 was attenuated in transgenic mice with cardiac-restricted overexpression of inducible ATF6. Ischemic PC increased the abundance of inducible nitric oxide synthase, cyclooxygenase-2, heme oxygenase-1 and aldose reductase to levels similar between WT and ATF3-null hearts; however, the increase in IL-6 and ICAM-1 was exaggerated in ATF3-null hearts. Genetic deletion of ATF3 did not increase infarct size in non-preconditioned hearts but abolished the cardioprotective effects of PC. Larger infarct size in preconditioned ATF3-null hearts was associated with greater neutrophil infiltration in the myocardium, but no ATF3-dependent changes in the total or relative abundance of inflammatory monocytes were observed.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ischemic PC activates the unfolded protein response (UPR) and the activation of ATF3 by ER stress is essential for the cardioprotective effects of late PC.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Brooks</LastName>
                    <ForeName>Alan C</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Singh</LastName>
                    <ForeName>Mahavir</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Yiru</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>McCracken</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xuan</LastName>
                    <ForeName>Yu-Ting</ForeName>
                    <Initials>YT</Initials>
                    <Affiliation>Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Srivastava</LastName>
                    <ForeName>Sanjay</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bolli</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhatnagar</LastName>
                    <ForeName>Aruni</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA. Electronic address: aruni@louisville.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Mol Cell Cardiol</MedlineTA>
            <NlmUniqueID>0262322</NlmUniqueID>
            <ISSNLinking>0022-2828</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ATF3</Keyword>
            <Keyword MajorTopicYN="N">infarct size</Keyword>
            <Keyword MajorTopicYN="N">inflammatory response</Keyword>
            <Keyword MajorTopicYN="N">ischemic preconditioning</Keyword>
            <Keyword MajorTopicYN="N">unfolded protein response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0022-2828(14)00258-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2014.08.011</ArticleId>
            <ArticleId IdType="pubmed">25151953</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151952</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-1220</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of steroid biochemistry and molecular biology</Title>
                <ISOAbbreviation>J. Steroid Biochem. Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>11??-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0960-0760(14)00190-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jsbmb.2014.08.011</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">11??-Hydroxysteroid dehydrogenase 1 (11??-HSD1) is an endoplasmic reticulum membrane enzyme with its catalytic site facing the luminal space. It functions primarily as a reductase, driven by the supply of its cosubstrate NADPH by hexose-6-phosphate dehydrogenase (H6PDH). Extensive research has been performed on the role of 11??-HSD1 in the regeneration of active glucocorticoids and its role in inflammation and metabolic disease. Besides its important role in the fine-tuning of glucocorticoid action, 11??-HSD1 is a multi-functional carbonyl reductase converting several 11- and 7-oxosterols into the respective 7-hydroxylated forms. Moreover, 11??-HSD1 has a role in phase I biotransformation reactions and catalyzes the carbonyl reduction of several non-steroidal xenobiotics. Recent observations from experiments using selective inhibitors and studies with transgenic mice indicated a role for 11??-HSD1 in oxysterol metabolism and in bile acid homeostasis, with evidence for glucocorticoid-independent effects on gene expression. This review focuses on the promiscuity of 11??-HSD1 to accept structurally distinct substrates and discusses recent progress mainly on non-glucocorticoid substrates. This article is part of a Special Issue entitled 'Steroid/Sterol signaling'.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Odermatt</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland. Electronic address: alex.odermatt@unibas.ch.</Affiliation>
                </Author>
                <Author>
                    <LastName>Klusonova</LastName>
                    <ForeName>Petra</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Steroid Biochem Mol Biol</MedlineTA>
            <NlmUniqueID>9015483</NlmUniqueID>
            <ISSNLinking>0960-0760</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">11??-Hydroxysteroid dehydrogenase</Keyword>
            <Keyword MajorTopicYN="N">Bile acid</Keyword>
            <Keyword MajorTopicYN="N">Carbonyl reduction</Keyword>
            <Keyword MajorTopicYN="N">Cholesterol</Keyword>
            <Keyword MajorTopicYN="N">Glucocorticoid</Keyword>
            <Keyword MajorTopicYN="N">Metabolism</Keyword>
            <Keyword MajorTopicYN="N">Xenobiotic</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0960-0760(14)00190-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jsbmb.2014.08.011</ArticleId>
            <ArticleId IdType="pubmed">25151952</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151948</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0006-3002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta</Title>
                <ISOAbbreviation>Biochim. Biophys. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CNBP modulates the transcription of Wnt signalling pathway components.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1874-9399(14)00227-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbagrm.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cellular nucleic acid binding protein (CNBP) is a small and highly conserved protein with nucleic acid chaperone activity that binds single-stranded nucleic acids. Data collected so far suggests that CNBP is required for proper craniofacial development. Despite the advances achieved in the last decade, the identity of the molecular targets of CNBP responsible for its role in rostral head development remains elusive. In this work we used the CNBP single-stranded DNA-consensus binding sequence to find out putative CNBP target genes present in the human, mouse, chicken, Xenopus and zebrafish genomes. Most of the identified genes are associated with embryonic developmental processes, being three of them (cdk14, ptk7 and tcf7l2) members of the Wnt signalling pathway. This finding, along with previous one showing that CNBP down-regulates the transcription of Wnt5, aimed our work to address the role of CNBP on the WNT signalling players and pathway regulation. Experiments carried out in zebrafish developing embryos revealed that craniofacial morphology was more adversely affected as CNBP abundance decreased. Furthermore, we observed that CNBP up-regulated in a dose-dependent fashion the transcription of cdk14, ptk7 and tcf7l2, which in turn was reflected in c-myc, ccnd1 and axin2 expression. Results reveal a role of CNBP in transcriptional control of components of the Wnt signalling pathway, which might explain its requirement for proper craniofacial development.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Margarit</LastName>
                    <ForeName>Ezequiel</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Instituto de Biolog??a Molecular y Celular de Rosario (IBR), Consejo Nacional de Investigaciones Cient??ficas y T??cnicas (CONICET) - Facultad de Ciencias Bioqu??micas y Farmac??uticas, Universidad Nacional de Rosario (UNR), Ocampo y Esmeralda, (S2000FHQ) Rosario, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Armas</LastName>
                    <ForeName>Pablo</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Instituto de Biolog??a Molecular y Celular de Rosario (IBR), Consejo Nacional de Investigaciones Cient??ficas y T??cnicas (CONICET) - Facultad de Ciencias Bioqu??micas y Farmac??uticas, Universidad Nacional de Rosario (UNR), Ocampo y Esmeralda, (S2000FHQ) Rosario, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Siburu</LastName>
                    <ForeName>Nicol??s Garc??a</ForeName>
                    <Initials>NG</Initials>
                    <Affiliation>Instituto de Biolog??a Molecular y Celular de Rosario (IBR), Consejo Nacional de Investigaciones Cient??ficas y T??cnicas (CONICET) - Facultad de Ciencias Bioqu??micas y Farmac??uticas, Universidad Nacional de Rosario (UNR), Ocampo y Esmeralda, (S2000FHQ) Rosario, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Calcaterra</LastName>
                    <ForeName>Nora B</ForeName>
                    <Initials>NB</Initials>
                    <Affiliation>Instituto de Biolog??a Molecular y Celular de Rosario (IBR), Consejo Nacional de Investigaciones Cient??ficas y T??cnicas (CONICET) - Facultad de Ciencias Bioqu??micas y Farmac??uticas, Universidad Nacional de Rosario (UNR), Ocampo y Esmeralda, (S2000FHQ) Rosario, Argentina. Electronic address: calcaterra@ibr-conicet.gov.ar.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochim Biophys Acta</MedlineTA>
            <NlmUniqueID>0217513</NlmUniqueID>
            <ISSNLinking>0006-3002</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cdk14</Keyword>
            <Keyword MajorTopicYN="N">cnbp</Keyword>
            <Keyword MajorTopicYN="N">craniofacial development</Keyword>
            <Keyword MajorTopicYN="N">ptk7</Keyword>
            <Keyword MajorTopicYN="N">tcf7l2</Keyword>
            <Keyword MajorTopicYN="N">zebrafish</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1874-9399(14)00227-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbagrm.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25151948</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151929</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7549</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>What makes a good mother? Implication of inter-, and intrastrain strain &quot;cross fostering&quot; for emotional changes in mouse offspring.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0166-4328(14)00533-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbr.2014.08.021</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Currently, the mouse represents the preferred model organism among mammals used for animal studies. Due to a great availability of mutant strains it represents a standard method to analyze in vivo the effects of targeted gene manipulations. While this - at least in theory - represents a valuable tool to elucidate the pathophysiology of certain human diseases, there are several caveats which need to be considered working with animals. In our study we aimed at elucidating, how a widely established breeding strategy, i.e. the use of &quot;foster mothers&quot; to save the survival of compromised mouse pups for ongoing experiments, per se, affects the emotional phenotype of the fostered offspring. Since it is a popular method to use outbred strains like NMRI to do this job, we sought to evaluate the potential effects of such an artificial postnatal condition and compare either offspring nurtured by their biological mothers or two different strains of foster mothers. Hence we analysed changes in maternal care and later on the emotional behaviour of male and female C57BL/6 mice reared by i.) their biological C57BL/6 mothers, ii.) C57BL/6 foster mothers and iii.) NMRI foster mothers in a behavioural test battery. In addition we assessed corticosterone levels as indicator for stressphysiological changes. Besides clear differences in maternal behaviour, our study indicates an altered emotional state (i.e. differences in anxiety and depressive-like features) in mice reared by different &quot;categories&quot; of mothers, which emphasizes the importance to embed such perinatal conditions in the evaluation of animal-deriving data.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lerch</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Interfaculty Biomedical Research Facility (IBF), University of Heidelberg, Central Institute of Mental Health (ZI) Mannheim, University of Heidelberg.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brandwein</LastName>
                    <ForeName>Christiane</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Interfaculty Biomedical Research Facility (IBF), University of Heidelberg, Central Institute of Mental Health (ZI) Mannheim, University of Heidelberg.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dormann</LastName>
                    <ForeName>Christof</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Interfaculty Biomedical Research Facility (IBF), University of Heidelberg, Central Institute of Mental Health (ZI) Mannheim, University of Heidelberg.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gass</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Interfaculty Biomedical Research Facility (IBF), University of Heidelberg, Central Institute of Mental Health (ZI) Mannheim, University of Heidelberg.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chourbaji</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Interfaculty Biomedical Research Facility (IBF), University of Heidelberg, Central Institute of Mental Health (ZI) Mannheim, University of Heidelberg. Electronic address: chourbaji@uni-heidelberg.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Depression</Keyword>
            <Keyword MajorTopicYN="N">Emotional behaviour</Keyword>
            <Keyword MajorTopicYN="N">Fostering</Keyword>
            <Keyword MajorTopicYN="N">Maternal environment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-4328(14)00533-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbr.2014.08.021</ArticleId>
            <ArticleId IdType="pubmed">25151929</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151907</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>94</Volume>
                    <Issue>22</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effects of fluvastatin on expression of p38 mitogen-activated protein kinase in renal tissue ofchronic graft versus host disease lupus nephritis in mice].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1736-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the effects of fluvastatin on expression of p38 mitogen-activated protein kinase (p38MAPK) in renal tissue of chronic graft versus host disease (cGVHD) lupus nephritis in mice.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Mice were randomly divided into 4 groups of model, low-dose fluvastatin intervention (5 mg??kg(-1)??d(-1)), high-dose fluvastatin intervention (10 mg??kg(-1)??d(-1)) and normal control. The 24 h total amount of urine protein was evaluated by biuret reaction colorimetric assay. And the protein and mRNA expression levels of p38MAPK, p-p38MAPK and TGF-??1 in renal tissue were detected by immunohistochemistry, Western blot and reverse transcription-polymerase chain reaction (RT-PCR) respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the normal control group, 24 h total amount of urine protein, protein and mRNA expression levels of p38MAPK, p-p38MAPK and TGF-??1 increased significantly in the model group respectively ((7.84 ?? 0.36) vs (1.15 ?? 0.15) mg/24 h, 0.81 ?? 0.03 vs 0.50 ?? 0.01, 0.69 ?? 0.02 vs 0.10 ?? 0.01, 0.76 ?? 0.02 vs 0.28 ?? 0.02, 0.84 ?? 0.04 vs 0.25 ?? 0.02, 0.82 ?? 0.04 vs 0.12 ?? 0.02, all P &lt; 0.01). Fluvastatin treatment suppressed markedly their increased expressions (P &lt; 0.05). And high-dose fluvastatin treatment suppressed more significantly than low-dose group (P &lt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The renal protection effect of fluvastatin may be achieved by inhibiting the signal pathway of p38MAPK.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qin</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Rheumatology, Zhongda Hospital, Southeast University, Nanjing 210009, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Meimei</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Email: wmm3272142@163. com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151907</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151896</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>94</Volume>
                    <Issue>22</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effects of gender on severity and pulmonary artery vascular reactivity in chronic hypoxic pulmonary hypertension in mice].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1692-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the effects of gender on pathology and pulmonary vascular reactivity in chronic hypoxic pulmonary hypertension (HPH) in mice.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">HPH was induced by a 4-week exposure of male and female mice (8 weeks old C57BL/6, n = 15 each) to chronic hypoxia (10%O2). Normoxic controls were established both in male and female groups (n = 15 each). Right ventricular systolic pressure (RVSP) and Fulton index were detected.Isolated pulmonary artery ring contraction induced by high potassium (K(+)) and U-46619 was recorded and compared between two groups.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Chronic hypoxia induced pulmonary hypertension after 4 weeks.RVSP significantly increased both in hypoxic female and male groups (normoxic vs hypoxic: (23.40 ?? 0.16) vs (31.46 ?? 2.33) and (24.71 ?? 0.44) vs (33.66 ?? 1.38) mmHg (1 mmHg = 0.133 kPa), P = 0.029 and P &lt; 0.001).However, there were no inter-group differences (P = 0.447). The Fulton index of hypoxic female and male mice was higher than normoxic counterparts (P = 0.001, P &lt; 0.001). But there were no gender differences (P = 0.471). Contraction of high K(+) and U-46619 was calcium ion (Ca(2+))-dependent and decreased markedly without calcium (P &lt; 0.001, P = 0.007). High K(+) and U-46619-induced contraction of pulmonary artery was concentration dependent and greater in chronic hypoxic female (P = 0.002, P &lt; 0.001) and male mice (both P &lt; 0.001). But no differences existed between male and female mice in high K(+) (P = 0.657) or U-46619 (P = 0.751)-induced contraction.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No significant correlation exists between gender and occurrence and severity of pulmonary hypertension or pulmonary artery vascular reactivity in HPH mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wan</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Respiratory &amp; Pulmonary Circulation Disorders, Department of Pulmonary &amp; Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Jason X J</ForeName>
                    <Initials>JX</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miao</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhai</LastName>
                    <ForeName>Zhenguo</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Mingyuan</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Yuanhua</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Email: cyh-birm@263.net.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151896</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151848</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-3907</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of proteome research</Title>
                <ISOAbbreviation>J. Proteome Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Low levels of survival of motor neuron (SMN) protein cause the neuromuscular disease spinal muscular atrophy (SMA), characterized by degeneration of lower motor neurons and atrophy of skeletal muscle. Recent work demonstrated that low levels of SMN also trigger pathological changes in Schwann cells, leading to abnormal axon myelination and disrupted deposition of extracellular matrix proteins in peripheral nerve. However, the molecular pathways linking SMN depletion to intrinsic defects in Schwann cells remained unclear. Label-free proteomics analysis of Schwann cells isolated from SMA mouse peripheral nerve revealed widespread changes to the Schwann cell proteome, including disruption to growth/proliferation, cell death/survival, and molecular transport pathways. Functional clustering analyses revealed significant disruption to a number of proteins contributing to ubiquitination pathways, including reduced levels of ubiquitin-like modifier activating enzyme 1 (Uba1). Pharmacological suppression of Uba1 in Schwann cells was sufficient to reproduce the defective myelination phenotype seen in SMA. These findings demonstrate an important role for SMN protein and ubiquitin-dependent pathways in maintaining Schwann cell homeostasis and provide significant additional experimental evidence supporting a key role for ubiquitin pathways, and Uba1 in particular, in driving SMA pathogenesis across a broad range of cells and tissues.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Aghamaleky Sarvestany</LastName>
                    <ForeName>Arwin</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Hunter</LastName>
                    <ForeName>Gillian</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Tavendale</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Lamont</LastName>
                    <ForeName>Douglas J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author>
                    <LastName>Llavero Hurtado</LastName>
                    <ForeName>Maica</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Graham</LastName>
                    <ForeName>Laura C</ForeName>
                    <Initials>LC</Initials>
                </Author>
                <Author>
                    <LastName>Wishart</LastName>
                    <ForeName>Thomas M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author>
                    <LastName>Gillingwater</LastName>
                    <ForeName>Thomas H</ForeName>
                    <Initials>TH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Proteome Res</MedlineTA>
            <NlmUniqueID>101128775</NlmUniqueID>
            <ISSNLinking>1535-3893</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr500492j</ArticleId>
            <ArticleId IdType="pubmed">25151848</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25151744</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0513-4870</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
                <ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-circulating liposomal daptomycin enhances protection against systemic methicillin-resistant Staphylococcus aureus infection with improved therapeutic potential.</ArticleTitle>
            <Pagination>
                <MedlinePgn>701-10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In the face of escalating problems with pathogen control, the development of proper formulations of existing antibiotics is as important as the development of novel antibiotics. Daptomycin is a lipopeptide antibiotic with potent activity against Gram-positive bacteria. Currently, only injectable solution of daptomycin has been approved for clinical use. In the present study, the formulation of PEGylated liposomal daptomycin (PLD) was prepared and optimized, and its efficacy against methicillin-resistant Staphylococcus aureus (MRSA252) strains was investigated. The obtained PLD had a mean vesicle diameter of (111.5 +/- 15.4) nm and a mean percent drug loading of (5.81 +/- 0.19) % with high storage stability. Potent activity of PLD against MRSA was demonstrated in vitro with a more sustained effect than that of conventional liposomal daptomycin and daptomycin solution. In addition, intravenous administration of a single dose (equal to human use) of PLD significantly increased the survival of mice in a MRSA252 systemic infection model compared with other formulations. Drug distribution in the lung was significantly enhanced following administration of PLD, and no measurable tissue lesions or pathological changes were detected during PLD treatment. Taken together, PEGylated liposomes loaded with daptomycin may represent a promising approach to reduce MRSA252 infections, especially those involving bloodstream dissemination, such as hematogenous pulmonary infection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xing-Liang</ForeName>
                    <Initials>XL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Ting-Ting</ForeName>
                    <Initials>TT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yan-Hong</ForeName>
                    <Initials>YH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Zhang-Bao</ForeName>
                    <Initials>ZB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chong</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Yao Xue Xue Bao</MedlineTA>
            <NlmUniqueID>21710340R</NlmUniqueID>
            <ISSNLinking>0513-4870</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151744</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25151732</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0513-4870</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
                <ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effect of a novel selective S1P1 agonist, Syl948, on mouse skin transplantation].</ArticleTitle>
            <Pagination>
                <MedlinePgn>627-31</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Syl948 is a synthesized selective S1P1 agonist with novel structure. HTRF-IP1 test indicated that Syl948-P, the active form of Syl948 in vitro, has strong activity against S1P1 (EC50: 83 +/- 16 nmol x L(-1)), but its effect on S1P3 was very weak (EC50: 1 026 +/- 90 nmol x L(-1)). In SD rats, oral administration of Syl948 10 mg x kg(-1) significantly decreased the peripheral blood lymphocytes (PBL), with the maximal PBL inhibition rate of 63%, which was as similar as equal dose of fingolimod (FTY720). Oral administration of Syl948 10 mg x kg(-1) had no effect on heart rate of SD rats, which was better than FTY720. Daily oral administration with Syl948 (2 or 4 mg x kg(-1)) significantly prolonged the survival time of the allografts of skin slice on mice. In summary, the above results demonstrated that Syl948 has great selectivity in vitro and good activity in vivo, which indicated its potential use as an anti-rejection drug in skin transplantation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Hai-Jing</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xiao-Jian</ForeName>
                    <Initials>XJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Wan-Qi</ForeName>
                    <Initials>WQ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Da-Li</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiao-Guang</ForeName>
                    <Initials>XG</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Yao Xue Xue Bao</MedlineTA>
            <NlmUniqueID>21710340R</NlmUniqueID>
            <ISSNLinking>0513-4870</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151732</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25151731</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0513-4870</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
                <ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[A novel HIF-1 inhibitor--manassantin A derivative LXY6099 inhibits tumor growth].</ArticleTitle>
            <Pagination>
                <MedlinePgn>622-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor on hypoxia responses in mammalian tissues. HIF-1 plays as a positive factor in solid tumor and leads to hypoxia-driven responses that enhance its downstream gene expression for tumor growth and survival. LXY6099 was obtained by the structural modification and optimization of manassantin A (MA) as a high potent HIF-1 inhibitor. Antitumor activity of LXY6099 was observed in this study. LXY6099 with an IC50 value of 2.46 x 10(-10) mol x L(-1) showed more sensitive inhibition activity to HIF-1 than that of MA detected by reporter gene assay (&gt; 100 folds). It showed strong inhibition on the growth of human solid tumor cell lines. Furthermore, LXY6099 exhibited significant antitumor activity against established human tumor xenografts in nu/nu mice with treatment of MX-1 breast cancer. Thus, LXY6099 as a novel HIF-1 inhibitor could be further developed into anti-cancer agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Fang-Fang</ForeName>
                    <Initials>FF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Xiao-Yu</ForeName>
                    <Initials>XY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Li-Wei</ForeName>
                    <Initials>LW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiao-Guang</ForeName>
                    <Initials>XG</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Yao Xue Xue Bao</MedlineTA>
            <NlmUniqueID>21710340R</NlmUniqueID>
            <ISSNLinking>0513-4870</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151731</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25151730</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0513-4870</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
                <ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Mycelium of Hirsutella hepiali Chen et Shen activates autophagy and protects against metabolic syndrome in mice fed with high fat diet].</ArticleTitle>
            <Pagination>
                <MedlinePgn>615-21</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>To investigate the protective effects and possible mechanism of Mycelium of Hirsutella hepiali Chen et Shen (MHCS) on metabolic syndromes, free fatty acid and MHCS-treated hepatocytes were used for detecting autophagy-related LC3, p62 and lipid accumulation. Moreover, high fat diet fed mice were used to establish metabolic syndromes model. 50-weeks age mice were randomly divided into: control group, model group and MHCS group. At 80-weeks age, 15 mice were randomly chosen from each group separately for examining oral glucose tolerance, serum insulin, insulin-like growth factor 1 (IGF-1), hepatic LC3, p62, p-NF-kappaB p65, NF-kappaB p65, IL-6 and CXCL-8. Moreover, insulin resistance index (IRI) was calculated. Hepatic pathological changes, including vacuoles, lipids accumulation and fibrosis were observed. Remaining mice were fed with diet separately to 110 weeks-age for statistics of mortality. MHCS promoted autophagy of free fatty acid treated hepatocytes. Mice fed with high fat plus MHCS diet exhibited improved oral glucose tolerance, insulin resistance, hepatic pathology, inflammation, mortality and activated autophagy. The protective effects of MHCS against metabolic syndroms might be through the activation of hepatic autophagy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Xiao-Ming</ForeName>
                    <Initials>XM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Zhuo-Wei</ForeName>
                    <Initials>ZW</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Yao Xue Xue Bao</MedlineTA>
            <NlmUniqueID>21710340R</NlmUniqueID>
            <ISSNLinking>0513-4870</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151730</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151659</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>4</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Myeloid-derived suppressor cells (MDSCs) exhibit potent immunosuppressive activities in cancer. MDSCs infiltrate tumors and strongly inhibit cancer-specific cytotoxic T cells. Their mechanism of differentiation and identification of MDSC-specific therapeutic targets are major areas of interest. We have devised a highly efficient and rapid method to produce very large numbers of melanoma-infiltrating MDSCs ex vivo without inducing tumors in mice. These MDSCs were used to study their differentiation, immunosuppressive activities and were compared to non-neoplastic counterparts and conventional dendritic cells using unbiased systems biology approaches. Differentially activated/deactivated pathways caused by cell type differences and by the melanoma tumor environment were identified. MDSCs increased the expression of trafficking receptors to sites of inflammation, endocytosis, changed lipid metabolism, and up-regulated detoxification pathways such as the expression of P450 reductase. These studies uncovered more than 60 potential novel therapeutic targets. As a proof of principle, we demonstrate that P450 reductase is the target of pro-drugs such as Paclitaxel, which depletes MDSCs following chemotherapy in animal models of melanoma and in human patients. Conversely, P450 reductase protects MDSCs against the cytotoxic actions of other chemotherapy drugs such as Irinotecan, which is ineffective for the treatment of melanoma.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liechtenstein</LastName>
                    <ForeName>Therese</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Division of infection and immunity. Rayne Institute. 5 University Street. WC1E 6JF. London. UK. Immunomodulation group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Perez-Janices</LastName>
                    <ForeName>Noemi</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Division of infection and immunity. Rayne Institute. 5 University Street. WC1E 6JF. London. UK. Cancer Epigenetics group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gato</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Immunomodulation group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Caliendo</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Immunomodulation group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kochan</LastName>
                    <ForeName>Grazyna</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Immunomodulation group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Blanco-Luquin</LastName>
                    <ForeName>Idoia</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Cancer Epigenetics group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Van der Jeught</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Therapy. Department of Biomedical Sciences. Laarbeeklaan, 103/E, B-1090 Jette. Vrije Universiteit Brussel, Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Arce</LastName>
                    <ForeName>Frederick</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Division of infection and immunity. Rayne Institute. 5 University Street. WC1E 6JF. London. UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guerrero-Setas</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Cancer Epigenetics group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fernandez-Irigoyen</LastName>
                    <ForeName>Joaquin</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Proteomics Unit. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Santamaria</LastName>
                    <ForeName>Enrique</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Proteomics Unit. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Breckpot</LastName>
                    <ForeName>Karine</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Proteomics Unit. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Escors</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Division of infection and immunity. Rayne Institute. 5 University Street. WC1E 6JF. London. UK. Immunomodulation group. Navarrabiomed-FMS, calle Irunlarrea 3, 31008 Pamplona, Navarra, Spain.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2279</ArticleId>
            <ArticleId IdType="pubmed">25151659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151644</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-953X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurobiology of disease</Title>
                <ISOAbbreviation>Neurobiol. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0969-9961(14)00243-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.nbd.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Vascular endothelial growth factor-A (VEGF-A) is best known as a key regulator of the formation of new blood vessels. Neutralization of VEGF-A with anti-VEGF therapy e.g. bevacizumab, can be painful, and this is hypothesized to result from a loss of VEGF-A-mediated neuroprotection. The multiple vegf-a gene products consist of two alternatively spliced families, typified by VEGF-A165a and VEGF-A165b (both contain 165 amino acids), both of which are neuroprotective. Under pathological conditions, such as in inflammation and cancer, the pro-angiogenic VEGF-A165a is upregulated and predominates over the VEGF-A165b isoform. We show here that in rats and mice VEGF-A165a and VEGF-A165b have opposing effects on pain, and that by blocking the proximal splicing event - leading to the preferential expression of VEGF-A165b over VEGF165a- prevents pain in vivo. VEGF-A165a sensitizes peripheral nociceptive neurons through actions on VEGFR2 and a TRPV1-dependent mechanism, thus enhancing nociceptive signaling. VEGF-A165b blocks the effect of VEGF-A165a. After nerve injury, the endogenous balance of VEGF-A isoforms switches to greater expression of VEGF-Axxxa compared to VEGF-Axxxb, through an SRPK1-dependent pre-mRNA splicing mechanism. Pharmacological inhibition of SRPK1 after traumatic nerve injury selectively reduced VEGF-Axxxa expression and reversed associated neuropathic pain. Exogenous VEGF-A165b also ameliorated neuropathic pain. We conclude that the relative levels of alternatively spliced VEGF-A isoforms are critical for pain modulation under both normal conditions and in sensory neuropathy. Altering VEGF-Axxxa/VEGF-Axxxb balance by targeting alternative RNA splicing may be a new analgesic strategy.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hulse</LastName>
                    <ForeName>R P</ForeName>
                    <Initials>RP</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; Cancer Biology, Division of Cancer and Stem Cells, School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Beazley-Long</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; School of Life Sciences, The Medical School, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hua</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kennedy</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Prager</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bevan</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Qiu</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fernandes</LastName>
                    <ForeName>E S</ForeName>
                    <Initials>ES</Initials>
                    <Affiliation>King's College London, London SE1 9NH, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gammons</LastName>
                    <ForeName>M V</ForeName>
                    <Initials>MV</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ballmer-Hofer</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Paul Scherrer Institut, 5232 Villigen, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gittenberger de Groot</LastName>
                    <ForeName>A C</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Anatomy and Embryology, Leiden University Medical Centre, 2300 RC, Leiden, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Churchill</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Clinical Sciences, University of Bristol, Bristol BS1 2LX, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Harper</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brain</LastName>
                    <ForeName>S D</ForeName>
                    <Initials>SD</Initials>
                    <Affiliation>King's College London, London SE1 9NH, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bates</LastName>
                    <ForeName>D O</ForeName>
                    <Initials>DO</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; Cancer Biology, Division of Cancer and Stem Cells, School of Medicine. Electronic address: David.Bates@nottingham.ac.uk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Donaldson</LastName>
                    <ForeName>L F</ForeName>
                    <Initials>LF</Initials>
                    <Affiliation>Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; School of Life Sciences, The Medical School, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH. Electronic address: Lucy.Donaldson@nottingham.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurobiol Dis</MedlineTA>
            <NlmUniqueID>9500169</NlmUniqueID>
            <ISSNLinking>0969-9961</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alternative mRNA splicing</Keyword>
            <Keyword MajorTopicYN="N">Vascular endothelial growth factor A</Keyword>
            <Keyword MajorTopicYN="N">neuropathy</Keyword>
            <Keyword MajorTopicYN="N">nociceptors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0969-9961(14)00243-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.nbd.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25151644</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151619</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7549</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pathogenic Tau Species Drive a Psychosis-Like Phenotype in a Mouse Model of Alzheimer's Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0166-4328(14)00542-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbr.2014.08.030</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Psychotic Alzheimer's disease (AD+P) is a rapidly progressive variant of AD associated with an increased burden of frontal tau pathology that affects up to 50% of those with AD, and is observed more commonly in females. To date, there are no safe and effective medication interventions with an indication for treatment in this condition, and there has been only very limited exploration of potential animal models for pre-clinical drug development. Pathogenic tau is over represented in the frontal cortex in AD+P, especially in females. In order to develop a candidate animal model of AD+P, we employed a tau mouse model with a heavy burden of frontal tau pathology, the rTg(tauP301L)4510 mouse, hereafter termed rTg4510. We explored deficits of prepulse inhibition of acoustic startle (PPI), a model of psychosis in rodents, and the correlation between pathogenic phospho-tau species associated with AD+P and PPI deficits in female mice. We found that female rTg4510 mice exhibit increasing PPI deficits relative to littermate controls from 4.5 to 5.5 months of age, and that these deficits are driven by insoluble fractions of the phospho-tau species pSer396/404, pSer202, and pThr231 found to be associated with human AD+P. This preliminary data suggests the utility of the rTg4510 mouse as a candidate disease model of human female AD+P. Further work expanded to include both genders and other behavioral outcome measures relevant to AD+P is necessary.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Koppel</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset. Electronic address: jkoppel@nshs.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jimenez</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Azose</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Touro College, Brooklyn, NY.</Affiliation>
                </Author>
                <Author>
                    <LastName>D'Abramo</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Acker</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Buthorn</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Greenwald</LastName>
                    <ForeName>Bs</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lewis</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, FL.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lesser</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Hofstra University, Hempstead LI.</Affiliation>
                </Author>
                <Author>
                    <LastName>Davies</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>The Feinstein Institute for Medical Research. Manhasset.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Acoustic Startle</Keyword>
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">Prepulse inhibition</Keyword>
            <Keyword MajorTopicYN="N">Psychosis</Keyword>
            <Keyword MajorTopicYN="N">Tangles</Keyword>
            <Keyword MajorTopicYN="N">Tau</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-4328(14)00542-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbr.2014.08.030</ArticleId>
            <ArticleId IdType="pubmed">25151619</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151611</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1876-7753</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cell research</Title>
                <ISOAbbreviation>Stem Cell Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The organoid-initiating cells in mouse pancreas and liver are phenotypically and functionally similar.</ArticleTitle>
            <Pagination>
                <MedlinePgn>275-283</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S1873-5061(14)00087-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.scr.2014.07.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Pancreatic Lgr5 expression has been associated with organoid-forming epithelial progenitor populations but the identity of the organoid-initiating epithelial cell subpopulation has remained elusive. Injury causes the emergence of an Lgr5(+) organoid-forming epithelial progenitor population in the adult mouse liver and pancreas. Here, we define the origin of organoid-initiating cells from mouse pancreas and liver prior to Lgr5 activation. This clonogenic population was defined as MIC1-1C3(+)/CD133(+)/CD26(-) in both tissues and the frequency of organoid initiation within this population was approximately 5% in each case. The transcriptomes of these populations overlapped extensively and showed enrichment of epithelial progenitor-associated regulatory genes such as Sox9 and FoxJ1. Surprisingly, pancreatic organoid cells also had the capacity to generate hepatocyte-like cells upon transplantation to Fah(-/-) mice, indicating a differentiation capacity similar to hepatic organoids. Although spontaneous endocrine differentiation of pancreatic progenitors was not observed in culture, adenoviral delivery of fate-specifying factors Pdx1, Neurog3 and MafA induced insulin expression without glucagon or somatostatin. Pancreatic organoid cultures therefore preserve many key attributes of progenitor cells while allowing unlimited expansion, facilitating the study of fate determination.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dorrell</LastName>
                    <ForeName>Craig</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tarlow</LastName>
                    <ForeName>Branden</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yuhan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Canaday</LastName>
                    <ForeName>Pamela S</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haft</LastName>
                    <ForeName>Annelise</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schug</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Streeter</LastName>
                    <ForeName>Philip R</ForeName>
                    <Initials>PR</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Finegold</LastName>
                    <ForeName>Milton J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shenje</LastName>
                    <ForeName>Lincoln T</ForeName>
                    <Initials>LT</Initials>
                    <Affiliation>OHSU Knight Cardiovascular Institute, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kaestner</LastName>
                    <ForeName>Klaus H</ForeName>
                    <Initials>KH</Initials>
                    <Affiliation>Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grompe</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Oregon Stem Cell Center, Oregon Health &amp; Science University, Portland, OR 97239, USA. Electronic address: grompem@ohsu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cell Res</MedlineTA>
            <NlmUniqueID>101316957</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1873-5061(14)00087-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.scr.2014.07.006</ArticleId>
            <ArticleId IdType="pubmed">25151611</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151530</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0720</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title>
                <ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Parameter optimization toward optimal microneedle-based dermal vaccination.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0928-0987(14)00313-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejps.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Microneedle-based vaccination has several advantages over vaccination by using conventional hypodermic needles. Microneedles are used to deliver a drug into the skin in a minimally-invasive and potentially pain free manner. Besides, the skin is a potent immune organ that is highly suitable for vaccination. However, there are several factors that influence the penetration ability of the skin by microneedles and the immune responses upon microneedle-based immunization. In this study we assessed several different microneedle arrays for their ability to penetrate ex vivo human skin by using trypan blue and (fluorescently or radioactively labeled) ovalbumin. Next, these different microneedles and several factors, including the dose of ovalbumin, the effect of using an impact-insertion applicator, skin location of microneedle application, and the area of microneedle application, were tested in vivo in mice. The penetration ability and the dose of ovalbumin that is delivered into the skin were shown to be dependent on the use of an applicator and on the microneedle geometry and size of the array. Besides microneedle penetration, the above described factors influenced the immune responses upon microneedle-based vaccination in vivo. It was shown that the ovalbumin-specific antibody responses upon microneedle-based vaccination could be increased up to 12 fold when an impact-insertion applicator was used, up to 8 fold when microneedles were applied over a larger surface area, and up to 36 fold dependent on the location of microneedle application. Therefore, these influencing factors should be considered to optimize microneedle-based dermal immunization technologies.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>van der Maaden</LastName>
                    <ForeName>Koen</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Varypataki</LastName>
                    <ForeName>Eleni Maria</ForeName>
                    <Initials>EM</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Huixin</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Romeijn</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiskoot</LastName>
                    <ForeName>Wim</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bouwstra</LastName>
                    <ForeName>Joke</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands. Electronic address: bouwstra@lacdr.leidenuniv.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Pharm Sci</MedlineTA>
            <NlmUniqueID>9317982</NlmUniqueID>
            <ISSNLinking>0928-0987</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">(trans)dermal drug delivery</Keyword>
            <Keyword MajorTopicYN="N">Microneedles</Keyword>
            <Keyword MajorTopicYN="N">Vaccine delivery</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0928-0987(14)00313-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejps.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25151530</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151501</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-3279</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Immunobiology</Title>
                <ISOAbbreviation>Immunobiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0171-2985(14)00132-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.imbio.2014.07.019</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lymph node cells (LNC) from SJL (H-2(s)) and BALB/c (H-2(d)) mice primed once with inactivated botulinum neurotoxin type A (BoNT/A) were examined for their T-cell responses to each of 32 synthetic overlapping peptides (19 residues each, L1-L32) that encompass the entire L chain (residues 1-448) of BoNT/A. LNC of SJL gave strong responses to 6 regions on, L2 (residues 15-23), L10/11/12 (127-173), L19 (253-271) and L21 (281-299), and moderate to weak responses to L9 (113-131), L14/15 (183-215) and L27 (365-383). In BALB/c, LNC gave a substantial T-cell response only against peptide L12 (residues 155-173), and responded very weakly to 9 other peptides. The results were compared with the recognition profiles determined previously in these two strains after multiple BoNT/A injections. Overall responses to the L-chain peptides of T cells in later profiles were found to be somewhat weakened in SJL and stayed essentially at a similar level in BALB/c, although responses to BoNT/A increased. In SJL, response to L10 (127-145) remained the highest in the later profile. Strong responses against L12 (155-173) observed in both strains at early stage were reduced to an insignificant level. Cross-reactivity to tetanus neurotoxin by BoNT/A-specific T cells was observed in SJL but not in BALB/c. Design of an effective synthetic peptide vaccine will require incorporation of both T cell- and Ab-recognition elements of the BoNT molecule. Significance and possible implications of these results on BoNT/A-specific T-cell responses of BoNT-treated patients are discussed.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier GmbH. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Oshima</LastName>
                    <ForeName>Minako</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Roger Aoki</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Allergan Inc., Irvine, CA 92612, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zouhair Atassi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: matassi@bcm.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Immunobiology</MedlineTA>
            <NlmUniqueID>8002742</NlmUniqueID>
            <ISSNLinking>0171-2985</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Botulinum neurotoxin type A</Keyword>
            <Keyword MajorTopicYN="N">L chain</Keyword>
            <Keyword MajorTopicYN="N">MHC control</Keyword>
            <Keyword MajorTopicYN="N">Synthetic peptides</Keyword>
            <Keyword MajorTopicYN="N">T cell epitopes</Keyword>
            <Keyword MajorTopicYN="N">T cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0171-2985(14)00132-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.imbio.2014.07.019</ArticleId>
            <ArticleId IdType="pubmed">25151501</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151491</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-2916</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature immunology</Title>
                <ISOAbbreviation>Nat. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/ni.2967</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The paradigm that macrophages that reside in steady-state tissues are derived from embryonic precursors has never been investigated in the intestine, which contains the largest pool of macrophages. Using fate-mapping models and monocytopenic mice, together with bone marrow chimera and parabiotic models, we found that embryonic precursor cells seeded the intestinal mucosa and demonstrated extensive in situ proliferation during the neonatal period. However, these cells did not persist in the intestine of adult mice. Instead, they were replaced around the time of weaning by the chemokine receptor CCR2-dependent influx of Ly6C(hi) monocytes that differentiated locally into mature, anti-inflammatory macrophages. This process was driven largely by the microbiota and had to be continued throughout adult life to maintain a normal intestinal macrophage pool.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bain</LastName>
                    <ForeName>Calum C</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>1] Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, Scotland, UK. [2] [3].</Affiliation>
                </Author>
                <Author>
                    <LastName>Bravo-Blas</LastName>
                    <ForeName>Alberto</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, Scotland, UK. [2].</Affiliation>
                </Author>
                <Author>
                    <LastName>Scott</LastName>
                    <ForeName>Charlotte L</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>1] Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, Scotland, UK. [2].</Affiliation>
                </Author>
                <Author>
                    <LastName>Perdiguero</LastName>
                    <ForeName>Elisa Gomez</ForeName>
                    <Initials>EG</Initials>
                    <Identifier Source="ORCID">0000000277177897</Identifier>
                    <Affiliation>1] Centre for Molecular and Cellular Biology of Inflammation, New Hunt's House, King's College London, London, UK. [2] Peter Gorer Department of Immunobiology, King's College London, London, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Geissmann</LastName>
                    <ForeName>Frederic</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>1] Centre for Molecular and Cellular Biology of Inflammation, New Hunt's House, King's College London, London, UK. [2] Peter Gorer Department of Immunobiology, King's College London, London, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Henri</LastName>
                    <ForeName>Sandrine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] Centre d'Immunologie de Marseille-Luminy, Aix Marseille Universit??, Marseille, France. [2] INSERM U1104, Marseille, France. [3] CNRS UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malissen</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] Centre d'Immunologie de Marseille-Luminy, Aix Marseille Universit??, Marseille, France. [2] INSERM U1104, Marseille, France. [3] CNRS UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Osborne</LastName>
                    <ForeName>Lisa C</ForeName>
                    <Initials>LC</Initials>
                    <Affiliation>Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Artis</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>1] Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. [2] Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mowat</LastName>
                    <ForeName>Allan McI</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, Scotland, UK.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Immunol</MedlineTA>
            <NlmUniqueID>100941354</NlmUniqueID>
            <ISSNLinking>1529-2908</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ni.2967</ArticleId>
            <ArticleId IdType="doi">10.1038/ni.2967</ArticleId>
            <ArticleId IdType="pubmed">25151491</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151489</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1529-2916</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature immunology</Title>
                <ISOAbbreviation>Nat. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>B cell homeostasis and follicle confines are governed by fibroblastic reticular cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/ni.2965</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Fibroblastic reticular cells (FRCs) are known to inhabit T cell-rich areas of lymphoid organs, where they function to facilitate interactions between T cells and dendritic cells. However, in vivo manipulation of FRCs has been limited by a dearth of genetic tools that target this lineage. Here, using a mouse model to conditionally ablate FRCs, we demonstrated their indispensable role in antiviral T cell responses. Unexpectedly, loss of FRCs also attenuated humoral immunity due to impaired B cell viability and follicular organization. Follicle-resident FRCs established a favorable niche for B lymphocytes via production of the cytokine BAFF. Thus, our study indicates that adaptive immunity requires an intact FRC network and identifies a subset of FRCs that control B cell homeostasis and follicle identity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cremasco</LastName>
                    <ForeName>Viviana</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>1] Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA. [2].</Affiliation>
                </Author>
                <Author>
                    <LastName>Woodruff</LastName>
                    <ForeName>Matthew C</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>1] Program in Cellular and Molecular Medicine, Children's Hospital, Boston, Massachusetts, USA. [2] Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts, USA. [3].</Affiliation>
                </Author>
                <Author>
                    <LastName>Onder</LastName>
                    <ForeName>Lucas</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Institute of Immunobiology, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cupovic</LastName>
                    <ForeName>Jovana</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute of Immunobiology, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nieves-Bonilla</LastName>
                    <ForeName>Janice M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schildberg</LastName>
                    <ForeName>Frank A</ForeName>
                    <Initials>FA</Initials>
                    <Affiliation>Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>1] Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA. [2] Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cremasco</LastName>
                    <ForeName>Floriana</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>1] Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Pharmacology, University of Milan, Milan, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Harvey</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wucherpfennig</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ludewig</LastName>
                    <ForeName>Burkhard</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Immunobiology, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carroll</LastName>
                    <ForeName>Michael C</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>1] Program in Cellular and Molecular Medicine, Children's Hospital, Boston, Massachusetts, USA. [2] Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Turley</LastName>
                    <ForeName>Shannon J</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>1] Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA. [3].</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Immunol</MedlineTA>
            <NlmUniqueID>100941354</NlmUniqueID>
            <ISSNLinking>1529-2908</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ni.2965</ArticleId>
            <ArticleId IdType="doi">10.1038/ni.2965</ArticleId>
            <ArticleId IdType="pubmed">25151489</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151457</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2430</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental neurology</Title>
                <ISOAbbreviation>Exp. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Osteopontin Expression in Acute Immune Response Mediates Hippocampal Synaptogenesis and Adaptive Outcome Following Cortical Brain Injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4886(14)00267-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.expneurol.2014.08.015</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Traumatic brain injury (TBI) produces axotomy, deafferentation and reactive synaptogenesis. Inflammation influences synaptic repair, and the novel brain cytokine osteopontin (OPN) has potential to support axon regeneration through exposure of its integrin receptor binding sites. This study explored whether OPN secretion and proteolysis by matrix metalloproteinases (MMPs) mediate the initial degenerative phase of synaptogenesis, targeting reactive neuroglia to affect successful repair. Adult rats received unilateral entorhinal cortex lesion (UEC) modeling adaptive synaptic plasticity. Over the first week postinjury, hippocampal OPN protein and mRNA were assayed and histology performed. At 1-2d, OPN protein increased up to 51 fold, and was localized within activated, mobilized glia. OPN transcript also increased over 50 fold, predominantly within reactive microglia. OPN fragments known to be derived from MMP proteolysis were elevated at 1d, consistent with prior reports of UEC glial activation and enzyme production. Postinjury minocycline immunosuppression attenuated MMP-9 gelatinase activity, which was correlated with reduction of neutrophil gelatinase-associated lipocalin (LCN2) expression, and reduced OPN fragment generation. The antibiotic also attenuated removal of synapsin-1 positive axons from the deafferented zone. OPN KO mice subjected to UEC had similar reduction of hippocampal MMP-9 activity, as well as lower synapsin-1 breakdown over the deafferented zone. MAP1B and N-cadherin, surrogates of cytoarchitecture and synaptic adhesion, were not affected. OPN KO mice with UEC exhibited time dependent cognitive deficits during the synaptogenic phase of recovery. This study demonstrates that OPN can mediate immune response during TBI synaptic repair, positively influencing synapse reorganization and functional recovery.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chan</LastName>
                    <ForeName>Julie L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Anatomy and Neurobiology, Virginia Commonwealth University, P.O. Box 980709, Richmond, VA 23298.</Affiliation>
                </Author>
                <Author>
                    <LastName>Reeves</LastName>
                    <ForeName>Thomas M</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>Department of Anatomy and Neurobiology, Virginia Commonwealth University, P.O. Box 980709, Richmond, VA 23298.</Affiliation>
                </Author>
                <Author>
                    <LastName>Phillips</LastName>
                    <ForeName>Linda L</ForeName>
                    <Initials>LL</Initials>
                    <Affiliation>Department of Anatomy and Neurobiology, Virginia Commonwealth University, P.O. Box 980709, Richmond, VA 23298. Electronic address: llphilli@vcu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Neurol</MedlineTA>
            <NlmUniqueID>0370712</NlmUniqueID>
            <ISSNLinking>0014-4886</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-4886(14)00267-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.expneurol.2014.08.015</ArticleId>
            <ArticleId IdType="pubmed">25151457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151393</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2190-5215</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in neurobiology</Title>
                <ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ganglioside storage diseases: on the road to management.</ArticleTitle>
            <Pagination>
                <MedlinePgn>485-99</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1154-7_22</ELocationID>
            <Abstract>
                <AbstractText>Although the biochemical and genetic basis for the GM1 and GM2 gangliosidoses has been known for decades, effective therapies for these diseases remain in early stages of development. The difficulty with many therapeutic strategies for treating the gangliosidoses comes largely from their inability to remove stored ganglioside once it accumulates in central nervous system (CNS) neurons and glia. This chapter highlights advances made using substrate reduction therapy and gene therapy in reducing CNS ganglioside storage. Information obtained from mouse and feline models provides insight on therapeutic strategies that could be effective in human clinical trials. In addition, information is presented showing how a calorie-restricted diet might facilitate therapeutic drug delivery to the CNS. The development of multiple new therapeutic approaches offers hope that longer-term management of these diseases can be achieved. It is also clear that multiple therapeutic strategies will likely be needed to provide the most complete management.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Seyfried</LastName>
                    <ForeName>Thomas N</ForeName>
                    <Initials>TN</Initials>
                    <Affiliation>Biology Department, Boston College, Chestnut Hill, MA, 02467, USA, seyfridt@bc.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rockwell</LastName>
                    <ForeName>Hannah E</ForeName>
                    <Initials>HE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heinecke</LastName>
                    <ForeName>Karie A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Douglas R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sena-Esteves</LastName>
                    <ForeName>Miguel</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Neurobiol</MedlineTA>
            <NlmUniqueID>101571545</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1154-7_22</ArticleId>
            <ArticleId IdType="pubmed">25151393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151385</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2190-5215</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in neurobiology</Title>
                <ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glycosphingolipids in the regulation of the nervous system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>307-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1154-7_14</ELocationID>
            <Abstract>
                <AbstractText>The highest expression of gangliosides, sialic acid-containing glycosphingolipids (GSLs), is found in the nervous tissue of vertebrates. Changes in the profiles of gangliosides during the development of nervous tissues indicate that they are involved in the regulation of neurogenesis and synaptogenesis. Their distinct distribution patterns support the suggestion that they are involved in both the differentiation and function of neural cells. In addition to results of studies of GSLs done using biochemical, histopathological, and cell biological approaches, recent progress in the genetic engineering of glycosyltransferase genes has resulted in novel findings and concepts about their roles in the nervous system. Roles of GSLs in the regulation of signaling that determine cell fates in membrane microdomains such as lipid rafts have been extensively studied. In particular, gene targeting of glycosyltransferases in mice has enabled investigation of the in vivo functions of GSLs. The majority of abnormal phenotypes exhibited by knockout (KO) mice may reflect an abnormal structure and a resultant altered function of lipid rafts caused by alterations in their GSL composition. Generally speaking, abnormal phenotypes found in most KO mice were milder than expected, suggesting that the remaining GSLs compensate for the functions of those lost. There are also functions that cannot be replaced by the remaining GSLs. Thus, there may be two modes of function of GSLs: one is nonspecific and can be carried out by multiple GSLs, the second mode is that in which the function of the missing GSL(s) cannot be compensated by others. Identification of natural ligands for individual GSLs is crucial in order to clarify the functions of each structure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Furukawa</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan, koichi@med.nagoya-u.ac.jp.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohmi</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohkawa</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tajima</LastName>
                    <ForeName>Orie</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furukawa</LastName>
                    <ForeName>Keiko</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Neurobiol</MedlineTA>
            <NlmUniqueID>101571545</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1154-7_14</ArticleId>
            <ArticleId IdType="pubmed">25151385</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151382</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2190-5215</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in neurobiology</Title>
                <ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of myelin-associated glycoprotein (siglec-4a) in the nervous system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>245-62</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1154-7_11</ELocationID>
            <Abstract>
                <AbstractText>Myelin-associated glycoprotein (MAG) is a 100 kDa glycoprotein located at the innermost layer of myelin sheets that remains in intimate contact with the axonal membrane. It is selectively expressed by myelinating cells including Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS). Due to its selective location and its effects on neurons, it was originally thought to be involved in axon-glia communication. The generation of MAG-deficient mice greatly expanded our knowledge about the physiological role of MAG, which helped to establish its critical roles in the normal formation and maintenance of myelinated axons. Interest in MAG was revived when it was described as the first myelin-derived inhibitor of axon regeneration. Since then numerous publications have provided detailed information about its axonal receptors and their signaling pathways. Recently, the nurture role of MAG on neurons was confirmed. On the other hand, MAG mediates signals coming from the axons that strongly impact on oligodendrocytes and Schwann cells, highlighting the bidirectional nature of axon-glia communication. Overall, MAG is a critical component of axon-glia interactions with multiple functions in the biology of both neurons and glial cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lopez</LastName>
                    <ForeName>Pablo H H</ForeName>
                    <Initials>PH</Initials>
                    <Affiliation>Laboratorio de Neurobiolog??a, Instituto de Investigaci??n M??dica Mercedes y Mart??n Ferreyra, INIMEC-CONICET-Universidad Nacional de C??rdoba, C??rdoba, Argentina, phhlopez@immf.uncor.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Neurobiol</MedlineTA>
            <NlmUniqueID>101571545</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1154-7_11</ArticleId>
            <ArticleId IdType="pubmed">25151382</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151377</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2190-5215</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in neurobiology</Title>
                <ISOAbbreviation>Adv Neurobiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Use of glycan-targeted antibodies/lectins to study the expression/function of glycosyltransferases in the nervous system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>117-27</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1154-7_6</ELocationID>
            <Abstract>
                <AbstractText>In the nervous system, various unique glycans not found in other tissues are expressed on glycoproteins, and their expression/functions have been studied using specific antibodies/lectins. Among brain-specific glycans in mammals, we focus on human natural killer-1 (HNK-1) and related Cat-315 epitopes, which can be detected using specific antibodies. It is known that the HNK-1 epitope is expressed on N- and O-mannosylated glycans and that Cat-315 mAb preferentially recognizes the HNK-1 epitope on brain-specific &quot;branched O-mannose glycan.&quot; The ??1,6-branched O-mannose structure is synthesized by a brain-specific glycosyltransferase, N-acetylglucosaminyltransferase-IX (GnT-IX, also designated as GnT-Vb). Using GnT-IX gene-deficient mice and specific antibodies/lectins, the function of GnT-IX was found to be quite different from that of its ubiquitous homologue, GnT-V. Using Cat-315 mAb, the receptor protein tyrosine phosphatase-beta (RPTP??) was identified as an in vivo target glycoprotein for GnT-IX. Analysis of the function of branched O-mannose glycan on RPTP?? indicated that its loss promoted the recovery process after myelin injury (called remyelination) in brain and that this phenomenon is probably caused in vivo by reduced activation of astrocytes in GnT-IX-deficient brain.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kizuka</LastName>
                    <ForeName>Yasuhiko</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Disease Glycomics Team, Systems Glycobiology Research Group, RIKEN-Max Planck Joint Research Center, Global Research Cluster, RIKEN, Hirosawa, Wako, Saitama, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanekiyo</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitazume</LastName>
                    <ForeName>Shinobu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taniguchi</LastName>
                    <ForeName>Naoyuki</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Neurobiol</MedlineTA>
            <NlmUniqueID>101571545</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1154-7_6</ArticleId>
            <ArticleId IdType="pubmed">25151377</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151354</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mouse tetrad analysis provides insights into recombination mechanisms and hotspot evolutionary dynamics.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/ng.3068</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The ability to examine all chromatids from a single meiosis in yeast tetrads has been indispensable for defining the mechanisms of homologous recombination initiated by DNA double-strand breaks (DSBs). Using a broadly applicable strategy for the analysis of chromatids from a single meiosis at two recombination hotspots in mouse oocytes and spermatocytes, we demonstrate here the unidirectional transfer of information-gene conversion-in both crossovers and noncrossovers. Whereas gene conversion in crossovers is associated with reciprocal exchange, the unbroken chromatid is not altered in noncrossover gene conversion events, providing strong evidence that noncrossovers arise from a distinct pathway. Gene conversion frequently spares the binding site of the hotspot-specifying protein PRDM9, with the result that erosion of the hotspot is slowed. Thus, mouse tetrad analysis demonstrates how unique aspects of mammalian recombination mechanisms shape hotspot evolutionary dynamics.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cole</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>1] Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, Texas, USA. [3].</Affiliation>
                </Author>
                <Author>
                    <LastName>Baudat</LastName>
                    <ForeName>Fr??d??ric</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>1] Institut de G??n??tique Humaine, Centre National de la Recherche Scientifique, Unit?? Propre de Recherche 1142, Montpellier, France. [2].</Affiliation>
                </Author>
                <Author>
                    <LastName>Grey</LastName>
                    <ForeName>Corinne</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institut de G??n??tique Humaine, Centre National de la Recherche Scientifique, Unit?? Propre de Recherche 1142, Montpellier, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Keeney</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Massy</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institut de G??n??tique Humaine, Centre National de la Recherche Scientifique, Unit?? Propre de Recherche 1142, Montpellier, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jasin</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.3068</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.3068</ArticleId>
            <ArticleId IdType="pubmed">25151354</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151305</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0384</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of biochemistry and biophysics</Title>
                <ISOAbbreviation>Arch. Biochem. Biophys.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of calpain-1 in the early phase of experimental ALS.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0003-9861(14)00306-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.abb.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Elevation in [Ca(2+)]i and activation of calpain-1 occur in central nervous system of SOD1(G93A) transgenic mice model of amyotrophic lateral sclerosis (ALS), but few data are available about the early stage of ALS. We here investigated the level of activation of the Ca(2+)-dependent protease calpain-1 in spinal cord of SOD1(G93A) mice to ascertain a possible role of the protease in the aetiology of ALS. Comparing the events occurring in the 120 day old mice, we found that [Ca(2+)]i and activation of calpain-1 were also increased in the spinal cord of 30 day old mice, as indicated by the digestion of some substrates of the protease such as nNOS, ??II-spectrin, and the NR2B subunit of NMDA-R. However, the digestion pattern of these proteins suggests that calpain-1 may play different roles depending on the phase of ALS. In fact, in spinal cord of 30 day old mice, activation of calpain-1 produces high amounts of nNOS active species, while in 120 day old mice enhanced-prolonged activation of calpain-1 inactivates nNOS and down-regulates NR2B. Our data reveal a critical role of calpain-1 in the early phase and during progression of ALS, suggesting new therapeutic approaches to counteract its onset and fatal course.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Stifanese</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>National Research Council (C.N.R.), Institute of Marine Sciences (I.S.MAR.), U.O.S. of Genoa, Via De Marini, 6, 16149 Genoa, Italy; University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy. Electronic address: stifanese@unige.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Averna</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>De Tullio</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pedrazzi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Milanese</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Pharmacy (DI.FAR.), Pharmacology and Toxicology Unit, Viale Cembrano, 4, 16147 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bonifacino</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Pharmacy (DI.FAR.), Pharmacology and Toxicology Unit, Viale Cembrano, 4, 16147 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bonanno</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Pharmacy (DI.FAR.), Pharmacology and Toxicology Unit, Viale Cembrano, 4, 16147 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Salamino</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pontremoli</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Melloni</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>University of Genoa, Genoa, Italy; Department of Experimental Medicine (DI.ME.S.), Section of Biochemistry, Viale Benedetto XV, 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (C.E.B.R.), Viale Benedetto XV, 9, 16132 Genoa, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Biochem Biophys</MedlineTA>
            <NlmUniqueID>0372430</NlmUniqueID>
            <ISSNLinking>0003-9861</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ALS</Keyword>
            <Keyword MajorTopicYN="N">Ca(2+)-dependent proteolysis</Keyword>
            <Keyword MajorTopicYN="N">Calpain</Keyword>
            <Keyword MajorTopicYN="N">NMDA-R</Keyword>
            <Keyword MajorTopicYN="N">NR2B</Keyword>
            <Keyword MajorTopicYN="N">Neurodegeneration</Keyword>
            <Keyword MajorTopicYN="N">SOD1/G93A transgenic mice</Keyword>
            <Keyword MajorTopicYN="N">nNOS</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0003-9861(14)00306-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.abb.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25151305</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151272</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-1174</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuromolecular medicine</Title>
                <ISOAbbreviation>Neuromolecular Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Propofol Protects Against Angiotensin II-Induced Mouse Hippocampal HT22 Cells Apoptosis Via Inhibition of p66(Shc) Mitochondrial Translocation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hippocampal neuronal oxidative stress and apoptosis have been reported to be involved in cognitive impairment, and angiotensin II could induce hippocampal oxidative stress and apoptosis. Propofol is a widely used intravenous anesthetic agent in clinical practice, and it demonstrates significant neuroprotective activities. In this study, we investigated the mechanism how propofol protected mouse hippocampal HT22 cells against angiotensin II-induced oxidative stress and apoptosis. Cell viability was evaluated with CCK8 kit. Protein expressions of active caspase 3, cytochrome c, p66(Shc), p-p66(shc)-Ser(36), protein kinase C ??II (PKC??II), Pin-1 and phosphatase A2 (PP2A) were measured by Western blot. Superoxide anion (O 2 (.-) ) accumulation was measured with the reduction of ferricytochrome c. Compared with the control group, angiotensin II up-regulated expression of PKC??II, Pin-1 and PP2A, induced p66(Shc)-Ser(36) phosphorylation, and facilitated p66(Shc) mitochondrial translocation, resulting in O 2 (.-) accumulation, mitochondrial cytochrome c release, caspase 3 activation, and the inhibition of cell viability. Importantly, we found propofol inhibited angiotensin II-induced PKC??II and PP2A expression and improved p66(Shc) mitochondrial translocation, O 2 (.-) accumulation, mitochondrial cytochrome c release, caspase 3 activation, inhibition of cell viability. On the other hand, propofol had no effects on angiotensin II-induced Pin-1 expression and p66(Shc)-Ser(36) phosphorylation. Moreover, the protective effects of propofol on angiotensin II-induced HT22 apoptosis were similar with calyculin A, an inhibitor of PP2A and CGP53353, an inhibitor of PKC??II. However, the protective effect of propofol could be reversed by FTY720, an activator of PP2A, rather than PMA, an activator of PKC??II. Our data indicated that propofol down-regulated PP2A expression, inhibiting dephosphorylation of p66(Shc)-Ser(36) and p66(Shc) mitochondrial translocation, decreasing O 2 (.-) accumulation, reducing mitochondrial cytochrome c release, inhibiting caspase 3 activation. By these mechanisms, it protects mouse hippocampal HT22 cells against angiotensin II-induced apoptosis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Minmin</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Anesthesiology, Fudan University Shanghai Cancer Center, No 270 DongAn Road, Shanghai, 200032, People's Republic of China, natalie7901@126.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Jiawei</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Wen</LastName>
                    <ForeName>Meilin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Zhirong</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Xia</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Miao</LastName>
                    <ForeName>Changhong</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuromolecular Med</MedlineTA>
            <NlmUniqueID>101135365</NlmUniqueID>
            <ISSNLinking>1535-1084</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-014-8326-6</ArticleId>
            <ArticleId IdType="pubmed">25151272</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151266</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature neuroscience</Title>
                <ISOAbbreviation>Nat. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gamma-range synchronization of fast-spiking interneurons can enhance detection of tactile stimuli.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/nn.3797</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We tested the sensory impact of repeated synchronization of fast-spiking interneurons (FS), an activity pattern thought to underlie neocortical gamma oscillations. We optogenetically drove 'FS-gamma' while mice detected naturalistic vibrissal stimuli and found enhanced detection of less salient stimuli and impaired detection of more salient ones. Prior studies have predicted that the benefit of FS-gamma is generated when sensory neocortical excitation arrives in a specific temporal window 20-25 ms after FS synchronization. To systematically test this prediction, we aligned periodic tactile and optogenetic stimulation. We found that the detection of less salient stimuli was improved only when peripheral drive led to the arrival of excitation 20-25 ms after synchronization and that other temporal alignments either had no effects or impaired detection. These results provide causal evidence that FS-gamma can enhance processing of less salient stimuli, those that benefit from the allocation of attention.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Siegle</LastName>
                    <ForeName>Joshua H</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>1] Department of Neuroscience and Institute for Brain Science, Brown University, Providence, Rhode Island, USA. [2] Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. [3].</Affiliation>
                </Author>
                <Author>
                    <LastName>Pritchett</LastName>
                    <ForeName>Dominique L</ForeName>
                    <Initials>DL</Initials>
                    <Identifier Source="ORCID">0000000311871162</Identifier>
                    <Affiliation>1] Department of Neuroscience and Institute for Brain Science, Brown University, Providence, Rhode Island, USA. [2] Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. [3] [4].</Affiliation>
                </Author>
                <Author>
                    <LastName>Moore</LastName>
                    <ForeName>Christopher I</ForeName>
                    <Initials>CI</Initials>
                    <Affiliation>Department of Neuroscience and Institute for Brain Science, Brown University, Providence, Rhode Island, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Neurosci</MedlineTA>
            <NlmUniqueID>9809671</NlmUniqueID>
            <ISSNLinking>1097-6256</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">nn.3797</ArticleId>
            <ArticleId IdType="doi">10.1038/nn.3797</ArticleId>
            <ArticleId IdType="pubmed">25151266</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151262</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature neuroscience</Title>
                <ISOAbbreviation>Nat. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mutual antagonism between Sox10 and NFIA regulates diversification of glial lineages and glioma subtypes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/nn.3790</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lineage progression and diversification is regulated by the coordinated action of unique sets of transcription factors. Oligodendrocytes (OL) and astrocytes (AS) comprise the glial sub-lineages in the CNS, and the manner in which their associated regulatory factors orchestrate lineage diversification during development and disease remains an open question. Sox10 and NFIA are key transcriptional regulators of gliogenesis associated with OL and AS. We found that NFIA inhibited Sox10 induction of OL differentiation through direct association and antagonism of its function. Conversely, we found that Sox10 antagonized NFIA function and suppressed AS differentiation in mouse and chick systems. Using this developmental paradigm as a model for glioma, we found that this relationship similarly regulated the generation of glioma subtypes. Our results describe the antagonistic relationship between Sox10 and NFIA that regulates the balance of OL and AS fate during development and demonstrate for the first time, to the best of our knowledge, that the transcriptional processes governing glial sub-lineage diversification oversee the generation of glioma subtypes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Glasgow</LastName>
                    <ForeName>Stacey M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Wenyi</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>1] Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. [2] Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stolt</LastName>
                    <ForeName>C Claus</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>Institut f??r Biochemie, Emil-Fischer-Zentrum, Universit??t Erlangen-N??rnberg, Erlangen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Teng-Wei</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>1] Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, USA. [2] Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Fuyi</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>LoTurco</LastName>
                    <ForeName>Joseph J</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Neul</LastName>
                    <ForeName>Jeffrey L</ForeName>
                    <Initials>JL</Initials>
                    <Identifier Source="ORCID">0000000256285872</Identifier>
                    <Affiliation>1] Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, USA. [2] Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, USA. [3] Department of Pediatrics, Neurology, and Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. [4] Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wegner</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institut f??r Biochemie, Emil-Fischer-Zentrum, Universit??t Erlangen-N??rnberg, Erlangen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mohila</LastName>
                    <ForeName>Carrie</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pathology, Texas Children's Hospital, Houston, Texas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Deneen</LastName>
                    <ForeName>Benjamin</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. [2] Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, Texas, USA. [3] Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, USA. [4] Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, USA. [5] Department of Pediatrics, Neurology, and Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. [6] Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Neurosci</MedlineTA>
            <NlmUniqueID>9809671</NlmUniqueID>
            <ISSNLinking>1097-6256</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">nn.3790</ArticleId>
            <ArticleId IdType="doi">10.1038/nn.3790</ArticleId>
            <ArticleId IdType="pubmed">25151262</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151232</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-264X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>100C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pharmaceutical and biomedical analysis</Title>
                <ISOAbbreviation>J Pharm Biomed Anal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Direct real-time quantitative PCR for measurement of host-cell residual DNA in therapeutic proteins.</ArticleTitle>
            <Pagination>
                <MedlinePgn>123-130</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0731-7085(14)00365-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jpba.2014.07.032</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Real-time quantitative PCR (qPCR) is important for quantification of residual host cell DNA (resDNA) in therapeutic protein preparations. Typical qPCR protocols involve DNA extraction steps complicating sample handling. Here, we describe a &quot;direct qPCR&quot; approach without DNA extraction. To avoid interferences of DNA polymerase with a therapeutic protein, proteins in the samples were digested with proteinase K (PK) in the presence of sodium dodecyl sulfate (SDS). Tween 20 and NaCl were included to minimize precipitation of therapeutic proteins in the PK/SDS mix. After PK treatment, the solution was applied directly for qPCR. Inhibition of DNA polymerase by SDS was prevented by adding 2% (v/v) of Tween 20 to the final qPCR mix. The direct qPCR approach was evaluated for quantification of resDNA in therapeutic proteins manufactured in Chinese hamster ovary (CHO) host cells. First, direct qPCR was compared with qPCR applied on purified DNA (&quot;extraction qPCR&quot;). For both qPCRs, the same CHO-specific primers and probes were used. Comparable residual DNA levels were detected with both PCR approaches in purified and highly concentrated drug proteins as well as in in-process-control samples. Finally, the CHO-specific direct qPCR protocol was validated according to ICH guidelines and applied for 25 different therapeutic proteins. The specific limits of quantification were 0.1-0.8ppb for 24 proteins, and 2.0ppb for one protein. General applicability of the direct qPCR was demonstrated by applying the sample preparation protocol for quantification of resDNA in therapeutic proteins manufactured in other hosts such as Escherichia coli and mouse cells.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Peper</LastName>
                    <ForeName>Grit</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics Process R&amp;D, Basel, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fankhauser</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics Process R&amp;D, Basel, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Merlin</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics QC, Basel, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Roscic</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics Process R&amp;D, Basel, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hofmann</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics Process R&amp;D, Basel, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obrdlik</LastName>
                    <ForeName>Petr</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Novartis Pharma AG, TRD Biologics Process R&amp;D, Basel, Switzerland. Electronic address: petr.obrdlik@novartis.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Pharm Biomed Anal</MedlineTA>
            <NlmUniqueID>8309336</NlmUniqueID>
            <ISSNLinking>0731-7085</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biologics</Keyword>
            <Keyword MajorTopicYN="N">CHO</Keyword>
            <Keyword MajorTopicYN="N">Real-time qPCR</Keyword>
            <Keyword MajorTopicYN="N">Residual DNA</Keyword>
            <Keyword MajorTopicYN="N">Therapeutic proteins</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0731-7085(14)00365-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jpba.2014.07.032</ArticleId>
            <ArticleId IdType="pubmed">25151232</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151223</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0041-008X(14)00300-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.taap.2014.08.008</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Clinical studies have demonstrated that conditionally replicating adenovirus is safe. We constructed an oncolytic adenovirus, Ad-hTERT-E1a-Apoptin, using a cancer-specific promoter (human telomerase reverse transcriptase promoter, hTERTp) and a cancer cell-selective apoptosis-inducing gene (Apoptin). Ad-hTERT-E1a-Apoptin was proven effective both in vitro and in vivo in our previous study. In this study, the preclinical safety profiles of Ad-hTERT-E1a-Apoptin in animal models were investigated. At doses of 5.0??10(8), 2.5??10(9), and 1.25??10(10) viral particles (VP)/kg, Ad-hTERT-E1a-Apoptin had no adverse effects on mouse behavior, muscle cooperation, sedative effect, digestive system, and nervous systems, or on beagle cardiovascular and respiratory systems at 5.0??10(8), 2.5??10(9), and 1.25??10(10) VP/kg doses. In acute toxicity tests in mice, the maximum tolerated dose&gt;5??10(10) VP/kg. There was no inflammation or ulceration at the injection sites within two weeks. In repeat-dose toxicological studies, the no observable adverse effect levels of Ad-hTERT-E1a-Apoptin in rats (1.25??10(10) VP/kg) and beagles (2.5??10(9) VP/kg) were 62.5- and 12.5-fold of the proposed clinical dose, respectively. The anti-virus antibody was produced in animal sera. Bone marrow examination revealed no histopathological changes. Guinea pigs sensitized by three repeated intraperitoneal injections of 1.35??10(10) VP/mL Ad-hTERT-E1a-Apoptin each and challenged by one intravenous injection of 1.67??10(8) VP/kg Ad-hTERT-E1a-Apoptin did not exhibit any sign of systemic anaphylaxis. Our data from different animal models suggest that Ad-hTERT-E1a-Apoptin is a safe anti-tumor therapeutic agent.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Qi</LastName>
                    <ForeName>Yanxin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Huanhuan</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; Changchun Brother Biotech Co., Ltd., Changchun, 130000, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Ningning</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130122, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Dongyun</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130122, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Shi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; School of Clinical Medicine, Jilin University, Changchun 130001, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chu</LastName>
                    <ForeName>Yunjie</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Yubin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130122, PR China. Electronic address: lixiao06@mails.jlu.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>LiLi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Head and Neck Surgery, Tumor Hospital of Jilin Province, Changchun 130012, PR China. Electronic address: linjiaxiaoya@163.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Ningyi</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130122, PR China. Electronic address: ningyij@126.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptin</Keyword>
            <Keyword MajorTopicYN="N">Conditionally replicating adenovirus</Keyword>
            <Keyword MajorTopicYN="N">Human telomerase reverse transcriptase</Keyword>
            <Keyword MajorTopicYN="N">Safety evaluation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25151223</ArticleId>
            <ArticleId IdType="pii">S0041-008X(14)00300-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2014.08.008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151221</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Revised Model of Ex-Vivo Reduction of Hexavalent Chromium in Human and Rodent Gastric Juices.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0041-008X(14)00302-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.taap.2014.08.010</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Chronic oral exposure to hexavalent chromium (Cr-VI) in drinking water has been shown to induce tumors in the mouse gastrointestinal (GI) tract and rat oral cavity. The same is not true for trivalent chromium (Cr-III). Thus reduction of Cr-VI to Cr-III in gastric juices is considered a protective mechanism, and it has been suggested that the difference between the rate of reduction among mice, rats, and humans could explain or predict differences in sensitivity to Cr-VI. We evaluated previously published models of gastric reduction and believe that they do not fully describe the data on reduction as a function of Cr-VI concentration, time, and (in humans) pH. The previous models are parsimonious in assuming only a single reducing agent in rodents and describing pH-dependence using a simple function. We present a revised model that assumes three pools of reducing agents in rats and mice with pH-dependence based on known speciation chemistry. While the revised model uses more fitted parameters than the original model, they are adequately identifiable given the available data, and the fit of the revised model to the full range of data is shown to be significantly improved. Hence the revised model should provide better predictions of Cr-VI reduction when integrated into a corresponding PBPK model.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Schlosser</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>U.S. Environmental Protection Agency, National Center for Environmental Assessment, Washington, DC. Electronic address: schlosser.paul@epa.gov.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sasso</LastName>
                    <ForeName>Alan F</ForeName>
                    <Initials>AF</Initials>
                    <Affiliation>U.S. Environmental Protection Agency, National Center for Environmental Assessment, Washington, DC.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">gastric juice</Keyword>
            <Keyword MajorTopicYN="N">hexavalent chromium</Keyword>
            <Keyword MajorTopicYN="N">human</Keyword>
            <Keyword MajorTopicYN="N">mouse</Keyword>
            <Keyword MajorTopicYN="N">rat</Keyword>
            <Keyword MajorTopicYN="N">reduction</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(14)00302-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2014.08.010</ArticleId>
            <ArticleId IdType="pubmed">25151221</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151220</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resveratrol attenuates methylglyoxal-induced mitochondrial dysfunction and apoptosis by Sestrin2 induction.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0041-008X(14)00303-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.taap.2014.08.011</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Methylglyoxal is found in high levels in the blood and other tissues of diabetic patients and exerts deleterious effects on cells and tissues. Previously, we reported that resveratrol, a polyphenol in grapes, induced expression of Sestrin2 (SESN2), a novel antioxidant protein, and inhibited hepatic lipogenesis. This study investigated whether resveratrol protects cells from the methylglyoxal-induced toxicity via SESN2 induction. Methylglyoxal significantly induced cell death in HepG2 cells. However, cells pretreated with resveratrol were rescued from methylglyoxal-induced apoptosis. Resveratrol attenuated glutathione (GSH) depletion and ROS production promoted by methylglyoxal. Moreover, mitochondrial damage was observed by methylglyoxal treatment, but resveratrol restored mitochondrial function, as evidenced by the observed lack of mitochondrial permeability transition and increased ADP/ATP ratio. Resveratrol treatment inhibited SESN2 depletion elicited by methylglyoxal. SESN2 overexpression repressed methylglyoxal-induced mitochondrial dysfunction and apoptosis. Likewise, rotenone-induced cytotoxicity was not observed in SESN2 overexpressed cells. Furthermore, siRNA knockdown of SESN2 reduced the ability of resveratrol to prevent methylglyoxal-induced mitochondrial permeability transition. In addition, when mice were exposed to methylglyoxal after infection of Ad-SESN2, increased the plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and GSH depletion by methylglyoxal in liver was reduced in Ad-SESN2 infected mice. Our results demonstrated that resveratrol is capable of protecting cells from methylglyoxal-induced mitochondrial dysfunction and oxidative stress via SESN2 induction.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Kyuhwa</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>College of Pharmacy, Chosun University, Gwangju 501-759, South Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seo</LastName>
                    <ForeName>Suho</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>College of Pharmacy, Chosun University, Gwangju 501-759, South Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Jae Yun</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>College of Pharmacy, Chosun University, Gwangju 501-759, South Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ki</LastName>
                    <ForeName>Sung Hwan</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>College of Pharmacy, Chosun University, Gwangju 501-759, South Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shin</LastName>
                    <ForeName>Sang Mi</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>College of Pharmacy, Chosun University, Gwangju 501-759, South Korea. Electronic address: smshin@chosun.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Methylglyoxal</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
            <Keyword MajorTopicYN="N">Resveratrol</Keyword>
            <Keyword MajorTopicYN="N">Sestrin2</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(14)00303-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2014.08.011</ArticleId>
            <ArticleId IdType="pubmed">25151220</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151201</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0380</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in genetics &amp; development</Title>
                <ISOAbbreviation>Curr. Opin. Genet. Dev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome maintenance and human longevity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>105-115</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0959-437X(14)00074-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.gde.2014.07.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Accumulation of DNA damage and mutations is considered an important causal factor in age-related diseases. Genetic defects in DNA repair cause premature onset and accelerated progression of age-related diseases and a shorter life span in humans and mice, providing strong evidence that genome maintenance is a bona fide longevity assurance pathway. However, the contribution of genome maintenance to human longevity itself remains to be established. Here, we review the results of human genetics studies, including genome wide association studies, and attempted to catalogue all genes involved in major DNA repair pathways that harbor variants associated with longevity. We hope to provide a comprehensive review to facilitate future endeavors aimed at uncovering the functional role of genome maintenance genes in human longevity.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Miook</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Suh</LastName>
                    <ForeName>Yousin</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: yousin.suh@einstein.yu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Curr Opin Genet Dev</MedlineTA>
            <NlmUniqueID>9111375</NlmUniqueID>
            <ISSNLinking>0959-437X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0959-437X(14)00074-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.gde.2014.07.002</ArticleId>
            <ArticleId IdType="pubmed">25151201</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151167</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1196</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chromatin immunoprecipitation and chromatin immunoprecipitation with massively parallel sequencing on mouse embryonic tissue.</ArticleTitle>
            <Pagination>
                <MedlinePgn>231-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1242-1_14</ELocationID>
            <Abstract>
                <AbstractText>Regulation of gene expression must be tightly controlled during embryonic development. A central mechanism to control gene expression is the binding of sequence-specific transcription factors to cis-regulatory elements in the genome. Chromatin immunoprecipitation (ChIP) is a widely used technique to analyze binding of transcription factors and histone modifications on chromatin; however, it is limited to looking at a small number of genes. ChIP with massively parallel sequencing (ChIP-seq) is a recently developed powerful tool to analyze genome-wide binding of transcription factors and histone modifications and provides a vast amount of information into the regulation of gene expression. This chapter describes how ChIP and ChIP-seq are performed on mouse embryonic tissue.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Amin</LastName>
                    <ForeName>Shilu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>School of Dentistry, Faculty of Medical &amp; Human Sciences, University of Manchester, Manchester, M13 9PT, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bobola</LastName>
                    <ForeName>Nicoletta</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1242-1_14</ArticleId>
            <ArticleId IdType="pubmed">25151167</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151159</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1196</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Genetics of Murine Hox Loci: TAMERE, STRING, and PANTHERE to Engineer Chromosome Variants.</ArticleTitle>
            <Pagination>
                <MedlinePgn>89-102</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1242-1_6</ELocationID>
            <Abstract>
                <AbstractText>Following their duplications at the base of the vertebrate clade, Hox gene clusters underwent remarkable sub- and neo-functionalization events. Many of these evolutionary innovations can be associated with changes in the transcriptional regulation of their genes, where an intricate relationship between the structure of the gene cluster and the architecture of the surrounding genomic landscape is at play. Here, we report on a portfolio of in vivo genome engineering strategies in mice, which have been used to probe and decipher the genetic and molecular underpinnings of the complex regulatory mechanisms implemented at these loci.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tschopp</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duboule</LastName>
                    <ForeName>Denis</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1242-1_6</ArticleId>
            <ArticleId IdType="pubmed">25151159</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151158</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1196</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hox Complex Analysis Through BAC Recombineering.</ArticleTitle>
            <Pagination>
                <MedlinePgn>59-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1242-1_5</ELocationID>
            <Abstract>
                <AbstractText>BAC transgenesis in mice has proved to be useful in exploring the regulatory mechanisms and functions of the Hox complexes. The large constructs used may include most of the relevant components of the cis-regulatory landscape. Manipulations can be accomplished without compromising the integrity of the endogenous complex which reduces the likelihood of producing confounding phenotypic abnormalities. The development of recombineering tools has been critical in providing the means necessary to make many types of precise and varied manipulations of these large constructs. Here, we will discuss the methodologies necessary to manipulate Hox complex BACs, generation of transgenic animals bearing these constructs and the utilization of these resources to address fundamental aspects of Hox biology.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Parrish</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Stowers Institute for Medical Research, 1000 E 50th Street, Kansas City, MO, 64110, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Youngwook</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nolte</LastName>
                    <ForeName>Christof</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Kumar</LastName>
                    <ForeName>Bony</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krumlauf</LastName>
                    <ForeName>Robb</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1242-1_5</ArticleId>
            <ArticleId IdType="pubmed">25151158</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151156</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1196</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetic lineage tracing analysis of anterior hox expressing cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>37-48</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1242-1_3</ELocationID>
            <Abstract>
                <AbstractText>Cell lineage studies have been widely used in developmental biology to establish which cells, and how many cells, in the early embryo will give rise to a specific structure and its derivatives. Several methods have been developed to label progenitor cells in the early embryo. Here, we describe the genetic tracing approach that relies on the use of the recombinase to genetically and permanently label progenitor cells as well as their progeny through specific activation of a conditional reporter gene, the ROSA26 reporter mouse. Labeling of progenitor cells is spatially controlled by the use of a tissue-specific promoter driving Cre, the Hoxb1 (IRES-Cre/+)???and the Hoxa1-enhIII-cre. ROSA26R mice and Hoxb1 (IRES-Cre/+)???or Hoxa1-enhIII-cremice are crossed together to generate embryos at different stages of development. Embryos are collected and dissected at a specific stage of development and fixed in paraformaldehyde. To follow Hoxb1 (+) and Hoxa1 (+) progeny, X-gal staining is performed to detect ??-galactosidase activity in embryos or developing organ such as the heart. Finally, X-gal-positive cells are observed on whole-mount embryos or dissected organ to determine the lineage contribution of Hoxa1 and Hoxb1 during development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Laforest</LastName>
                    <ForeName>Brigitte</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Inserm, GMGF UMR_S910, Aix-Marseille Universit??, 13385, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertrand</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zaffran</LastName>
                    <ForeName>St??phane</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1242-1_3</ArticleId>
            <ArticleId IdType="pubmed">25151156</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151147</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evolving possible link between PI3K and NO pathways in neuroprotective mechanism of ischemic postconditioning in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The present study was conducted to pharmacologically investigate the influence of NO signaling pathway in PI3K mediated neuroprotective mechanism of ischemic postconditioning (iPoCo). Bilateral carotid artery occlusion (BCAO) of 12??min followed by reperfusion for 24??h was employed to produce ischemia/reperfusion-induced cerebral injury in male Swiss mice. Memory was assessed using Morris water maze test. Degree of motor incoordination was evaluated using inclined beam walk test, rotarod test, and lateral push test. Cerebral infarct size was measured using triphenyltetrazolium chloride staining. Brain acetylcholinesterase activity, thiobarbituric acid reactive species (TBARS), nitrite/nitrate and reduced glutathione (GSH) levels were also estimated. BCAO followed by reperfusion produced significant rise in cerebral infarct size, acetylcholinesterase activity, and TBARS levels along with fall in nitrite/nitrate and GSH levels. A significant impairment of memory and motor coordination was also noted. iPoCo consisting of three episodes of 10??s carotid artery occlusion and reperfusion significantly attenuated infarct size, memory impairment, motor incoordination, and altered biochemicals. iPoCo-induced neuroprotective effects were significantly abolished by wortmannin (a selective PI3K inhibitor). However, administration of L-Arginine (a NO precursor) in the presence of wortmannin restored the protective effect of ischemic postconditioning. It may be concluded that neuroprotective mechanism of iPoCo involves PI3K-mediated pathway with NO signaling as an important downstream step.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gulati</LastName>
                    <ForeName>Puja</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, 147002, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Singh</LastName>
                    <ForeName>Nirmal</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-014-2193-1</ArticleId>
            <ArticleId IdType="pubmed">25151147</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151118</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Novel Role Of Peroxiredoxin-2 In Red Cell Membrane Protein Homeostasis And Senescence.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0891-5849(14)00378-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.freeradbiomed.2014.08.004</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Peroxiredoxin-2 (Prx2), a typical 2-cysteine (Cys) peroxiredoxin, is the third most abundant protein in red cells. Although progress has been made in the functional characterization of Prx2, its role in red cell membrane protein homeostasis is still under investigation. Here, we studied Prx2-/- mouse red cells. The absence of Prx2 promotes (i) activation of oxidative-induced Syk pathway; (ii) increased band 3 Tyr-phosphorylation, with clustered band-3 and (iii) increased heat-shock-proteins (HSP27 and 70) membrane translocation. This was associated with enhanced in vitro erythrophagocytosis of Prx2-/- red cells and reduced Prx2-/- red cell survival, indicating the possible role of Prx2 membrane recruitment in red cell aging and in the clearance of oxidized hemoglobin and damaged proteins through microparticles. Indeed, we observed an increased release of microparticles from Prx2-/- mouse red cells. The mass-spectrometric analysis of erythroid microparticles found hemoglobin chains, membrane proteins and HSPs. To test these findings, we treated in vivo Prx2-/- mice with antioxidants. We observed that N-Acetyl-Cysteine reduced (i) Syk-activation; (ii) band-3 clusterization; (iii) HSP27 membrane association and (iv) erythroid-microparticles release, resulting in increased Prx2-/- mouse red cell survival. Thus, we propose that Prx2 may play a cytoprotective role in red cell membrane protein homeostasis and senescence.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Matte'</LastName>
                    <ForeName>Alessandro</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medicine, Section of Internal Medicine, University of Verona, AOUI-Policlinico GB Rossi, Verona; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pantaleo</LastName>
                    <ForeName>Antonella</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biomedical Sciences, University of Sassari, Sassari; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ferru</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Oncology, University of Torino, Torino; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Turrini</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Oncology, University of Torino, Torino; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bertoldi</LastName>
                    <ForeName>Mariarita</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Oncology, University of Torino, Torino; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lupo</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Medicine, Section of Internal Medicine, University of Verona, AOUI-Policlinico GB Rossi, Verona; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Siciliano</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medicine, Section of Internal Medicine, University of Verona, AOUI-Policlinico GB Rossi, Verona; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zoon</LastName>
                    <ForeName>Chae Ho</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>School of Biological Science and Technology, Chonnam National University, Gwangjiu, Korea; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Franceschi</LastName>
                    <ForeName>Lucia De</ForeName>
                    <Initials>LD</Initials>
                    <Affiliation>Department of Medicine, Section of Internal Medicine, University of Verona, AOUI-Policlinico GB Rossi, Verona; Italy; Department of Life and Reproduction Sciences, Section of Biochemistry, University of Verona, Verona; Italy. Electronic address: lucia.defranceschi@univr.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Microparticles</Keyword>
            <Keyword MajorTopicYN="N">N-Acetyl-cysteine</Keyword>
            <Keyword MajorTopicYN="N">Oxidative Stress</Keyword>
            <Keyword MajorTopicYN="N">Peroxiredoxin-2</Keyword>
            <Keyword MajorTopicYN="N">Red Cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(14)00378-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.08.004</ArticleId>
            <ArticleId IdType="pubmed">25151118</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151099</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1705</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International immunopharmacology</Title>
                <ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective effects of scoparone against lipopolysaccharide-induced acute lung injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1567-5769(14)00328-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.intimp.2014.08.014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The purpose of this study was to investigate the protective effects and molecular mechanisms of scoparone on lipopolysaccharide (LPS)-induced acute lung injury in mice. Mice model of acute lung injury (ALI), induced by intranasal instillation of LPS, was used to investigate the protective effects of scoparone in vivo. The alveolar macrophages were used to investigate the molecular mechanisms of scoparone in vitro. The results showed that scoparone treatment remarkably attenuated LPS-induced pulmonary edema, histological severities, myeloperoxidase activity, and TNF-??, IL-6 and IL-1?? production in vivo. We also found that scoparone inhibited LPS-induced TLR4 expression, NF-??B activation, TNF-??, IL-6 and IL-1?? production in alveolar macrophages in vitro. In conclusion, our results suggest that scoparone has a protective effect on LPS-induced ALI via suppression of TLR4-mediated NF-??B signaling pathways.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Niu</LastName>
                    <ForeName>Niu</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China. Electronic address: niuniugz01@163.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Baolan</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Xuebing</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Haiqing</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Beijing Tuberculosis and Thoracic Tumor Research Institute Medicine, Department of Beijing Chest Hospital, CMMU, Beijing 101149, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int Immunopharmacol</MedlineTA>
            <NlmUniqueID>100965259</NlmUniqueID>
            <ISSNLinking>1567-5769</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Acute lung injury</Keyword>
            <Keyword MajorTopicYN="N">LPS</Keyword>
            <Keyword MajorTopicYN="N">NF-??B</Keyword>
            <Keyword MajorTopicYN="N">Scoparone</Keyword>
            <Keyword MajorTopicYN="N">TLR4</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1567-5769(14)00328-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.intimp.2014.08.014</ArticleId>
            <ArticleId IdType="pubmed">25151099</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151060</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0341</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>468-470C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virology</Title>
                <ISOAbbreviation>Virology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Escape variants of the XPR1 gammaretrovirus receptor are rare due to reliance on a splice donor site and a short hypervariable loop.</ArticleTitle>
            <Pagination>
                <MedlinePgn>63-71</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0042-6822(14)00366-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.virol.2014.07.049</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Entry determinants in the XPR1 receptor for the xenotropic/polytropic mouse leukemia viruses (XP-MLVs) lie in its third and fourth putative extracellular loops (ECLs). The critical ECL3 receptor determinant overlies a splice donor and is evolutionarily conserved in vertebrate XPR1 genes; 2 of the 3 rare replacement mutations at this site destroy this receptor determinant. The 13 residue ECL4 is hypervariable, and replacement mutations carrying an intact ECL3 site alter but do not abolish receptor activity, including replacement of the entire loop with that of a jellyfish (Cnidaria) XPR1. Because ECL4 deletions are found in all X-MLV-infected Mus subspecies, we deleted each ECL4 residue to determine if deletion-associated restriction is residue-specific or is effected by loop size. All deletions influence receptor function, although different deletions affect different XP-MLVs. Thus, receptor usage of a constrained splice site and a loop that tolerates mutations severely limits the likelihood of host escape mutations.</AbstractText>
                <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Xiaoyu</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Martin</LastName>
                    <ForeName>Carrie</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bouchard</LastName>
                    <ForeName>Christelle</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Whitney Laboratory for Marine Bioscience, University of Florida, St. Augustine, FL 32136, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kozak</LastName>
                    <ForeName>Christine A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States. Electronic address: ckozak@niaid.nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Virology</MedlineTA>
            <NlmUniqueID>0110674</NlmUniqueID>
            <ISSNLinking>0042-6822</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Retrovirus entry</Keyword>
            <Keyword MajorTopicYN="N">Retrovirus evolution</Keyword>
            <Keyword MajorTopicYN="N">Retrovirus restriction genes</Keyword>
            <Keyword MajorTopicYN="N">XPR1 gammaretrovirus receptor</Keyword>
            <Keyword MajorTopicYN="N">Xenotropic/polytropic gammaretroviruses</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0042-6822(14)00366-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.virol.2014.07.049</ArticleId>
            <ArticleId IdType="pubmed">25151060</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151046</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Acta tropica</Title>
                <ISOAbbreviation>Acta Trop.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Biological cycle and preliminary data on vectorial competence of Triatoma boliviana in laboratory conditions.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0001-706X(14)00275-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.actatropica.2014.08.014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">With more than 140 potential vectors of Chagas disease, it is important to better know the biology and especially the vectorial capacity of the triatomine species which live in the surroundings of human dwellings. In Bolivia where 17 triatomine species are reported, the principal vector is Triatoma infestans. In some valleys of the department of La Paz where T. infestans is not present, a new species (Triatoma boliviana) was described in 2007. This species lives in a sylvatic environment not far away from the dwellings, and occasionally some individuals are found inside the houses. This study was carried out to describe the biological cycle of T. boliviana and to determine its vectorial competence. The development of a cohort of 95 nymphs of first instar (N1) was followed through nymphal instars and adult stage until death in laboratory (22??C). They were fed twice a week on an immobilized mouse. The median egg-to-adult development time was 8.4 months. The mortality by nymphal instar was lower than 7% except for N1 (67%) and N5 (18%). All nymph instars needed at least two feedings to molt (until six feedings for N5). The differentiation of a nymph into a female or a male could not be detected until the fifth instar for which the food intake was greater for a nymph developing into a female. Adults fed about once a week. The adult life span was around 400 days. The fecundity was 4.2 eggs/female/week, with a hatching rate of 50% and a hatching time of 39 days. In the same conditions, T. infestans showed a similar fecundity but a greater hatching rate and hatching time. A trial for rearing the adults at a higher temperature (26??C) showed a drastic fall in the fecundity and in the hatching rate. The vectorial competence was analyzed for fifth instars and adults by three parameters: the ability to feed on human beings, the capacity to be infected by T. cruzi and the postfeeding defecation delay. Results showed a relatively high vectorial competence: 1) insects fed easily on the tested human being; 2) 100% of the specimens became infected by T. cruzi just by one infected meal; and 3) although the adults defecated after a median postfeeding delay greater than that of T. infestans, results on N5 suggest that they could be as good vectors as T. infestans males.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dur??n</LastName>
                    <ForeName>Pamela</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Laboratorio Entomolog??a M??dica, INLASA, Rafael Zubieta No. 1889, Miraflores, La Paz, Bolivia. Electronic address: pamela.duran.toledo@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Si??ani</LastName>
                    <ForeName>Edda</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Laboratorio Entomolog??a M??dica, INLASA, Rafael Zubieta No. 1889, Miraflores, La Paz, Bolivia. Electronic address: edpatzi@yahoo.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Depick??re</LastName>
                    <ForeName>St??phanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratorio Entomolog??a M??dica, INLASA, Rafael Zubieta No. 1889, Miraflores, La Paz, Bolivia; Institut de Recherche pour le D??veloppement (IRD), c/o Embajada Francia, CP 9214 La Paz, Bolivia. Electronic address: stephanie.depickere@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Acta Trop</MedlineTA>
            <NlmUniqueID>0370374</NlmUniqueID>
            <ISSNLinking>0001-706X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Chagas disease</Keyword>
            <Keyword MajorTopicYN="N">Defecation index</Keyword>
            <Keyword MajorTopicYN="N">Laboratory rearing</Keyword>
            <Keyword MajorTopicYN="N">Life cycle</Keyword>
            <Keyword MajorTopicYN="N">Triatoma boliviana</Keyword>
            <Keyword MajorTopicYN="N">Vectorial competence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0001-706X(14)00275-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.actatropica.2014.08.014</ArticleId>
            <ArticleId IdType="pubmed">25151046</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151041</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2518</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccine</Title>
                <ISOAbbreviation>Vaccine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0264-410X(14)01136-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.vaccine.2014.08.023</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We have established that the efficacy of a heterologous poxvirus vectored HIV vaccine, fowlpox virus (FPV)-HIV gag/pol prime followed by attenuated vaccinia virus (VV)-HIV gag/pol booster immunisation, is strongly influenced by the cytokine milieu at the priming vaccination site, with endogenous IL-13 detrimental to the quality of the HIV specific CD8+ T cell response induced. We have now developed a novel HIV vaccine that co-expresses a C-terminal deletion mutant of the mouse IL-4, deleted for the essential tyrosine (Y119) required for signalling. In our vaccine system, the mutant IL-4C118 can bind to IL-4 type I and II receptors with high affinity, and transiently prevent the signalling of both IL-4 and IL-13 at the vaccination site. When this IL-4C118 adjuvanted vaccine was used in an intranasal rFPV/intramuscular rVV prime-boost immunisation strategy, greatly enhanced mucosal/systemic HIV specific CD8+ T cells with higher functional avidity, expressing IFN-??, TNF-?? and IL-2 and greater protective efficacy were detected. Surprisingly, the IL-4C118 adjuvanted vaccines also induced robust long-lived HIV gag-specific serum antibody responses, specifically IgG1 and IgG2a. The p55-gag IgG2a responses induced were of a higher magnitude relative to the IL-13R??2 adjuvant vaccine. More interestingly, our recently tested IL-13R??2 adjuvanted vaccine which only inhibited IL-13 activity, even though induced excellent high avidity HIV-specific CD8+ T cells, had a detrimental impact on the induction of gag-specific IgG2a antibody immunity. Our observations suggest that (i) IL-4 cell-signalling in the absence of IL-13 retarded gag-specific antibody isotype class switching, or (ii) IL-13R??2 signalling was involved in inducing good gag-specific B cell immunity. Thus, we believe our novel IL-4R antagonist adjuvant strategy offers great promise not only for HIV-1 vaccines, but also against a range of chronic infections where sustained high quality mucosal and systemic T and B cell immunity are required for protection.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jackson</LastName>
                    <ForeName>Ronald J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Worley</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Trivedi</LastName>
                    <ForeName>Shubhanshi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ranasinghe</LastName>
                    <ForeName>Charani</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia. Electronic address: Charani.Ranasinghe@anu.edu.au.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Vaccine</MedlineTA>
            <NlmUniqueID>8406899</NlmUniqueID>
            <ISSNLinking>0264-410X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD8+ T cell avidity</Keyword>
            <Keyword MajorTopicYN="N">HIV vaccines</Keyword>
            <Keyword MajorTopicYN="N">IL-13Ra2 adjuvanted vaccines</Keyword>
            <Keyword MajorTopicYN="N">IL-4R antagonist</Keyword>
            <Keyword MajorTopicYN="N">IgG1 and IgG2a</Keyword>
            <Keyword MajorTopicYN="N">Mucosal/systemic immunity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0264-410X(14)01136-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.08.023</ArticleId>
            <ArticleId IdType="pubmed">25151041</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25151037</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-5169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Peptides</Title>
                <ISOAbbreviation>Peptides</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: New potential treatment of abdominal pain associated with inflammatory bowel diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0196-9781(14)00243-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.peptides.2014.08.005</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Biphalin, a mixed MOP/DOP agonist, displays a potent antinociceptive activity in numerous animal models of pain. The aim of the study was to characterize the anti-inflammatory and antinociceptive action of biphalin in the mouse models of colitis. The anti-inflammatory effect of biphalin (5mg/kg, twice daily, i.c. and i.p.) was characterized in a semi-chronic mouse model of colitis, induced by i.c. injection of trinitrobenzenesulfonic acid (TNBS). The antinociceptive action of biphalin (5mg/kg, i.p. and i.c.) in inflamed mice was assessed in mustard oil-induced model of visceral pain and in the hot plate test. In the semi-chronic mouse model of colitis, biphalin i.c. (5mg/kg), but not i.p. improved colitis macroscopic score (2.88??0.19 and 4.99??0.80 units for biphalin and vehicle treated animals, respectively). Biphalin injected i.p. and i.c. (5mg/kg) displayed a potent antinociceptive action in the mustard oil-induced pain test. In the hot plate test, biphalin (5mg/kg, i.p.) produced a potent antinociceptive activity in inflamed mice, suggesting central site of action. Our data suggest that biphalin may become a novel opioid-based analgesic agent in IBD therapy and warrant further investigation of its pharmacological profile.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sobczak</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pilarczyk</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jonakowski</LastName>
                    <ForeName>Mateusz</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jarmu??</LastName>
                    <ForeName>Agata</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sa??aga</LastName>
                    <ForeName>Maciej</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lipkowski</LastName>
                    <ForeName>Andrzej W</ForeName>
                    <Initials>AW</Initials>
                    <Affiliation>Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fichna</LastName>
                    <ForeName>Jakub</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland; Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. Electronic address: jakub.fichna@umed.lodz.pl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Peptides</MedlineTA>
            <NlmUniqueID>8008690</NlmUniqueID>
            <ISSNLinking>0196-9781</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biphalin</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory pain</Keyword>
            <Keyword MajorTopicYN="N">Mixed opioid agonist</Keyword>
            <Keyword MajorTopicYN="N">Opioid receptors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0196-9781(14)00243-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.peptides.2014.08.005</ArticleId>
            <ArticleId IdType="pubmed">25151037</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151009</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Analysis of Chromosomal Aberrations in Murine HCC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>213-26</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_19</ELocationID>
            <Abstract>
                <AbstractText>Liver cancer-also called hepatocellular carcinoma (HCC)-is the most frequent primary liver cancer in humans. As of today, it is mainly induced by chronic virus infections such as Hepatitis B and C viruses, which induce chronic hepatitis and fibrosis, the two most important conditions predisposing towards HCC development. Besides, chronic alcohol or drug consumption contributes to chronic liver injury and HCC development. Of note, in industrialized countries virus infections have recently been outcompeted by a high-fat and high-sugar diet as the most important etiology for HCC development in humans-now representing the fastest growing cancer in the USA as of today. It is believed that soon also in Europe high-fat diet caused HCC will become the fastest growing cancer. Today more than 800,000 people die every year due to cancer; however, despite a great research effort in the last 20 years, no efficient curative therapy is available at the moment. It has turned out that various subtypes of HCC exist in humans, complicating the therapy for HCC patients in general, and leading to the need for therapies of stratified patient cohorts as the variability of HCC phenotypes (6 different subtypes exist as of today) influences the responsiveness to treatment. Thus, it is important to dissect and characterize the various HCC subtypes in humans as well as in mouse models to identify the sub-cohorts that are responsive to particular therapies. One step to do so is the characterization of HCC nodules on genetic level. Here, we describe a protocol to characterize individual HCC nodules on genomic level, enabling to stratify the respective liver carcinoma and select them for a more targeted therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Unger</LastName>
                    <ForeName>Kristian</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Research Unit of Radiation Cytogenetics, Helmholtz-Zentrum M??nchen f??r Gesundheit und Umwelt (HMGU), Neuherberg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heikenw??lder</LastName>
                    <ForeName>Mathias</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_19</ArticleId>
            <ArticleId IdType="pubmed">25151009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151008</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Experimental mouse models of T cell-dependent inflammatory bowel disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>199-211</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_18</ELocationID>
            <Abstract>
                <AbstractText>Inflammatory bowel diseases (IBD) represent idiopathic chronic inflammatory disorders of the intestinal tract that are associated with aberrant immune responses against intestinal bacteria. Here, we describe two T cell-dependent models of experimental murine IBD. In the &quot;T cell transfer&quot; model, lymphopenic (scid or Rag (-/-) ) mice develop colitis upon adoptive transfer of na??ve CD4(+) T cells. This model has also been extensively employed to identify mechanisms through which CD4(+)CD25(+) regulatory T cells suppress intestinal inflammation in vivo. We also describe a model of T cell-dependent IBD in immunocompetent mice, induced by infection with the intestinal bacterium Helicobacter hepaticus and concomitant treatment with a blocking ??IL-10R mAb, which leads to the development of chronic inflammation of the caecum and colon (typhlocolitis). Both models reproduce many facets of human IBD pathology, including epithelial hyperplasia, goblet cell depletion, and leukocyte infiltration. These models provide reliable and tractable systems for the analyses of the induction and regulation of chronic inflammation in the gut.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Song-Zhao</LastName>
                    <ForeName>George X</ForeName>
                    <Initials>GX</Initials>
                    <Affiliation>Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maloy</LastName>
                    <ForeName>Kevin J</ForeName>
                    <Initials>KJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_18</ArticleId>
            <ArticleId IdType="pubmed">25151008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151007</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Induction of Passive EAE Using Myelin-Reactive CD4+ T Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>187-98</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_17</ELocationID>
            <Abstract>
                <AbstractText>Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease of the central nervous system (CNS) often used as a model for the early inflammatory stages of multiple sclerosis and also as a model of organ-specific autoimmune disease.This protocol describes the induction of passive EAE in mice, either using T cells isolated from mice primed with myelin antigens, or through the use of na??ve TCR transgenic T cells activated in vitro in the presence of myelin-derived antigens.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>McPherson</LastName>
                    <ForeName>Rhoanne C</ForeName>
                    <Initials>RC</Initials>
                    <Affiliation>MRC Centre for Inflammation Research and Centre for Multiple Sclerosis Research, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cambrook</LastName>
                    <ForeName>Helen E</ForeName>
                    <Initials>HE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connor</LastName>
                    <ForeName>Richard A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anderton</LastName>
                    <ForeName>Stephen M</ForeName>
                    <Initials>SM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_17</ArticleId>
            <ArticleId IdType="pubmed">25151007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151006</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aldara-induced psoriasis-like skin inflammation: isolation and characterization of cutaneous dendritic cells and innate lymphocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>171-85</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_16</ELocationID>
            <Abstract>
                <AbstractText>Psoriasis is a chronic auto-inflammatory skin disease of unknown etiology affecting millions of people worldwide. Dissecting the cellular networks and molecular signals promoting the development of psoriasis critically depends on appropriate animal models. Topical application of Aldara cream containing the Toll-like receptor (TLR)7-ligand Imiquimod induces skin inflammation and pathology in mice closely resembling plaque-type psoriasis in humans. The particular power of the Aldara model lies in examining the early events during psoriatic plaque formation, which is difficult to achieve in patients. Hence, recent reports using this model have challenged currently prevailing concepts concerning the pathophysiology of psoriasis. Here, we describe the induction and phenotype of Aldara-mediated dermatitis in mice and, in particular, analysis of the inflammatory cell infiltrate using flow cytometry.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wohn</LastName>
                    <ForeName>C T</ForeName>
                    <Initials>CT</Initials>
                    <Affiliation>Department of Immunology, Erasmus MC, University Medical Center Rotterdam, 3015 GE, Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pantelyushin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ober-Bl??baum</LastName>
                    <ForeName>J L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clausen</LastName>
                    <ForeName>B E</ForeName>
                    <Initials>BE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_16</ArticleId>
            <ArticleId IdType="pubmed">25151006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151004</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Induction of colitis in mice (T-cell transfer model).</ArticleTitle>
            <Pagination>
                <MedlinePgn>143-51</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_14</ELocationID>
            <Abstract>
                <AbstractText>Animal model of intestinal inflammation is essential for the understanding of the pathomechanisms of inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Typically, na??ve T-cells were transferred into immunocompromised mice and develop gut inflammation because of inappropriate downregulation. Here, we describe the isolation, purification, and transfer of CD4(+)CD25(-) T-cells into recipients to obtain an experimental colitis model for the analysis of pathogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weigmann</LastName>
                    <ForeName>Benno</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Medical Clinic I, Research-Campus, University of Erlangen-Nuremberg, Hartmannstr. 14, 91052, Erlangen, Germany, benno.weigmann@uk-erlangen.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_14</ArticleId>
            <ArticleId IdType="pubmed">25151004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151003</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mouse models of allergic airway disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>127-41</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_13</ELocationID>
            <Abstract>
                <AbstractText>In the last decades there has been a substantial increase in the prevalence of allergic diseases such as asthma. Hence there is a basic necessity to investigate disease mechanisms of allergic disorders and to trace novel treatment approaches. Indeed, allergic asthma is a disorder which is characterized by airway inflammation, airway obstruction, and hyperresponsiveness. Several of these features can be studied in models of allergic airway disease. In this chapter different mouse models of allergic diseases are described. These include frequently models of allergic airway disease utilizing sensitization and challenge towards ovalbumin. Furthermore a model using the human-relevant allergen-specific house dust mite is described. In addition, information about DC-induced models and analysis of in vitro-generated T cell following transfer into recipients are described as well as analysis of a humanized mouse model is provided.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Meyer-Martin</LastName>
                    <ForeName>Helen</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pulmonogy, III. Medical Clinic, University Medical Center, Mainz, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reuter</LastName>
                    <ForeName>Sebastian</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taube</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_13</ArticleId>
            <ArticleId IdType="pubmed">25151003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151002</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Method for the Generation of TCR Retrogenic Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>117-26</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_12</ELocationID>
            <Abstract>
                <AbstractText>Retrogenic mice provide a unique system for rapidly analyzing the function of genes in the hematopoietic system. Here, we provide a detailed protocol for the production of retrogenic mice expressing genes coding for T cell receptor (TCR) for antigen. This technology should be easy to establish in any laboratory and should allow for a rapid progress in our understanding of the functional roles of TCR repertoires in immunity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kieback</LastName>
                    <ForeName>Elisa</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Max Delbrueck Center for Molecular Medicine, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hilgenberg</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fillatreau</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_12</ArticleId>
            <ArticleId IdType="pubmed">25151002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25151001</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro polarization of T-helper cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>105-13</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_11</ELocationID>
            <Abstract>
                <AbstractText>In vitro polarization of CD4(+) T cells along distinct T-helper (Th) lineages is critical for defining the factors and properties that determine the differentiation, stability, and effector functions of each Th subset. Furthermore, polarized cells can be transferred into na??ve syngeneic mice to investigate their trafficking patterns and pathological or therapeutic roles in the setting of infection, autoimmunity, and neoplasia. In this chapter, we describe methods for generating and characterizing a spectrum of CD4(+) Th cell lines in vitro. Protocols are provided that use na??ve wild-type or T cell receptor (TCR) transgenic CD4+ T cells, or a polyclonal population of primed CD4+ T cells from immunized mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rumble</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neurology, Holtom-Garrett Program in Neuroimmunology and Multiple Sclerosis Center, University of Michigan, 3013 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109-2200, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segal</LastName>
                    <ForeName>Benjamin M</ForeName>
                    <Initials>BM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_11</ArticleId>
            <ArticleId IdType="pubmed">25151001</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150995</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intracellular staining for cytokines and transcription factors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>39-49</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_5</ELocationID>
            <Abstract>
                <AbstractText>Within the past years immune cells in general and T cells in particular have been categorized into a vast variety of subsets with different functional properties. One of the key technologies fueling this emerging complexity is intracellular staining for effector cytokines and/or lineage-defining transcription factors. Here we discuss the critical steps for performing successful multicolor immunophenotyping of mouse T cells in combination with analysis of intracellular molecules after ex vivo isolation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mair</LastName>
                    <ForeName>Florian</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Institute of Experimental Immunology, University of Z??rich, Winterthurerstrasse 190, 8057, Z??rich, Switzerland, mair@immunology.uzh.ch.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tosevski</LastName>
                    <ForeName>Vinko</ForeName>
                    <Initials>V</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_5</ArticleId>
            <ArticleId IdType="pubmed">25150995</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150994</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>T cell isolation from mouse kidneys.</ArticleTitle>
            <Pagination>
                <MedlinePgn>27-35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_4</ELocationID>
            <Abstract>
                <AbstractText>The kidneys contain very few lymphocytes under homeostatic conditions. One kidney from a healthy mouse per average contains only 1-5????????10(3) CD4(+) T cells. In immune-mediated kidney disease, ???? T cells, NKT cells, CD4(+) T cells, CD8(+) T cells, and regulatory T cells (Treg) infiltrate the kidney. Their numbers and subset composition of infiltrating T cells varies between the different forms of nephritis. For example, in glomerulonephritis CD4(+) T cells mediate renal injury, by local cytokine production, effector cell activation and/or by helping B cells to produce nephritogenic antibodies. A better understanding of the pathomechanisms of immune-mediated kidney diseases requires a method to isolate T cells from the kidney for ex vivo analysis. Here we describe an effective and specific isolation protocol for T cells from the murine kidney.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ludwig-Portugall</LastName>
                    <ForeName>Isis</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Institute of Experimental Immunology, Rheinische Friedrich-Wilhelms-University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurts</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_4</ArticleId>
            <ArticleId IdType="pubmed">25150994</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150992</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1940-6029</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1193</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Methods in molecular biology (Clifton, N.J.)</Title>
                <ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Isolation of leukocytes from mouse central nervous system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>15-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-4939-1212-4_2</ELocationID>
            <Abstract>
                <AbstractText>During neuroinflammatory or neurodegenerative diseases, it is often critical to characterize the composition of infiltrating immune cells. This protocol describes a reliable, fast, and simple method for the isolation of leukocytes from murine central nervous system (CNS) during steady state or inflammation for analysis by flow cytometry or other techniques.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lelios</LastName>
                    <ForeName>Iva</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Institute of Experimental Immunology, University of Z??rich, Winterthurerstrasse 190, 8057, Z??rich, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greter</LastName>
                    <ForeName>Melanie</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Methods Mol Biol</MedlineTA>
            <NlmUniqueID>9214969</NlmUniqueID>
            <ISSNLinking>1064-3745</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1212-4_2</ArticleId>
            <ArticleId IdType="pubmed">25150992</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150989</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-6771</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of anaesthesia</Title>
                <ISOAbbreviation>Br J Anaesth</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Propofol modulates phasic and tonic GABAergic currents in spinal ventral horn interneurones.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">aeu269</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Surgical interventions like skin incisions trigger withdrawal reflexes which require motor neurones and local circuit interneurones in the spinal ventral horn. This region plays a key role in mediating immobilizing properties of the GABAergic anaesthetic propofol. However, it is unclear how propofol modulates GABA(A) receptors in the spinal ventral horn and whether tonic or phasic inhibition is involved.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Organotypic spinal cord tissue slices were prepared from mice. Whole-cell recordings were performed for quantifying effects of propofol on GABA(A) receptor-mediated phasic transmission and tonic conductance.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Propofol increased GABAergic phasic transmission by a prolongation of the decay time constant in a concentration-dependent manner. The amount of the charge transferred per inhibitory post-synaptic current, described by the area under the curve, was significantly augmented by 1 ??M propofol (P&lt;0.01). A GABA(A) receptor-mediated tonic current was not induced by 1 ??M propofol but at a concentration of 5 ??M (P&lt;0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Propofol depresses ventral horn interneurones predominantly by phasic rather than by tonic GABA(A) receptor-mediated inhibition. However, the present results suggest that the involvement of a tonic inhibition might contribute to the efficacy of propofol to depress nociceptive reflexes at high concentrations of the anaesthetic.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Eckle</LastName>
                    <ForeName>V S</ForeName>
                    <Initials>VS</Initials>
                    <Affiliation>Experimental Anaesthesiology Section, Department of Anaesthesiology and Intensive Care, Eberhard-Karls-University, T??bingen, Germany veit-simon.eckle@uni-tuebingen.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rudolph</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>Laboratory of Genetic Neuropharmacology, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Antkowiak</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Experimental Anaesthesiology Section, Department of Anaesthesiology and Intensive Care, Eberhard-Karls-University, T??bingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grasshoff</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Experimental Anaesthesiology Section, Department of Anaesthesiology and Intensive Care, Eberhard-Karls-University, T??bingen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Br J Anaesth</MedlineTA>
            <NlmUniqueID>0372541</NlmUniqueID>
            <ISSNLinking>0007-0912</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">anaesthetics i.v., propofol</Keyword>
            <Keyword MajorTopicYN="N">brain, anaesthesia, molecular effects</Keyword>
            <Keyword MajorTopicYN="N">ions, ion channels, pharmacology</Keyword>
            <Keyword MajorTopicYN="N">pharmacology, propofol</Keyword>
            <Keyword MajorTopicYN="N">spinal cord, GABA</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">aeu269</ArticleId>
            <ArticleId IdType="doi">10.1093/bja/aeu269</ArticleId>
            <ArticleId IdType="pubmed">25150989</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150942</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-7064</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuropharmacology</Title>
                <ISOAbbreviation>Neuropharmacology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-affinity GABA uptake by neuronal GAT1 transporters provokes release of [(3)H]GABA by homoexchange and through GAT1-independent Ca(2+)-mediated mechanisms.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0028-3908(14)00290-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neuropharm.2014.08.007</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">High-affinity uptake of GABA into nerve terminals may have functions other than recapture of the neurotransmitter. Synaptosomes purified from mouse cerebellum were prelabelled with [(3)H]GABA and then superfused with GABA and drugs selective for some presynaptic targets. Influx of GABA through GAT1 transporters stimulated efflux of [(3)H]GABA in a concentration-dependent manner (EC50 ??? 3 ??M). The efflux of the transmitter occurred in part by GAT1 reversal through the so called homoexchange. The ion fluxes (particularly Na(+) influx) accompanying GABA uptake triggered intraterminal Ca(2+) signals through both plasmalemmal Na(+)/Ca(2+) exchangers, sensitive to KB-R7943 or to ifenprodil and mitochondrial Na(+)/Ca(2+) exchangers, sensitive to CGP37157. These Ca(2+) signals likely facilitated GABA release from nerve terminals via niflumic acid- and NPPB-sensitive anion channels. The results show that GABA, at concentrations corresponding to the high-affinity uptake, can evoke GABA release which occurs in part by the expected GAT1-mediated homoexchange, while the transporter-independent component of the GABA uptake-evoked GABA release takes place by hitherto unsuspected mechanisms which include Na(+)/Ca(2+) exchangers and anion channels. The significance of the novel function of the GABA high-affinity uptake here identified deserves further multidisciplinary investigation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Romei</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy, Pharmacology and Toxicology Section, University of Genoa, Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sabolla</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy, Pharmacology and Toxicology Section, University of Genoa, Genoa, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Raiteri</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pharmacy, Pharmacology and Toxicology Section, University of Genoa, Genoa, Italy; Center of Excellence for Biomedical Research. University of Genoa, Genoa, Italy; National Institute of Neuroscience, Genoa, Italy. Electronic address: lraiter@pharmatox.unige.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuropharmacology</MedlineTA>
            <NlmUniqueID>0236217</NlmUniqueID>
            <ISSNLinking>0028-3908</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anion channels</Keyword>
            <Keyword MajorTopicYN="N">GABA GAT1 transporter</Keyword>
            <Keyword MajorTopicYN="N">GABA homoexchange</Keyword>
            <Keyword MajorTopicYN="N">GABA release</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial Na(+)/Ca(2+) exchanger</Keyword>
            <Keyword MajorTopicYN="N">Plasmalemmal Na(+)/Ca(2+) exchanger</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0028-3908(14)00290-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2014.08.007</ArticleId>
            <ArticleId IdType="pubmed">25150942</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150941</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-1484</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>236</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Atherosclerosis</Title>
                <ISOAbbreviation>Atherosclerosis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>p66(Shc)-induced redox changes drive endothelial insulin resistance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>426-429</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0021-9150(14)01303-3</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.atherosclerosis.2014.07.027</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Obesity-induced insulin resistance (IR) precipitates cardiovascular disease (CVD). Impairment of insulin signalling in the endothelium is emerging as a trigger of IR but the underlying mechanisms remain elusive. The mitochondrial adaptor p66(Shc) drives endothelial dysfunction via reactive oxygen species (ROS) generation. This study investigates p66(Shc) role in obesity-induced impairment of endothelial insulin signalling.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">All experiments were performed in leptin-deficient (Lep(Ob/Ob)) and wild-type (WT) mice.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Endothelium-dependent relaxations to insulin were blunted in Lep(Ob/Ob) as compared to WT. Interestingly, in??vivo gene silencing of p66(Shc) restored insulin response via IRS-1/Akt/eNOS pathway. Furthermore, p66(Shc) knockdown in endothelial cells isolated from Lep(Ob/Ob) mice attenuated ROS production, free fatty acids (FFA) oxidation and prevented dysregulation of redox-sensitive pathways such as nuclear factor-kappa-B (NF-kB), AGE precursor methylglyoxal and PGI2 synthase.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Targeting endothelial p66(Shc) may represent a promising strategy to prevent IR and CVD in obese individuals.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Paneni</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Cardiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden; Cardiology, Department of Clinical and Molecular Medicine, University of Rome &quot;Sapienza&quot;, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Costantino</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Cardiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cosentino</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Cardiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden. Electronic address: francesco.cosentino@ki.se.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Atherosclerosis</MedlineTA>
            <NlmUniqueID>0242543</NlmUniqueID>
            <ISSNLinking>0021-9150</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
            <Keyword MajorTopicYN="N">Endothelial insulin resistance</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">Obesity</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0021-9150(14)01303-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.07.027</ArticleId>
            <ArticleId IdType="pubmed">25150941</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150938</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-1484</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>236</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Atherosclerosis</Title>
                <ISOAbbreviation>Atherosclerosis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hypoxia-induced endothelial dysfunction in apolipoprotein E-deficient mice; effects of infliximab and l-glutathione.</ArticleTitle>
            <Pagination>
                <MedlinePgn>400-410</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0021-9150(14)01342-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.atherosclerosis.2014.08.021</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Obstructive sleep apnoea (OSA) has been implicated as a risk factor for atherosclerosis. The aim of our study was to examine the effects of chronic intermittent hypoxia in apoE-/- mice serving as model of OSA on endothelial dysfunction and oxidative stress and to evaluate the reversibility of hypoxia-induced changes under anti-inflammatory infliximab and anti-oxidative l-glutathione.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">ApoE-/- mice were divided into 4 groups (n??=??9 each): 1. intermittent hypoxia 8??h/day for 6 weeks, 2. intermittent hypoxia??+??injections of infliximab, 3. intermittent hypoxia??+??injections of l-glutathione, 4. normoxia??=??control.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Endothelial function was impaired under hypoxia compared to control. Application of infliximab and l-glutathione improved it to a level of control. The percentage of endothelial microparticles increased under hypoxia compared to other groups. Levels of NADPH oxidase 2-derived reactive oxygen species were approximately 9 times higher in the hypoxia group. The number of sca-1/flk-1+ endothelial progenitor cells was higher in bone marrow and lower in blood under hypoxia vs. other groups. Stromal cell derived factor-1alpha- and matrix metalloproteinase-9-dependent release of these cells from bone marrow was attenuated under hypoxia. The number of DilacLDL+/lectin??+??early outgrowth progenitor cells and that of colony forming units from these cells were higher under hypoxia. Atherosclerotic plaques in the aorta were more frequent under hypoxia and control in comparison with both drug groups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Intermittent hypoxia contributes to endothelial dysfunction by the local increase in reactive oxygen species and reduction of the peripheral repair capacity. Infliximab and l-glutathione prevent hypoxia-induced vascular and extravascular changes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tuleta</LastName>
                    <ForeName>Izabela</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Internal Medicine II - Cardiology, Pulmonology, University of Bonn, Bonn, Germany. Electronic address: Izabela.Tuleta@ukb.uni-bonn.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fran??a</LastName>
                    <ForeName>Carolina Nunes</ForeName>
                    <Initials>CN</Initials>
                    <Affiliation>Department of Internal Medicine II - Cardiology, Pulmonology, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wenzel</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Physiology I, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fleischmann</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Physiology I, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nickenig</LastName>
                    <ForeName>Georg</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Internal Medicine II - Cardiology, Pulmonology, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Werner</LastName>
                    <ForeName>Nikos</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Internal Medicine II - Cardiology, Pulmonology, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Skowasch</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Internal Medicine II - Cardiology, Pulmonology, University of Bonn, Bonn, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Atherosclerosis</MedlineTA>
            <NlmUniqueID>0242543</NlmUniqueID>
            <ISSNLinking>0021-9150</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Endothelium</Keyword>
            <Keyword MajorTopicYN="N">Free radicals</Keyword>
            <Keyword MajorTopicYN="N">Hypoxia</Keyword>
            <Keyword MajorTopicYN="N">Progenitor cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0021-9150(14)01342-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.atherosclerosis.2014.08.021</ArticleId>
            <ArticleId IdType="pubmed">25150938</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25150882</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-1803</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>109</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Basic research in cardiology</Title>
                <ISOAbbreviation>Basic Res. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>434</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00395-014-0434-9</ELocationID>
            <Abstract>
                <AbstractText>This study aimed to investigate whether interferon regulatory factor 9 (IRF9) is involved in the pathogenesis of myocardial ischemia-reperfusion (I/R) injury and to explore the underlying molecular mechanisms of this process. Cell death plays a major role in myocardial I/R injury. We recently determined the importance of IRF9 in coordinating molecular events in response to hypertrophic stress in cardiomyocytes. However, the roles of IRF9 in lethal myocardial injury remain to be elucidated. The involvement of IRF9 was assessed via functional assays in a mouse myocardial I/R injury model by genetic knockout and cardiomyocyte-specific transgenic overexpression of IRF9, and its effects on cardiomyocyte apoptosis and inflammation were further studied in vivo and in vitro. IRF9 was upregulated in human ischemic heart tissue and mouse hearts after I/R injury. Ablation of IRF9 protected the heart against I/R-induced cardiomyocyte death, development of inflammation, and loss of heart function. In contrast, cardiomyocyte-specific transgenic overexpression of IRF9 aggravated myocardial reperfusion injury and inflammation. IRF9 negatively regulated the Sirt1-p53 axis under I/R conditions in vivo and in vitro. Downregulation of Sirt1 expression and its downstream apoptosis-related signaling cascade, which results from I/R, was ameliorated by loss of IRF9 and exacerbated by overexpression of IRF9. Cardiomyocyte-specific deletion of Sirt1 abolished the protective effect of IRF9 knockout against I/R injury, which further indicated that IRF9 mediated myocardial reperfusion injury by modulating the Sirt1-p53 axis. Thus, IRF9 may be a novel therapeutic target for the prevention of I/R injury resulting from revascularization therapy after acute myocardial infarction (MI).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Xiaoxiong</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>She</LastName>
                    <ForeName>Zhi-Gang</ForeName>
                    <Initials>ZG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Ding-Sheng</ForeName>
                    <Initials>DS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wan</LastName>
                    <ForeName>Nian</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xia</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Xue-Hai</ForeName>
                    <Initials>XH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Xiang</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao-Dong</ForeName>
                    <Initials>XD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hongliang</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Basic Res Cardiol</MedlineTA>
            <NlmUniqueID>0360342</NlmUniqueID>
            <ISSNLinking>0300-8428</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00395-014-0434-9</ArticleId>
            <ArticleId IdType="pubmed">25150882</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150830</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-5875</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The international journal of biochemistry &amp; cell biology</Title>
                <ISOAbbreviation>Int. J. Biochem. Cell Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Notch ??-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-??/Smad2/3 signaling pathway activation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1357-2725(14)00260-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.biocel.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Kidney fibrosis is a common feature of chronic kidney disease (CKD). A recent study suggests that abnormal Notch signaling activation contributes to the development of renal fibrosis. However, the molecular mechanism that regulates this process remains unexplored. Unilateral ureteral obstruction (UUO) or sham-operated C57BL6 mice (aged 10 weeks) were randomly assigned to receive dibenzazepine (DBZ, 250??g/100g/d) or vehicle for 7 days. Histologic examinations were performed on the kidneys using Masson's trichrome staining and immunohistochemistry. Real-time PCR and western blot analysis were used for detection of mRNA expression and protein phosphorylation. The expression of Notch 1, 3, and 4, Notch intracellular domain (NICD), and its target genes Hes1 and HeyL were upregulated in UUO mice, while the increase in NICD protein was significantly attenuated by DBZ. After 7 days, the severity of renal fibrosis and expression of fibrotic markers, including collagen 1??1/3??1, fibronectin, and ??-smooth muscle actin, were markedly increased in UUO compared with sham mice. In contrast, administration of DBZ markedly attenuated these effects. Furthermore, DBZ significantly inhibited UUO-induced expression of transforming growth factor (TGF)-??, phosphorylated Smad 2, and Smad 3. Mechanistically, Notch signaling activation in tubular epithelial cells enhanced fibroblast proliferation and activation in a coculture experiment. Our study provides evidence that Notch signaling is implicated in renal fibrogenesis. The Notch inhibitor DBZ can ameliorate this process via inhibition of the TGF-??/Smad2/3 signaling pathway, and might be a novel drug for preventing chronic kidney disease.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Xiao</LastName>
                    <ForeName>Zhicheng</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Peng</LastName>
                    <ForeName>Xiaogang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dong</LastName>
                    <ForeName>Yanjun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jia</LastName>
                    <ForeName>Lixin</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Huihua</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Physiology and Pathophysiology, Capital Medical University, Beijing, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Du</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Beijing AnZhen Hospital, Capital Medical University; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing; Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China. Electronic address: jdu@bcm.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Biochem Cell Biol</MedlineTA>
            <NlmUniqueID>9508482</NlmUniqueID>
            <ISSNLinking>1357-2725</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Notch</Keyword>
            <Keyword MajorTopicYN="N">TGF-??</Keyword>
            <Keyword MajorTopicYN="N">epithelial-to-mesenchymal transition</Keyword>
            <Keyword MajorTopicYN="N">fibroblast</Keyword>
            <Keyword MajorTopicYN="N">kidney fibrosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1357-2725(14)00260-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biocel.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25150830</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150791</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-9157</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of autoimmunity</Title>
                <ISOAbbreviation>J. Autoimmun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0896-8411(14)00125-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jaut.2014.07.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mice immunized with ??2-glycoprotein I (??2GPI) are an experimental model of the antiphospholipid syndrome (eAPS) displaying elevated titers of antiphospholipid antibodies (aPL). We presently studied whether the behavioral hyperactivity in eAPS mice is associated with in??vivo binding and accumulation of IgG in the brain. At 6 weeks post immunization eAPS mice had significantly higher levels of aPL (1.32??????0.28 and 0.02??????0.01 AU, p??&lt;??0.001 by t-test) compared to adjuvant immunized controls, as measured by ELISA. Significant hyperactivity in a staircase test in the eAPS mice compared to controls was found in stair-climbing (18.4??????0.9 and 12.0??????1.7, respectively) and rearing measures (23.5??????2.1 and 12.5??????1.9, p??&lt;??0.01 by t-test). Immunofluorescence staining in eAPS mice revealed significant in??vivo accumulation of IgG in cortical and hippocampal neurons which was not seen in controls. Staining for IgG was markedly intense in inhibitory interneurons co-stained for GAD67 in the hippocampus of eAPS mice. The integrity of the blood brain barrier (BBB) evaluated by injection of Evans blue (EB) was impaired in eAPS and adjuvant immunized mice compared to na??ve mice. Electrophysiological recordings in hippocampal brain slices showed altered response to paired pulse stimulation as well as dysregulation of carbachol-induced ??- oscillations in eAPS mice compared to control. Penetration into the brain and direct interaction of aPL with inhibitory interneurons in the hippocampus may explain the hyperactive behavior of the eAPS mice. A direct role of aPL in causing CNS dysfunction points to these antibodies as an important therapeutic target in APS.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Katzav</LastName>
                    <ForeName>Aviva</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel. Electronic address: avivakatzav@gmail.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Menachem</LastName>
                    <ForeName>Assaf</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel; Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maggio</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel; The Talpiot Medical Leadership Program, Sheba Medical Center, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pollak</LastName>
                    <ForeName>Lea</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pick</LastName>
                    <ForeName>Chaim G</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chapman</LastName>
                    <ForeName>Joab</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel; Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Israel.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Autoimmun</MedlineTA>
            <NlmUniqueID>8812164</NlmUniqueID>
            <ISSNLinking>0896-8411</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antiphospholipid antibodies</Keyword>
            <Keyword MajorTopicYN="N">Blood brain barrier</Keyword>
            <Keyword MajorTopicYN="N">Experimental antiphospholipid syndrome</Keyword>
            <Keyword MajorTopicYN="N">Hippocampus</Keyword>
            <Keyword MajorTopicYN="N">Hyperactivity</Keyword>
            <Keyword MajorTopicYN="N">Inhibitory interneurons</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0896-8411(14)00125-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaut.2014.07.006</ArticleId>
            <ArticleId IdType="pubmed">25150791</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150729</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3492</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinica chimica acta; international journal of clinical chemistry</Title>
                <ISOAbbreviation>Clin. Chim. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development and application of a comparative fatty acid analysis method to investigate voriconazole-induced hepatotoxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0009-8981(14)00355-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.cca.2014.08.013</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As fatty acids play an important role in biological regulation, the profiling of fatty acid expression has been used to discover various disease markers and to understand disease mechanisms. This study developed an effective and accurate comparative fatty acid analysis method using differential labeling to speed the metabolic profiling of fatty acids.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Fatty acids were derivatized with unlabeled (D0) or deuterated (D3) methanol, followed by GC-MS analysis. The comparative fatty acid analysis method was validated using a series of samples with different ratios of D0/D3-labeled fatty acid standards and with mouse liver extracts.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Using a lipopolysaccharide (LPS)-treated mouse model, we found that the fatty acid profiles after LPS treatment were similar between the conventional single sample analysis approach and the proposed comparative approach, with a Pearson's correlation coefficient of approximately 0.96. We applied the comparative method to investigate voriconazole-induced hepatotoxicity and revealed the toxicity mechanism as well as the potential of using fatty acids as toxicity markers.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, the comparative fatty acid profiling technique was determined to be fast and accurate and to allow the discovery of potential fatty acid biomarkers in a more economical and efficient manner.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Guan-Yuan</ForeName>
                    <Initials>GY</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiu</LastName>
                    <ForeName>Huai-Hsuan</ForeName>
                    <Initials>HH</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Shu-Wen</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tseng</LastName>
                    <ForeName>Yufeng Jane</ForeName>
                    <Initials>YJ</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan; Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan; Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tsai</LastName>
                    <ForeName>Sung-Jeng</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kuo</LastName>
                    <ForeName>Ching-Hua</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: kuoch@ntu.edu.tw.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Chim Acta</MedlineTA>
            <NlmUniqueID>1302422</NlmUniqueID>
            <ISSNLinking>0009-8981</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">bioanalysis</Keyword>
            <Keyword MajorTopicYN="N">comparative fatty acid analysis</Keyword>
            <Keyword MajorTopicYN="N">gas chromatography-mass spectrometry</Keyword>
            <Keyword MajorTopicYN="N">hepatotoxicity</Keyword>
            <Keyword MajorTopicYN="N">stable isotope labeling</Keyword>
            <Keyword MajorTopicYN="N">voriconazole</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009-8981(14)00355-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cca.2014.08.013</ArticleId>
            <ArticleId IdType="pubmed">25150729</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150689</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1769-714X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Microbes and infection / Institut Pasteur</Title>
                <ISOAbbreviation>Microbes Infect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adipocytes in both brown and white adipose tissue of adult mice are functionally connected via gap junctions: implications for Chagas disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1286-4579(14)00111-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.micinf.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Adipose tissue serves as a host reservoir for the protozoan Trypanosoma cruzi, the causative organism in Chagas disease. Gap junctions interconnect cells of most tissues, serving to synchronize cell activities including secretion in glandular tissue, and we have previously demonstrated that gap junctions are altered in various tissues and cells infected with T. cruzi. Herein, we examined the gap junction protein connexin 43 (Cx43) expression in infected adipose tissues. Adipose tissue is the largest endocrine organ of the body and is also involved in other physiological functions. In mammals, it is primarily composed of white adipocytes. Although gap junctions are a prominent feature of brown adipocytes, they have not been explored extensively in white adipocytes, especially in the setting of infection. Thus, we examined functional coupling in both white and brown adipocytes in mice. Injection of electrical current or the dye Lucifer Yellow into adipocytes within fat tissue spread to adjacent cells, which was reduced by treatment with agents known to block gap junctions. Moreover, Cx43 was detected in both brown and white fat tissue. At thirty and ninety days post-infection, Cx43 was downregulated in brown adipocytes and upregulated in white adipocytes. Gap junction-mediated intercellular communication likely contributes to hormone secretion and other functions in white adipose tissue and to nonshivering thermogenesis in brown fat, and modulation of the coupling by T. cruzi infection is expected to impact these functions.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Masson SAS.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Burke</LastName>
                    <ForeName>Shoshana</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departments of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Departments of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nagajyothi</LastName>
                    <ForeName>Fnu</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Departments of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thi</LastName>
                    <ForeName>Mia M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Departments of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Departments of Orthopedic Surgery, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hanani</LastName>
                    <ForeName>Menachem</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Experimental Surgery, Hadassah-Hebrew University- Medical Center, Mount Scopus, Jerusalem, 91120, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Scherer</LastName>
                    <ForeName>Philipp E</ForeName>
                    <Initials>PE</Initials>
                    <Affiliation>Department of Internal Medicine and Cell Biology and the Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanowitz</LastName>
                    <ForeName>Herbert B</ForeName>
                    <Initials>HB</Initials>
                    <Affiliation>Departments of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Departments of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Spray</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Departments of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Departments of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: david.spray@einstein.yu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Microbes Infect</MedlineTA>
            <NlmUniqueID>100883508</NlmUniqueID>
            <ISSNLinking>1286-4579</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BAT</Keyword>
            <Keyword MajorTopicYN="N">Chagas disease</Keyword>
            <Keyword MajorTopicYN="N">Cx43</Keyword>
            <Keyword MajorTopicYN="N">T. cruzi</Keyword>
            <Keyword MajorTopicYN="N">Trypanosoma cruzi</Keyword>
            <Keyword MajorTopicYN="N">WAT</Keyword>
            <Keyword MajorTopicYN="N">adipose tissue</Keyword>
            <Keyword MajorTopicYN="N">brown adipose tissue</Keyword>
            <Keyword MajorTopicYN="N">connexin43</Keyword>
            <Keyword MajorTopicYN="N">gap junctions</Keyword>
            <Keyword MajorTopicYN="N">white adipose tissue</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1286-4579(14)00111-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.micinf.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25150689</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150573</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1558-1497</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurobiology of aging</Title>
                <ISOAbbreviation>Neurobiol. Aging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of age-related loss of P/Q-type calcium channels in a mice model of peripheral nerve injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0197-4580(14)00494-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neurobiolaging.2014.07.025</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We analyzed the role of P/Q-type calcium channels in sciatic nerve regeneration after lesion induced by chronic constriction injury (CCI) in heterozygous null mutant mice lacking the CaV2.1??1 subunit of these channels (Cacna1a+/-). Compared with wild type, Cacna1a+/- mice showed an initial reduction of the CCI-induced allodynia, indicating a reduced pain perception, but they also evidenced a lack of recovery over time, with atrophy of the injured hindpaw still present 3??months after CCI when wild-type mice fully recovered. In parallel, Cacna1a+/- mice exhibited an early onset of age-dependent loss of P/Q-type channels, which can be responsible for the lack of functional recovery. Moreover, Cacna1a+/- mice showed an early age-dependent reduction of muscular strength, as well as of Schwann cells proliferation and sciatic nerve remyelination. This study demonstrates the important role played by P/Q-type channels in recovery from nerve injury and has important implications for the knowledge of age-related processes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Marinelli</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Eleuteri</LastName>
                    <ForeName>Cecilia</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Vacca</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Strimpakos</LastName>
                    <ForeName>Georgios</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mattei</LastName>
                    <ForeName>Elisabetta</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Severini</LastName>
                    <ForeName>Cinzia</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pavone</LastName>
                    <ForeName>Flaminia</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luvisetto</LastName>
                    <ForeName>Siro</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>CNR National Research Council of Italy, Cell Biology and Neurobiology Institute, IRCCS Santa Lucia Foundation, Rome, Italy. Electronic address: siro.luvisetto@cnr.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurobiol Aging</MedlineTA>
            <NlmUniqueID>8100437</NlmUniqueID>
            <ISSNLinking>0197-4580</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Allodynia</Keyword>
            <Keyword MajorTopicYN="N">Cacna1a</Keyword>
            <Keyword MajorTopicYN="N">Muscle</Keyword>
            <Keyword MajorTopicYN="N">Nerve regeneration</Keyword>
            <Keyword MajorTopicYN="N">P/Q-type channels</Keyword>
            <Keyword MajorTopicYN="N">Schwann cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0197-4580(14)00494-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.025</ArticleId>
            <ArticleId IdType="pubmed">25150573</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150572</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1558-1497</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurobiology of aging</Title>
                <ISOAbbreviation>Neurobiol. Aging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Beta amyloid-induced upregulation of death receptor 6 accelerates the toxic effect of N-terminal fragment of amyloid precursor protein.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0197-4580(14)00496-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.neurobiolaging.2014.07.027</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Amyloid precursor protein (APP) plays essential roles in the development of the Alzheimer's disease. Although full-length APP has been thoroughly studied, the role of the cleavage fragments especially the N-terminal fragments (N-APPs) in Alzheimer's disease pathogenesis was still elusive. In this study, we demonstrated that application of recombinant APP18-286 could enhance beta amyloid (A??)-induced neuronal injuries which were related to the activation of apoptosis proteins. A?? treatment could induce a slight increase of N-APPs release. In addition, expression of death receptor 6 (DR6) was increased in A??-treated neurons and APP transgenic mice. Moreover, the effect of APP18-286 on A??-induced injuries could be suppressed by the application of recombinant DR641-341 and DR6 antibody. Furthermore, pull-down assay revealed that APP18-286 could bind both exogenous and endogenous DR6. A?? promoted APP18-286 targeting to neuron which was accompanied with the increase of DR6 expression, whereas downregulation of DR6 by interference RNA could alleviate the binding of N-APPs to neuron and also suppressed A??-dependent toxic effect with N-APPs. These results suggested that APP N-terminal fragments might play neurotoxic roles in A??-induced neuronal injuries through cell surface DR6.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Yuxia</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Dandan</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Chemistry and Institute of Biomedical Sciences, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Chemistry and Institute of Biomedical Sciences, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shan</LastName>
                    <ForeName>Ye</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tan</LastName>
                    <ForeName>Xiangshi</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Chemistry and Institute of Biomedical Sciences, Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Cuiqing</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China. Electronic address: cqzhu@shmu.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurobiol Aging</MedlineTA>
            <NlmUniqueID>8100437</NlmUniqueID>
            <ISSNLinking>0197-4580</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis pathway</Keyword>
            <Keyword MajorTopicYN="N">Death receptor 6</Keyword>
            <Keyword MajorTopicYN="N">N-terminal fragment of APP</Keyword>
            <Keyword MajorTopicYN="N">??-Amyloid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0197-4580(14)00496-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.027</ArticleId>
            <ArticleId IdType="pubmed">25150572</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150543</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1939-0084</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioral neuroscience</Title>
                <ISOAbbreviation>Behav. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>L-Dopa Reverses Behavioral Deficits in the Pitx3 Mouse Fetus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Studies of fetal rodents have provided evidence that early emerging behaviors, such as the suckling response, are dependent on the developing dopaminergic system. Although connections have been made between manipulations of dopamine and altered behavioral responses, the specific neural pathways involved have yet to be discovered. In this study, we examined the neurobehavioral output of the nigrostriatal pathway, using the Pitx3ak/2J mouse model (Pitx3). Used extensively in the study of Parkinson's disease, the Pitx3 mouse has very specific prenatal loss of dopaminergic neurons solely in the nigrostriatal pathway. Because of this specificity, we hypothesized that behavioral deficits specific to the nigrostriatal pathway would be reversed with administration of the dopamine precursor 3,4-dihydroxyphenylalanine (l-dopa). To test this hypothesis, homozygous mutant and heterozygous control fetal subjects were administered 1 of 4 doses (0, 25, 50, or 75 mg/kg) of l-dopa on the day before birth. Quantification of fetal behavior was scored from video recordings of behavioral observations. The behavioral measures used were (a) spontaneous movement activity; (b) state organization, from quantifications of high- and low-amplitude movements; (c) interlimb movement synchrony, a measure of limb coordination; and (d) oral grasp, similar to a newborn infant suckling response. Specific behavioral deficits observed in the Pitx3 mutants were reversed by l-dopa administration in a dose-dependent manner. However, different deficits required dissimilar doses for reversal, suggesting that some early emerging behaviors may be more sensitive to the administration of l-dopa. Taken together, this study provides valuable information about prenatal behaviors dependent on the nigrostriatal pathway. (PsycINFO Database Record (c) 2014 APA, all rights reserved).</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kleven</LastName>
                    <ForeName>Gale A</ForeName>
                    <Initials>GA</Initials>
                </Author>
                <Author>
                    <LastName>Booth</LastName>
                    <ForeName>Heather M</ForeName>
                    <Initials>HM</Initials>
                </Author>
                <Author>
                    <LastName>Voogd</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Ronca</LastName>
                    <ForeName>April E</ForeName>
                    <Initials>AE</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Behav Neurosci</MedlineTA>
            <NlmUniqueID>8302411</NlmUniqueID>
            <ISSNLinking>0735-7044</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2014-35410-001</ArticleId>
            <ArticleId IdType="doi">10.1037/bne0000016</ArticleId>
            <ArticleId IdType="pubmed">25150543</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150532</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-1506</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>59</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>2</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of oral biology</Title>
                <ISOAbbreviation>Arch. Oral Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impaired mastication reduced newly generated neurons at the accessory olfactory bulb and pheromonal responses in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1272-1278</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0003-9969(14)00203-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.archoralbio.2014.07.018</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">A large number of neurons are generated at the subventricular zone (SVZ) even during adulthood. In a previous study, we have shown that a reduced mastication impairs both neurogenesis in the SVZ and olfactory functions. Pheromonal signals, which are received by the vomeronasal organ, provide information about reproductive and social states. Vomeronasal sensory neurons project to the accessory olfactory bulb (AOB) located on the dorso-caudal surface of the main olfactory bulb. Newly generated neurons at the SVZ migrate to the AOB and differentiate into granule cells and periglomerular cells. This study aimed to explore the effects of changes in mastication on newly generated neurons and pheromonal responses.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Bromodeoxyuridine-immunoreactive (BrdU-ir; a marker of DNA synthesis) and Fos-ir (a marker of neurons excited) structures in sagittal sections of the AOB after exposure to urinary odours were compared between the mice fed soft and hard diets.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The density of BrdU-ir cells in the AOB in the soft-diet-fed mice after 1 month was essentially similar to that of the hard-diet-fed mice, while that was lower in the soft-diet-fed mice for 3 or 6 months than in the hard-diet-fed mice. The density of Fos-ir cells in the soft-diet-fed mice after 2 months was essentially similar to that in the hard-diet-fed mice, while that was lower in the soft-diet-fed mice for 4 months than in the hard-diet-fed mice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present results suggest that impaired mastication reduces newly generated neurons at the AOB, which in turn impairs olfactory function at the AOB.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Utsugi</LastName>
                    <ForeName>Chizuru</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan; Department of Sensory Physiology, Asahikawa Medical University, Asahikawa 078-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miyazono</LastName>
                    <ForeName>Sadaharu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Sensory Physiology, Asahikawa Medical University, Asahikawa 078-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Osada</LastName>
                    <ForeName>Kazumi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Oral Biology, School of Dentistry, Health Sciences University of Hokkaido, Tohbetu 061-0293, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Matsuda</LastName>
                    <ForeName>Mitsuyoshi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kashiwayanagi</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Sensory Physiology, Asahikawa Medical University, Asahikawa 078-8510, Japan. Electronic address: yanagi@asahikawa-med.ac.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>2</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Oral Biol</MedlineTA>
            <NlmUniqueID>0116711</NlmUniqueID>
            <ISSNLinking>0003-9969</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hard diet</Keyword>
            <Keyword MajorTopicYN="N">Mastication</Keyword>
            <Keyword MajorTopicYN="N">Olfactory function</Keyword>
            <Keyword MajorTopicYN="N">Pheromone</Keyword>
            <Keyword MajorTopicYN="N">Soft diet</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0003-9969(14)00203-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.archoralbio.2014.07.018</ArticleId>
            <ArticleId IdType="pubmed">25150532</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150527</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-inflammatory activity of animal oils from the Peruvian Amazon.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-8741(14)00604-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jep.2014.08.010</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">animal oils and fats from the fishes Electrophorus electricus and Potamotrygon motoro, the reptiles Boa constrictor, Chelonoidis denticulata (Geochelone denticulata) and Melanosuchus niger and the riverine dolphin Inia geoffrensis are used as anti-inflammatory agents in the Peruvian Amazon.</AbstractText>
                <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">The aim of the study was to assess the topic anti-inflammatory effect of the oils/fats as well as to evaluate its antimicrobial activity and fatty acid composition.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The oils/fats were purchased from a traditional store at the Iquitos market of Belen, Peru. The topic anti-inflammatory effect was evaluated by the mice ear oedema induced by arachidonic acid (AA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) at the dose of 3mg oil/ear. Indomethacine and nimesulide were used as reference anti-inflammatory drugs. The application resembles the traditional topical use of the oils. The antimicrobial effect of the oils/fats was assessed by the microdilution test against reference strains of Escherichia coli, Staphylococcus aureus and Salmonella enteritidis. The fatty acid composition of the oils/fats (as methyl esters) was determined by GC and GC-MS analysis after saponification.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All oils/fats showed topic anti-inflammatory activity, with better effect in the TPA-induced mice ear oedema assay. The most active drugs were Potamotrygon motoro, Melanosuchus niger and Geochelone denticulata. In the AA-induced assay, the best activity was found for P. motoro and Electrophorus electricus oil. The oil of E. electricus also showed a weak antimicrobial effect with MIC values of 250??g/mL against E. coli ATCC 25922 and Salmonella enteritidis-MI. The main fatty acids in the oils were oleic, palmitic and linoleic acids.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Topical application of all the oils/fats investigated showed anti-inflammatory activity in the mice ear oedema assay. The effect can be related with the identity and composition of the fatty acids in the samples. This study gives support to the traditional use of animal oils/fats as ant-inflammatory agents in the Peruvian Amazon. However, new alternative should be encouraged due to the conservation status of several of the animal sources of the crude drugs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Schmeda-Hirschmann</LastName>
                    <ForeName>Guillermo</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Laboratorio de Qu??mica de Productos Naturales, Instituto de Qu??mica de Recursos Naturales, Universidad de Talca, Casilla 747, 3460000 Talca, Chile. Electronic address: schmeda@utalca.cl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Delporte</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratorio de Productos Naturales, Facultad de Ciencias Qu??micas y Farmac??uticas, Universidad de Chile, Casilla 233, Santiago 1, Chile.</Affiliation>
                </Author>
                <Author>
                    <LastName>Valenzuela-Barra</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Laboratorio de Productos Naturales, Facultad de Ciencias Qu??micas y Farmac??uticas, Universidad de Chile, Casilla 233, Santiago 1, Chile.</Affiliation>
                </Author>
                <Author>
                    <LastName>Silva</LastName>
                    <ForeName>Ximena</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Unidad de Pruebas Biol??gicas, Instituto de Salud P??blica de Chile, Marathon 1000, Santiago, Chile.</Affiliation>
                </Author>
                <Author>
                    <LastName>Vargas-Arana</LastName>
                    <ForeName>Gabriel</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Universidad Cient??fica del Peru. Avda. Abelardo Qui??ones Km 2.5, Iquitos, Peru.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lima</LastName>
                    <ForeName>Beatriz</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Instituto de Biotecnolog??a, Facultad de Ingenier??a, Universidad Nacional de San Juan, Av. Libertador General San Martin 1109 (oeste), CP 5400, San Juan, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Feresin</LastName>
                    <ForeName>Gabriela E</ForeName>
                    <Initials>GE</Initials>
                    <Affiliation>Instituto de Biotecnolog??a, Facultad de Ingenier??a, Universidad Nacional de San Juan, Av. Libertador General San Martin 1109 (oeste), CP 5400, San Juan, Argentina.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Amazonian Peru</Keyword>
            <Keyword MajorTopicYN="N">Animal oils</Keyword>
            <Keyword MajorTopicYN="N">Ethnozoology</Keyword>
            <Keyword MajorTopicYN="N">Geochelone denticulate</Keyword>
            <Keyword MajorTopicYN="N">Melanosuchus niger</Keyword>
            <Keyword MajorTopicYN="N">Potamotrygon motoro</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-8741(14)00604-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2014.08.010</ArticleId>
            <ArticleId IdType="pubmed">25150527</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150504</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1519</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Respiratory physiology &amp; neurobiology</Title>
                <ISOAbbreviation>Respir Physiol Neurobiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of ovariectomy on inflammation induced by intermittent hypoxia in a mouse model of sleep apnea.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1569-9048(14)00209-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.resp.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Patient data report marked gender and pre-vs-postmenopausal differences in obstructive sleep apnea (OSA). However, no experimental data are available on how sexual hormones modulate OSA consequences. Here we report novel results on estrogen-modulated heart and brain inflammation in female mice subjected to intermittent hypoxia, a major injurious challenge in OSA. C57BL/6J (14-week old) intact and ovariectomized mice (n=6 each) were subjected to intermittent hypoxia (20 s at 5% and 40 s at 21%, 60 cycles/h; 6h/day). Identical intact and ovariectomized groups breathing room air were controls. After 30 days, the gene expressions of interleukines 6 and 8 (IL-6, IL-8) in the brain and heart tissues were measured. Whereas, compared with normoxia, intermittent hypoxia considerably increased IL-6 and IL-8 gene expressions in intact females, no change was found in ovariectomized mice when comparing normoxia and intermittent hypoxia. These data suggest that estrogens modulate the inflammatory effects of intermittent hypoxia and point to further studies on the role played by sex hormones in OSA.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Torres</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>CIBER de Enfermedades Respiratorias, Madrid, Spain; Laboratori del Son, Hospital Cl??nic, Universitat de Barcelona-IDIBAPS, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Palomer</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>CIBER de Diabetes y Enfermedades Metab??licas Asociadas, Madrid, Spain; Department de Farmacologia i Qu??mica Terap??utica, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Facultat de Farm??cia, Universitat de Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Montserrat</LastName>
                    <ForeName>Josep M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>CIBER de Enfermedades Respiratorias, Madrid, Spain; Laboratori del Son, Hospital Cl??nic, Universitat de Barcelona-IDIBAPS, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>V??zquez-Carrera</LastName>
                    <ForeName>Manel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>CIBER de Diabetes y Enfermedades Metab??licas Asociadas, Madrid, Spain; Department de Farmacologia i Qu??mica Terap??utica, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Facultat de Farm??cia, Universitat de Barcelona, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Farr??</LastName>
                    <ForeName>Ramon</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>CIBER de Enfermedades Respiratorias, Madrid, Spain; Unitat Biof??sica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona-IDIBAPS, Spain. Electronic address: rfarre@ub.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Respir Physiol Neurobiol</MedlineTA>
            <NlmUniqueID>101140022</NlmUniqueID>
            <ISSNLinking>1569-9048</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Inflammation.</Keyword>
            <Keyword MajorTopicYN="N">Intermittent hypoxia</Keyword>
            <Keyword MajorTopicYN="N">Obstructive sleep apnea</Keyword>
            <Keyword MajorTopicYN="N">Ovariectomy</Keyword>
            <Keyword MajorTopicYN="N">Sexual hormones</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1569-9048(14)00209-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.resp.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25150504</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150496</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-170X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature medicine</Title>
                <ISOAbbreviation>Nat. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The G protein ?? subunit G??s is a tumor suppressor in Sonic hedgehog-driven medulloblastoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/nm.3666</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Medulloblastoma, the most common malignant childhood brain tumor, exhibits distinct molecular subtypes and cellular origins. Genetic alterations driving medulloblastoma initiation and progression remain poorly understood. Herein, we identify GNAS, encoding the G protein G??s, as a potent tumor suppressor gene that, when expressed at low levels, defines a subset of aggressive Sonic hedgehog (SHH)-driven human medulloblastomas. Ablation of the single Gnas gene in anatomically distinct progenitors in mice is sufficient to induce Shh-associated medulloblastomas, which recapitulate their human counterparts. G??s is highly enriched at the primary cilium of granule neuron precursors and suppresses Shh signaling by regulating both the cAMP-dependent pathway and ciliary trafficking of Hedgehog pathway components. Elevation in levels of a G??s effector, cAMP, effectively inhibits tumor cell proliferation and progression in Gnas-ablated mice. Thus, our gain- and loss-of-function studies identify a previously unrecognized tumor suppressor function for G??s that can be found consistently across Shh-group medulloblastomas of disparate cellular and anatomical origins, highlighting G protein modulation as a potential therapeutic avenue.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Xuelian</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>1] Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China. [2] Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Liguo</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Life Sciences, Xiamen University, Fujian, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Remke</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shih</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Fanghui</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Haibo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Deng</LastName>
                    <ForeName>Yaqi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Pediatrics, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xia</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Xiaochong</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramaswamy</LastName>
                    <ForeName>Vijay</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Fan</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Wenhao</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Burns</LastName>
                    <ForeName>Dennis K</ForeName>
                    <Initials>DK</Initials>
                    <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Se Hoon</ForeName>
                    <Initials>SH</Initials>
                    <Identifier Source="ORCID">0000000175167372</Identifier>
                    <Affiliation>Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kool</LastName>
                    <ForeName>Marcel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pfister</LastName>
                    <ForeName>Stefan M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Weinstein</LastName>
                    <ForeName>Lee S</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pomeroy</LastName>
                    <ForeName>Scott L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Department of Neurology, Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gilbertson</LastName>
                    <ForeName>Richard J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rubin</LastName>
                    <ForeName>Joshua B</ForeName>
                    <Initials>JB</Initials>
                    <Affiliation>Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hou</LastName>
                    <ForeName>Yiping</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Forensic Medicine, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, School of Preclinical and Forensic Medicine, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wechsler-Reya</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Tumor Development Program, Sanford-Burnham Medical Research Institute, La Jolla, California, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Q Richard</ForeName>
                    <Initials>QR</Initials>
                    <Affiliation>1] Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. [2] Department of Pediatrics, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Second Hospital, Sichuan University, Chengdu, China. [3] Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Med</MedlineTA>
            <NlmUniqueID>9502015</NlmUniqueID>
            <ISSNLinking>1078-8956</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">nm.3666</ArticleId>
            <ArticleId IdType="doi">10.1038/nm.3666</ArticleId>
            <ArticleId IdType="pubmed">25150496</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150483</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1874-1754</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of cardiology</Title>
                <ISOAbbreviation>Int. J. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0167-5273(14)01517-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ijcard.2014.08.011</ELocationID>
            <AuthorList>
                <Author>
                    <LastName>Gonz??lez</LastName>
                    <ForeName>Germ??n E</ForeName>
                    <Initials>GE</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina; Instituto de Bioqu??mica y Medicina Molecular (IBIMOL), UBA-CONICET, Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cassaglia</LastName>
                    <ForeName>Pablo</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina; Instituto de Bioqu??mica y Medicina Molecular (IBIMOL), UBA-CONICET, Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Noli Truant</LastName>
                    <ForeName>Sof??a</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>C??tedra de Inmunolog??a and Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-UBA, Facultad de Farmacia y Bioqu??mica, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fern??ndez</LastName>
                    <ForeName>Marisa M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>C??tedra de Inmunolog??a and Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-UBA, Facultad de Farmacia y Bioqu??mica, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wilensky</LastName>
                    <ForeName>Luciana</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina; Instituto de Bioqu??mica y Medicina Molecular (IBIMOL), UBA-CONICET, Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Volberg</LastName>
                    <ForeName>Ver??nica</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Malchiodi</LastName>
                    <ForeName>Emilio L</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>C??tedra de Inmunolog??a and Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-UBA, Facultad de Farmacia y Bioqu??mica, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morales</LastName>
                    <ForeName>Celina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina; Instituto de Bioqu??mica y Medicina Molecular (IBIMOL), UBA-CONICET, Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gelpi</LastName>
                    <ForeName>Ricardo J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Instituto de Fisiopatolog??a Cardiovascular (INFICA), Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Argentina; Instituto de Bioqu??mica y Medicina Molecular (IBIMOL), UBA-CONICET, Departamento de Patolog??a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Electronic address: rgelpi@fmed.uba.ar.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Cardiol</MedlineTA>
            <NlmUniqueID>8200291</NlmUniqueID>
            <ISSNLinking>0167-5273</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Galectin-3</Keyword>
            <Keyword MajorTopicYN="N">Healing</Keyword>
            <Keyword MajorTopicYN="N">Myocardial infarction</Keyword>
            <Keyword MajorTopicYN="N">Ventricular remodeling</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0167-5273(14)01517-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijcard.2014.08.011</ArticleId>
            <ArticleId IdType="pubmed">25150483</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150436</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3557</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>135C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy</Title>
                <ISOAbbreviation>Spectrochim Acta A Mol Biomol Spectrosc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthesis, spectroscopic, structural and thermal characterizations of vanadyl(IV) adenine complex prospective as antidiabetic drug agent.</ArticleTitle>
            <Pagination>
                <MedlinePgn>850-864</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S1386-1425(14)01155-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.saa.2014.07.074</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The vanadyl(IV) adenine complex; [VO(Adn)2]???SO4; was synthesized and characterized. The molar conductivity of this complex was measured in DMSO solution that showed an electrolyte nature. Spectroscopic investigation of the green solid complex studied here indicate that the adenine acts as a bidentate ligand, coordinated to vanadyl(IV) ions through the nitrogen atoms N7 and nitrogen atom of amino group. Thus, from the results presented the vanadyl(IV) complex has square pyramid geometry. Further characterizations using thermal analyses and scanning electron techniques was useful. The aim of this paper was to introduce a new drug model for the diabetic complications by synthesized a novel mononuclear vanadyl(IV) adenine complex to mimic insulin action and reducing blood sugar level. The antidiabetic ability of this complex was investigated in STZ-induced diabetic mice. The results suggested that VO(IV)/adenine complex has antidiabetic activity, it improved the lipid profile, it improved liver and kidney functions, also it ameliorated insulin hormone and blood glucose levels. The vanadyl(IV) complex possesses an antioxidant activity and this was clear through studying SOD, CAT, MDA, GSH and methionine synthase. The current results support the therapeutic potentiality of vanadyl(IV)/adenine complex for the management and treatment of diabetes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>El-Megharbel</LastName>
                    <ForeName>Samy M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Chemistry, Faculty of Science, Taif University, Al-Haweiah, P.O. Box 888, 21974 Taif, Saudi Arabia; Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hamza</LastName>
                    <ForeName>Reham Z</ForeName>
                    <Initials>RZ</Initials>
                    <Affiliation>Department of Zoology, Faculty of Science, Zagazig University, Zagazig, Egypt.</Affiliation>
                </Author>
                <Author>
                    <LastName>Refat</LastName>
                    <ForeName>Moamen S</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>Department of Chemistry, Faculty of Science, Taif University, Al-Haweiah, P.O. Box 888, 21974 Taif, Saudi Arabia; Department of Chemistry, Faculty of Science, Port Said University, Port Said, Egypt. Electronic address: msrefat@yahoo.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Spectrochim Acta A Mol Biomol Spectrosc</MedlineTA>
            <NlmUniqueID>9602533</NlmUniqueID>
            <ISSNLinking>1386-1425</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adenine</Keyword>
            <Keyword MajorTopicYN="N">Diabetic</Keyword>
            <Keyword MajorTopicYN="N">Mimic insulin</Keyword>
            <Keyword MajorTopicYN="N">Spectroscopic</Keyword>
            <Keyword MajorTopicYN="N">Vanadyl ion</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1386-1425(14)01155-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.saa.2014.07.074</ArticleId>
            <ArticleId IdType="pubmed">25150436</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150391</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1556-5653</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Fertility and sterility</Title>
                <ISOAbbreviation>Fertil. Steril.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Germ cell transplantation into mouse testes procedure.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0015-0282(14)01296-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.fertnstert.2014.07.669</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To illustrate the step-by-step protocol followed to assay germ cell transplantation into the seminiferous epithelium of mouse testes.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Video presentation of an animal model for research in reproductive and regenerative medicine.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">Research laboratory.</AbstractText>
                <AbstractText Label="ANIMAL(S)" NlmCategory="METHODS">Male nude mice (NU-Foxn1(nu)).</AbstractText>
                <AbstractText Label="INTERVENTION(S)" NlmCategory="METHODS">Mice were chemically sterilized with alkylant compounds (busulfan) followed by gonadal microsurgery to inject donor germ cells.</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURE(S)" NlmCategory="METHODS">Donor cells should be labeled with reporter genes, such as green fluorescent protein (GFP), lactose operon (LacZ), or alternatively design an effective strategy with specific antibodies to track them within the recipient testes. Sperm detection in the ejaculate can also be used as a read out. However, in this case detection of the donor genotype in the sperm is mandatory to elucidate their origin.</AbstractText>
                <AbstractText Label="RESULT(S)" NlmCategory="RESULTS">In the present study we describe the complete protocol for germ cell transplant by efferent duct injection, including the preparation of recipient mice, surgery for the germ cell transplant, and analysis of recipient testes. The main strength of this technique is that it constitutes the gold standard for a functional test of the germ cell potential as only spermatogonial stem cells are able to properly colonize the seminal lumen. Both fresh and frozen/thawed testicular cells are suitable for this technique as donor germ cells. Also, enrichment of living spermatogonial stem cells, previous to the transplant, seems to improve the efficiency of colonization. For proper colonization of germ cells, the niche should be available and thus mouse strains that lack endogenous spermatogenesis such as W/W(v) mutant mice are usually used. In the case of nonmatched donor cells, seminiferous epithelium of immune-suppressed recipient mice should be germ cell depleted before the transplant. One limitation of this technique is that the procedure can take up to 3??months. Also, in contrast to the full recovery of spermatogenesis in mouse-to-mouse transplants, xenotransplantation of germ cells from phylogenetically distant species, such as humans into mouse recipients, results in colonization of donor cells and spermatogonial expansion, but fail in their spermatogenic progression due to evolutive incompatibilities with the recipient niche. Xenografting of pieces of donor testis tissue under the skin of mouse hosts is an alternative approach that is currently being investigated to try to solve this limitation.</AbstractText>
                <AbstractText Label="CONCLUSION(S)" NlmCategory="CONCLUSIONS">Transplantation of spermatogonial stem cells into the seminal lumen of mouse testes is a functional assay that defines this cellular subpopulation by its ability to colonize it. This technique can be used as a model to elucidate the insights of spermatogonial stem cells, to produce transgenic animals by genetically manipulating donor cells before transplantation, but also it has potential applications in fertility preservation in cattle and humans as it is feasible in large animals, as recent reports have demonstrated with rhesus monkeys, that recovered spermatogenesis after allogenic transplantation, and even from human cadaver testes. Therefore spermatogonial stem cells isolated from prepuberal boys, who are treated with alkylant chemotherapy, could be returned to their testis to regenerate spermatogenesis in the future.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Medrano</LastName>
                    <ForeName>Jose V</ForeName>
                    <Initials>JV</Initials>
                    <Affiliation>Fundaci??n Instituto Valenciano de Infertilidad, Valencia University and INCLIVA Biomedical Research Institute, Valencia, Spain; Fundaci??n Instituto de Investigaci??n Sanitaria La Fe, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mart??nez-Arroyo</LastName>
                    <ForeName>Ana M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Fundaci??n Instituto Valenciano de Infertilidad, Valencia University and INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sukhwani</LastName>
                    <ForeName>Meena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation>
                </Author>
                <Author>
                    <LastName>Noguera</LastName>
                    <ForeName>Inmaculada</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Animal facility, Faculty of Pharmacy, Valencia University, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Qui??onero</LastName>
                    <ForeName>Alicia</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Fundaci??n Instituto Valenciano de Infertilidad, Valencia University and INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mart??nez-Jabaloyas</LastName>
                    <ForeName>Jose M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pellicer</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Fundaci??n Instituto de Investigaci??n Sanitaria La Fe, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Remoh??</LastName>
                    <ForeName>Jose</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Orwig</LastName>
                    <ForeName>Kyle E</ForeName>
                    <Initials>KE</Initials>
                    <Affiliation>Animal facility, Faculty of Pharmacy, Valencia University, Valencia, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sim??n</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Fundaci??n Instituto Valenciano de Infertilidad, Valencia University and INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Obstetrics and Gynecology, Institute for Stem Cell Biology and Regenerative Medicine, Center for Reproductive and Stem Cell Biology, Stanford University, Stanford, California. Electronic address: carlos.simon@ivi.es.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Fertil Steril</MedlineTA>
            <NlmUniqueID>0372772</NlmUniqueID>
            <ISSNLinking>0015-0282</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Spermatogonial stem cells</Keyword>
            <Keyword MajorTopicYN="N">colonization of seminiferous epithelium</Keyword>
            <Keyword MajorTopicYN="N">germ cell transplantation</Keyword>
            <Keyword MajorTopicYN="N">regeneration of spermatogenesis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0015-0282(14)01296-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2014.07.669</ArticleId>
            <ArticleId IdType="pubmed">25150391</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150364</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>24</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1472-6882</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC complementary and alternative medicine</Title>
                <ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Astragalosides from Radix Astragali benefits experimental autoimmune encephalomyelitis in C57BL /6 mice at multiple levels.</ArticleTitle>
            <Pagination>
                <MedlinePgn>313</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Radix Astragali is famous for its beneficial effect on inflammation associated diseases. This study was to assess the efficacy of astragalosides (AST) extracted from Radix Astragali, on the progression of experimental autoimmune encephalomyelitis (EAE), and explore its possible underlying molecular mechanisms.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">EAE was induced by subcutaneous immunization of MOG35-55. Infiltration of inflammatory cells was examined by HE staining. ROS level was detected by measuring infiltrated hydroethidine. Leakage of blood brain barrier (BBB) was assessed using Evan's blue dye extravasation method. Levels of inflammatory cytokines were measured using ELISA kits. Activities of total-SOD, GSH-Px, and iNOS and MDA concentration were measured using biochemical analytic kits. Gene expression was detected using real-time PCR method. Protein expression was assayed using western blotting approach.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">AST administration attenuated the progression of EAE in mice remarkably. Further studies manifested that AST treatment inhibited infiltration of inflammatory cells, lessened ROS production and decreased BBB leakage. In peripheral immune-systems, AST up-regulated mRNA expression of transcriptional factors T-bet and Foxp3 but decreased that of RORgammat to modulate T cell differentiation. In CNS, AST stopped BBB leakage, reduced ROS production by up-regulation of T-SOD, and reduced neuroinflammation by inhibition of iNOS and other inflammatory cytokines. Moreover, AST inhibited production of p53 and phosphorylation of tau by modulation of the Bcl-2/Bax ratio.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AST orchestrated multiple pathways, including immuno-regulation, anti-oxidative stress, anti-neuroinflammation and anti-neuroapoptosis involved in the MS pathogenesis, to prevent the deterioration of EAE, which paves the way for the application of it in clinical prevention/therapy of MS.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Yi-Xin</ForeName>
                    <Initials>YX</Initials>
                </Author>
                <Author>
                    <LastName>Du</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Hai-Lian</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Hong-Shuai</ForeName>
                    <Initials>HS</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Bei-Bei</ForeName>
                    <Initials>BB</Initials>
                </Author>
                <Author>
                    <LastName>Dou</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Xiao-Jun</ForeName>
                    <Initials>XJ</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Zheng-Tao</ForeName>
                    <Initials>ZT</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Complement Altern Med</MedlineTA>
            <NlmUniqueID>101088661</NlmUniqueID>
            <ISSNLinking>1472-6882</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1472-6882-14-313</ArticleId>
            <ArticleId IdType="doi">10.1186/1472-6882-14-313</ArticleId>
            <ArticleId IdType="pubmed">25150364</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150312</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0028-2685</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neoplasma</Title>
                <ISOAbbreviation>Neoplasma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.4149/neo_2014_082</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Breast cancer is a???highly aggressive malignancy and always has a???poor prognosis. The current therapeutic strategies including surgery, chemotherapy and radiotherapy benefit little for patients survival. Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in a???wide range of cancer cells, such as breast cancer, it also has cytotoxicity to normal cells. To improve the selectivity of TRAIL expression to breast cancer cells, we inserted miRNA response elements (MREs) of let-7 and miR-122 into a???TRAIL-expressing adenoviral vector (Ad-TRAIL-MRE-7-122) to restrict its expression within breast cancer cells. qPCR assay confirmed that the levels of let-7 and miR-122 were downregulated in breast cancer samples and cell lines, compared with normal tissues and cell lines. Luciferase assay indicated that MREs of let-7 and miR-122 was able to confer luciferase expression with the selectivity to breast cancer. Ad-TRAIL-MRE-7-122 highly expressed TRAIL in breast cancer cells, but not in normal cells. The breast cancer-specific apoptosis was detected after the infection of Ad-TRAIL-MRE-7-122. The viability of breast cancer cells, rather than normal cells, was reduced by the treatment of Ad-TRAIL-MRE-7-122. Animal experiments further confirmed that Ad-TRAIL-MRE-7-122 and Ad-TRAIL both greatly impeded the growth of breast cancer xenograft in mice. Taken together, we constructed a???TRAIL-expressing recombinant adenovirus regulated by MREs of let-7 and miR-122 and showed evidences that this strategy may be promising for breast cancer treatment. Keywords: breast cancer, adenovirus, let-7, miR-122, TRAIL.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Q</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neoplasma</MedlineTA>
            <NlmUniqueID>0377266</NlmUniqueID>
            <ISSNLinking>0028-2685</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4149/neo_2014_082</ArticleId>
            <ArticleId IdType="pubmed">25150312</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150311</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0028-2685</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neoplasma</Title>
                <ISOAbbreviation>Neoplasma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.4149/neo_2014_081</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cryoablation combination therapy with blockade of the T-cell inhibitory receptor CTL-associated antigen-4 (CTLA-4) may augment the anti-tumor immune response (ATIR). It is crucial to determine the duration of ATIR after cryoablation and anti-CTLA-4 antibody therapy to determine the most appropriate treatment interval of therapy. To investigate the characteristics of ATIR induced by cryoablation and anti-CTLA-4 antibody therapy, we developed a???prostate cancer model system to test the capacity of cryoablation and anti -CTLA-4 antibody to generate ATIR. Mice were randomly assigned to receive no treatment (group A), cryoablation only (group B), cryoablation plus anti-CTLA-4 antibody (group C), or anti-CTLA-4 antibody only (group D). We collected specimens on days 0, 7, 14 and 21 to study the ATIR through different techniques. Our results indicated that cryoablation induced ATIR and further enhanced this effect and reduced the number of distant metastases through combination with anti-CTLA-4 antibody. ATIR induced by cryoablation was achieved through decreasing regulatory T???cell (Treg) number. The number of Tregs induced by cryoablation was lowest on day 14 but then returned to preoperative levels on day 21, indicating that ATIR induced by cryoablation was time-dependent. However, ATIR induced by anti-CTLA-4 antibody might be mainly achieved through influencing Treg function, which was exactly not by decreasing Treg number and still maintain its ATIR effect on day 21 after therapy. In conclusion, ATIR induced by cryoablation was achieved through decreasing Treg number and is time-dependent, whereas ATIR caused by anti-CTLA-4 antibody was achieved exactly not by decreasing Treg number and not time-dependent in the first 21 days after therapy. Keywords: T???cells, prostate cancer, immune response, cryoablation, anti-CTLA-4 antibody.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Si</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Qi</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neoplasma</MedlineTA>
            <NlmUniqueID>0377266</NlmUniqueID>
            <ISSNLinking>0028-2685</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4149/neo_2014_081</ArticleId>
            <ArticleId IdType="pubmed">25150311</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150308</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0028-2685</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neoplasma</Title>
                <ISOAbbreviation>Neoplasma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting HMGB1 inhibits bladder cancer cells bioactivity by lentivirus-mediated RNA interference.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.4149/neo_2014_079</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">High mobility group box 1(HMGB1) has been reported to be associate with tumor clinical stage and pathological grade in bladder cancer (BC). In this study, we investigated the underlying mechanism through lentivirus-mediated HMGB1 knockdown. HMGB1 was strongly inhibited in BC cells stably transfected with shRNA against HMGB1. MTT and colony formation assays demonstrated that the down-regulation of HMGB1 attenuated the growth of BC cells in vitro. The HMGB1 knockdown (KD) group displayed an increased proportion of cells in the G0/G1 phase and higher apoptosis rates of BC cells comparing with the control (CON) group. The transwell assay revealed that the KD group cells had much lower invasive activity. To assess the influence of HMGB1 inhibition on tumorigenicity in BC cells, shRNA-HMGB1 lentivirus were injected into the tumors of xenograft models and the results showed that the tumorigenesis in mice were significantly suppressed by shRNA-HMGB1 lentivirus. Furthermore, the expression level of VEGF-C in KD group was significantly decreased comparing with the CON group. The NF-??B inhibitor PDTC reduced the expression of VEGF-C, while HMGB1, as a???NF-??B agonist, enhanced the VEGF-C expression. In conclusion, our results suggested that lentiviruses delivering shRNA against HMGB1 may be a???promising tool for BC therapy. Keywords: HMGB1, bladder cancer, RNA interference, proliferation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Q</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neoplasma</MedlineTA>
            <NlmUniqueID>0377266</NlmUniqueID>
            <ISSNLinking>0028-2685</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4149/neo_2014_079</ArticleId>
            <ArticleId IdType="pubmed">25150308</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150295</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-02-554543</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">RUNX1 is a master transcription factor in hematopoiesis, and mediates the specification and homeostasis of hematopoietic stem and progenitor cells (HSPCs). Disruptions in RUNX1 are well known to lead to hematological disease. In this study, we sought to identify and characterize RUNX1 target genes in HSPCs by performing RUNX1 chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq) using a murine HSPC line and complementing this data with our previously described gene expression profiling of primary wildtype and RUNX1-deficient HSPCs (Lineage-/cKit+/Sca1+). From this analysis, we identified and confirmed that Hmga2, a known oncogene, as a direct target of RUNX1. Hmga2 was strongly up-regulated in RUNX1-deficient HSPCs, and the promoter of Hmga2 was responsive in a cell-type dependent manner upon co-expression of RUNX1. Conditional Runx1 knockout mice exhibit expansion of their HSPCs and myeloid progenitors as hallmark phenotypes. To further validate and establish that Hmga2 plays a role in inducing HSPC expansion, we generated mouse models of HMGA2 and RUNX1 deficiency. Although mice lacking both factors continued to display higher frequencies of HSPCs, the expansion of myeloid progenitors was effectively rescued. The data presented here establish Hmga2 as a transcriptional target of RUNX1 and a critical regulator of myeloid progenitor expansion.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lam</LastName>
                    <ForeName>Kentson</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Muselman</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Du</LastName>
                    <ForeName>Randal</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Harada</LastName>
                    <ForeName>Yuka</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Scholl</LastName>
                    <ForeName>Amanda G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Matsuura</LastName>
                    <ForeName>Shinobu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Weng</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Harada</LastName>
                    <ForeName>Hironori</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Dong-Er</ForeName>
                    <Initials>DE</Initials>
                    <Affiliation>Departments of Pathology and Division of Biological Sciences, University of California, San Diego, La Jolla, CA, United States d7zhang@ucsd.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-02-554543</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-02-554543</ArticleId>
            <ArticleId IdType="pubmed">25150295</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150294</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2013-02-484196</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Juvenile Myelomonocytic Leukemia (JMML), Acute Myeloid Leukemia (AML) and other myeloproliferative neoplasms (MPN) are genetically heterogeneous but frequently display activating mutations in Ras GTPases and activation of Signal Transducer and Activator of Transcription 3 (STAT3). Altered STAT3 activity is observed in up to 50% of AML correlating with poor prognosis. Activated STAT proteins, classically associated with tyrosine phosphorylation, support tumor development as transcription factors, but alternative STAT functions independent of tyrosine phosphorylation have been documented, including roles for serine phosphorylated STAT3 in mitochondria supporting transformation by oncogenic Ras. We examined requirements for STAT3 in experimental murine K-Ras-dependent hematopoietic neoplasia. We show that STAT3 is phosphorylated on S727 but not Y705 in diseased animals. Moreover, a mouse with a point mutation abrogating STAT3 S727 phosphorylation displayed delayed onset and decreased disease severity with significantly extended survival. Activated K-Ras required STAT3 for cytokine-independent growth of myeloid progenitors in vitro, and mitochondrially restricted STAT3 and STAT3-Y705F, both transcriptionally inert mutants, supported factor-independent growth. STAT3 was dispensable for growth of normal or K-Ras-mutant myeloid progenitors in response to cytokines. However, abrogation of STAT3-S727 phosphorylation impaired factor-independent malignant growth. These data document that serine phosphorylated mitochondrial STAT3 supports neoplastic hematopoietic cell growth induced by K-Ras.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gough</LastName>
                    <ForeName>Daniel J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Department of Pathology and NYU Cancer Institute, New York University Langone School of Medicine, New York, NY, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mari??</LastName>
                    <ForeName>Isabelle J</ForeName>
                    <Initials>IJ</Initials>
                    <Affiliation>Department of Pathology and NYU Cancer Institute, New York University Langone School of Medicine, New York, NY, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lobry</LastName>
                    <ForeName>Camille</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pathology and NYU Cancer Institute, New York University Langone School of Medicine, New York, NY, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aifantis</LastName>
                    <ForeName>Iannis</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Pathology and NYU Cancer Institute, New York University Langone School of Medicine, New York, NY, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Levy</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                    <Affiliation>Department of Pathology and NYU Cancer Institute, New York University Langone School of Medicine, New York, NY, United States david.levy@nyumc.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2013-02-484196</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2013-02-484196</ArticleId>
            <ArticleId IdType="pubmed">25150294</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25150292</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-04-571679</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Adenosine Triphosphate (ATP) and its metabolite, adenosine, are key regulators of polymorphonuclear neutrophils (PMNs) functions. PMNs have recently been implicated in the initiation of thrombosis. We investigated the role of ATP and adenosine in PMN activation and recruitment at the site of endothelial injury. Following binding to the injured vessel wall, PMNs are activated and release elastase. The recruitment of PMNs and the subsequent fibrin generation and thrombus formation are strongly affected in mice deficient in the P2X1-ATP receptor and in wild-type mice treated with CGS 21680, an agonist of the A2A adenosine receptor or NF449 a P2X1 antagonist. Infusion of wild-type PMNs into P2X1-deficient mice increases fibrin generation but not thrombus formation. Restoration of thrombosis requires infusion of both platelets and PMNs from wild-type mice. In vitro, ATP activates PMNs, whereas CGS 21680 prevents their binding to activated endothelial cells. These data indicate that ATP contributes to PMN activation leading to their adhesion at the site of laser-induced endothelial injury, a necessary step leading to the generation of fibrin and subsequent platelet-dependent thrombus formation. Altogether, our study identifies previously unknown mechanisms by which ATP and adenosine are key molecules involved in thrombosis by regulating the activation state of PMNs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Darbousset</LastName>
                    <ForeName>Roxane</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Aix Marseille Universite, INSERM UMR-S1076, Marseille, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Delierneux</LastName>
                    <ForeName>C??line</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>GIGA-R, Laboratory of Thrombosis and Hemostasis, University of Liege, Liege, Belgium;</Affiliation>
                </Author>
                <Author>
                    <LastName>Mezouar</LastName>
                    <ForeName>Soraya</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Aix Marseille Universite, INSERM UMR-S1076, Marseille, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Hego</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>GIGA-R, Laboratory of Thrombosis and Hemostasis, University of Liege, Liege, Belgium;</Affiliation>
                </Author>
                <Author>
                    <LastName>Lecut</LastName>
                    <ForeName>Christelle</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>GIGA-R, Laboratory of Thrombosis and Hemostasis, University of Liege, Liege, Belgium;</Affiliation>
                </Author>
                <Author>
                    <LastName>Guillaumat</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Actelion Pharmaceuticals Ltd., Allschwil, Switzerland;</Affiliation>
                </Author>
                <Author>
                    <LastName>Riederer</LastName>
                    <ForeName>Markus A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Actelion Pharmaceuticals Ltd., Allschwil, Switzerland;</Affiliation>
                </Author>
                <Author>
                    <LastName>Evans</LastName>
                    <ForeName>Richard J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dignat-George</LastName>
                    <ForeName>Fran??oise</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Aix Marseille Universite, INSERM UMR-S1076, Marseille, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Panicot-Dubois</LastName>
                    <ForeName>Laurence</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Aix Marseille Universite, INSERM UMR-S1076, Marseille, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Oury</LastName>
                    <ForeName>C??cile</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>GIGA-R, Laboratory of Thrombosis and Hemostasis, University of Liege, Liege, Belgium;</Affiliation>
                </Author>
                <Author>
                    <LastName>Dubois</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Aix Marseille Universite, INSERM UMR-S1076, Marseille, France; christophe.dubois@univ-amu.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-04-571679</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-04-571679</ArticleId>
            <ArticleId IdType="pubmed">25150292</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
